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Abstract 
 
Vaccines and antibiotics have had a profound impact on human and animal 
health in the last century. Despite their success, there are several disadvantages 
associated with current regimens, including multiple immunizations that result in 
poor patient compliance, high reactogenicity, unpleasant side effects, and poor 
efficacy against intracellular pathogens. In this regard, innovative delivery platforms 
can facilitate the development of effective single-dose treatment regimens to control 
emerging and re-emerging infectious diseases. The work presented in this 
dissertation describes how rational design principles can be successfully employed 
to develop targeted polyanhydride platforms for drug and vaccine delivery. Initial 
studies sought to define the interactions of various polyanhydride micro- and 
nanoparticle formulations with antigen presenting cells (APCs), a type of immune 
cell critical to the initiation of immune responses. Experiments focused on particle 
internalization, uptake mechanism(s), and intracellular trafficking revealed striking 
chemistry and size dependent effects. Knowledge gained from these studies was 
then used to strategically select specific particle sizes and chemistries to test the 
efficacy of doxycycline-loaded particles against an in vitro infection with the 
intracellular pathogen Brucella. 
Subsequent chapters in this dissertation detail how a multidisciplinary 
approach utilizing tools from cell biology, immunology, biomaterials engineering, 
carbohydrate chemistry, and informatics analysis delineated the complex patterns 
observed during host-pathogen interactions. These observations were then used to 
identify the properties of polyanhydride nanoparticles that mimicked the ability of 
 xv 
bacterial pathogens to induce a robust immune response. Specifically, surface 
functionalization, including the addition of carbohydrates, made nanoparticles more 
“pathogen-mimicking” in terms of their intracellular fate, persistence and APC 
activation compared to Yersinia pestis or Escherichia coli. Carbohydrate 
functionalization also enhanced microparticle internalization by targeting the C-type 
lectin receptors present on APCs. Studies were also performed to evaluate the effect 
of vaccine antigen functionalization in combination with the polyanhydride 
nanoparticle platform. Modification of the plague antigen F1-V with α-galactose 
induced T cell expansion as well as a high titer, high avidity antibody response with 
broad epitope recognition of F1-V peptides when administered with polyanhydride 
nanoparticles. In summary, the studies described herein support the rational design 
and selection of delivery platforms to meet the needs of a spectrum of biomedical 
applications, including drug and vaccine delivery. 
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CHAPTER 1  
Literature Review 
 
Polymeric vaccine delivery 
Introduction 
Since the development of the first vaccine by Edward Jenner, against cowpox 
virus, the human race has witnessed major feats in this field. These include 
complete eradication of small pox, increase in life expectancy by more than 20 
years, decrease in incidences of several diseases by up to 95% and being on the 
verge of eradicating polio1-5.  
Despite these advantages, the existing vaccines also have many associated 
disadvantages such as high frequency of adverse effects and multi-dose 
requirements to generate robust immune response resulting in poor patient 
compliance. In fact, after the first immunization a (or as much as) 70% drop in 
patient compliance is reported in developing countries. Moreover, new challenges to 
human health have considerably changed the medical needs of the present society. 
Thus, new vaccines are required to address the current health problems posed by 
high proportion of elderly people, emerging and re-emerging infections and 
neglected diseases. In order to achieve these goals, it is important to understand the 
mechanisms of action of traditional vaccines and use that knowledge in combination 
with our recent advances in immunobiology, host-pathogen interaction studies and 
biotechnology to develop novel vaccines. 
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Traditional vaccines 
The basic tenet of vaccine design is to induce an immune response that 
mimics the response generated during an active infection without the associated 
adverse effects. This goal can be accomplished in multiple ways and, based on the 
method used, vaccines can be categorized into three classes, each with their own 
advantages and disadvantages. 
 
Killed Whole Cell Vaccines  
These vaccines contain pathogens killed by chemical or heat treatment. 
Examples of these vaccines include pertussis, typhus and cholera. Although the first 
killed whole cell vaccine was developed in 1890s, this method is still employed today 
because of the potent humoral response generated by the vaccine and the inability 
of the organism to revert to its pathogenicity. These vaccines, however, have several 
disadvantages also. Multiple immunizations are required to generate a protective 
immune response and induction of a Th2 polarized immune response. Also, the 
immunostimulants used in these vaccines can cause mild to severe inflammatory 
reactions.  
 
Live Attenuated Vaccines   
To prepare these vaccines, live pathogenic organisms are rendered non-
pathogenic by two methods; by culturing them in vitro in non-human cell cultures for 
hundreds of passages or, by genetic manipulation of the organism to specifically 
delete virulence gene(s). Some of the successfully used live attenuated vaccines 
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include oral polio vaccine (OPV), rotavirus and Bacille Calmette-Guérin (BCG) 
vaccines6-8.   
Since these vaccines contain live organisms that can replicate inside of their 
host, the immune response induced closely resembles that generated during a 
natural infection. This response is strong, durable and includes humoral as well as 
cell mediated immunity. Furthermore, no additional adjuvants and fewer 
immunizations are required for induction of protective immunity. Although 
successful, there are number of risks associated with this strategy. The biggest 
drawback of using attenuated organisms is the risk of their reversion to the virulent 
phenotype causing a genuine infection as seen in the case of OPV9. 
Immunocompromised individuals, due to lack of a competent immune system are 
more prone to infection after getting vaccinated with an attenuated vaccine. Further, 
the attenuated organisms may persist in the vaccinee for long periods of time and 
infect other non vaccinated individuals. Finally, as documented for whole killed 
vaccines, the live attenuated vaccines can also cause mild to severe side effects.  
 
Subunit Vaccines 
The advent of biotechnology and our increased understanding of the immune 
system lead to the development of subunit vaccines. These vaccines contain highly 
purified antigens thus providing the specificity not present in the whole cell vaccines.  
Subunit vaccines offer many advantages over whole cell vaccines. They 
possess a very good safety profile due to the lack of unwanted microbial 
components like lipopolysaccharides, mRNA and other TLR ligands that trigger overt 
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inflammatory response. Also, due to the progress made in biotechnology their large 
scale production is cost efficient, ultimately leading to cheaper vaccines10-12. 
Despite being safe, there are many disadvantages of subunit vaccines. The 
purified antigens, on their own, are weak immunogens so addition of external 
excipients known as adjuvants is required to enhance the immunogenicity of the 
vaccine. They also require multiple immunizations to induce protective immunity. 
Lastly, they primarily induce humoral immune response and have minimal effects on 
cell mediated response. Thus, to overcome these challenges, there is a need of 
better adjuvant systems. 
 
Biodegradable Vaccine Adjuvants 
Micro (size >1 µm) and nanoparticles (size < 1 µm) synthesized from 
biodegradable polymers have been studies as vaccine adjuvants for numerous 
reasons. They provide controlled release of the encapsulated antigen for prolonged 
periods of time13. Changing the polymer chemistry can modulate the release kinetics 
of the antigen. These two characteristics, in turn, may allow for designing single 
dose vaccines14,15. Moreover, the immunomodulatory properties of these particles 
allows for induction of a balanced immune response.  
Biodegradable particles are usually synthesized from materials that have 
been tested for biocompatibility and have already been used in other medical 
applications e.g. drug delivery. These particles can be degraded by enzymatic or 
hydrolytic breakdown generating non-toxic monomers thus eliminating the need of 
their removal from the body16. Another advantage is their capability to be 
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administered via non-parenteral routes such as intra-nasal and oral administration17. 
There are mainly three classes of biodegradable synthetic polymers that are 
currently under investigation as vaccine delivery agents. 
 
Polyesters 
 Polyesters are the most studied polymeric biomaterials due to their low 
cytotoxicity which is a result of its degradation products that can be metabolized by 
neighboring cells. Copolymers based on two chemistries, poly(lactic acid) (PLA) and 
poly(glycolic acid) (PGA) are investigated for their application as vaccine delivery 
vehicles13,18-22.  
PGA degrades by a bulk erosion method whereby it burst releases all the 
encapsulated cargo (Figure 2A). To control the degradation rate, it is copolymerized 
with slow eroding, hydrophobic PLA leading to formation of poly(lactic-co-glycolic 
acid) PLGA copolymers. However the amount of PLA that can be added may not 
exceed 50% due to lower solubility of the copolymer in solvents.  
PLGA micro and nanoparticles gained considerable interest for delivery of 
antigens such as hepatitis B antigen and diphtheria toxoid, malaria, tetanus 
toxoid16,21,23-27. Despite of their excellent safety profiles, they could not be 
commercialized because of antigen stability issues. During degradation of PLGA, 
hydrolysis of ester bonds generates acidic by-products which substantially influence 
the encapsulated protein’s stability. Moreover, the encapsulation process itself is 
harsh on the proteins causing them to unfold or aggregate.  
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Due to these limitations other biomaterials have been evaluated for their vaccine 
delivery capabilities. 
 
Polyethers 
 Few studies have shown potential of utilizing polyethers such as poly(ethylene 
glycol) (PEG) for vaccine delivery application. Incorporation of polyethers in the 
backbone of other polymeric biomaterials is utilized to provide a more amphiphilic 
environment28-32. Moreover PEGylation is a common strategy to impart stealth 
qualities to micro or nanoparticles to reduce their non-specific mucociliary clearance 
from the body. Studies performed in mice showed particles comprised of PEG and 
poly(propylene sulfide) (PPS) reached draining lymph nodes and were efficiently 
internalized by APCs. Further studies are required to evaluate them as vaccine 
delivery candidates. 
 
Polyanhydrides 
 Polyanhydrides are another class of biomaterials extensively studied for their 
vaccine and drug delivery capabilities. The characteristic properties include protein 
stability33,34, sustained release of antigen35, immunostimulation15,36 and excellent 
safety profile. In fact, polyanhydride wafer (Gliadel) composed of sebacic acid (SA) 
(Figure 1) and 1,3-bis(p-carboxyphenoxy)propane (CPP) is approved by U.S. Food 
and Drug Administration (FDA) for the treatment of brain tumor37.  
The rate of degradation of polyanhydrides can be controlled by mixing fast 
degrading aliphatic polyanhydrides with their slow counterparts that are aromatic in 
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nature. As appose to bulk erosion of PLGA polymers, polyanhydrides degrade by 
surface erosion (Figure 2B). This property is especially helpful in vaccine delivery 
because the rate of antigen release becomes similar to rate of polymer degradation 
allowing for well-controlled release kinetics.  
Polyanhydride copolymers based on SA and 1,6-bis(p-
carboxyphenoxy)hexane (CPH) have been widely investigated for their 
immunomodulatory properties. SA degrades much faster than other polyanhydride 
chemistries, whereas degradation of CPH is much slower. Copolymers of SA and 
CPH exhibit a more controlled degradation pattern, however, they are very 
hydrophobic. Amphiphilic polymers can be made by incorporating triethylene glycol 
into CPH backbone resulting in poly(1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane) 
(CPTEG). Studies have investigated use of polyanhydride micro and nanoparticles 
as vaccine adjuvants based upon copolymers of CPH:SA and CPTEG:CPH mixed in 
different ratios to form 20:80 CPH:SA, 50:50 CPH:SA, 20:80 CPTEG:CPH and 50:50 
CPTEG:CPH. These properties are discussed in the section “Mimicking pathogens 
for rational design of adjuvants” of this review. 
 
Targeting APCs 
Polymeric vaccines work by delivering the antigen to the APCs. To enhance 
the antigen delivery, various targeting strategies have been applied such as surface 
functionalization of particles or antigen with DC targeting antibodies and 
carbohydrate conjugation. One category of the important candidates for targeting 
includes C-type lectin receptors that are abundantly present on DC membrane. 
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These receptors contain conserved carbohydrate recognition domains that facilitates 
their binding to various sugars present on pathogens in a calcium dependent 
manner38. Binding of pathogen to CLRs not only triggers internalization but it also 
activates cell signaling pathways39. Examples of CLRs include mannose receptor 
(MR)40-43, DC-SIGN44-47, DEC-20548-51, Dectin-138,47 and Dectin-252,53. 
 
APC targeting strategies 
Antibody mediated targeting 
 Antibody mediated targeting holds promise for increasing the efficacy of 
vaccines because of the high specificity of the monoclonal antibodies. Kwon et al 
conjugated anti-DEC 205 antibody to the microparticles for targeting them to DEC-
205 proteins present on DC surface. In vivo studies showed a three fold increase in 
microparticle uptake for antibody functionalized microparticles compared to control 
particles54. Another study showed the benefits of APC targeting, in terms of uptake 
and immune response, by conjugating anti-CD11c antibody on liposomes55,56. The 
high cost of monoclonal antibody production had made researchers look into 
alternative strategies for APC targeting. 
 
 
Carbohydrate mediated targeting 
 This strategy is based on the fact that CLRs present on APCs contain 
carbohydrate recognition domains that can recognize various carbohydrates 
residues. Although, specificity to bind a receptor is lower compared to antibody 
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mediated targeting, carbohydrates can be produced at a relatively low cost thus can 
be more cost effective. Studies have shown that liposomes and chitosan particles 
functionalized with mannose are internalized better than non-functionalized 
controls57,58. Together, antibody and carbohydrate modification of antigens or 
delivery vehicles offers exciting opportunities to enhance the efficacy of the vaccine. 
 
Mechanisms of uptake 
 Therapeutic potential of particulate delivery agents is directly influenced by 
their interactions with APCs. The mechanisms by which these particles are 
internalized decide not only their fate but also of the host cell that harbors them59. 
Several reports have discussed the internalization pathways of these delivery agents 
that can be divided into two phagocytosis and endocytosis60-62 (Figure 3). 
 
Phagocytosis 
It is an energy dependent, highly regulated process involving cell surface 
receptors and signaling moieties such as Rho-family GTPases63,64. Phagocytosis is 
primarily conducted by specialized cells such as macrophages, DCs and neutrophils. 
Other cells types including epithelial and endothelial cells may also exhibit some 
phagocytic activity but to a lower extent. The lower size limit for a particle to be 
phagocytized is 0.5 micron. 
 In the first step, the particles get attached to the surface of the cell by binding 
to receptors such as Fc receptors (FcR), complement receptors (CR) and scavenger 
receptors (SR). This triggers the signaling cascade involving Rho-GTPases that in 
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turn cause polymerization of actin and subsequent uptake of the particle surrounded 
by a phagosome65-68. After passing through a series of fusion and fission events the 
phagosomes then mature into endosome and ultimately to lysosome69-72.  
 
Endocytosis 
 Endocytosis is a process by which eukaryotic cells internalize 
macromolecules by membrane convolutions. It plays important roles in uptake of 
nutrients, surface receptors expression and regulating cell signaling73-75. It is 
classified into clathrin mediated endocytosis (CME), caveolae mediated endocytosis, 
macropinocytosis and clathrin-and caveolin independent endocytosis. 
 
Clathrin mediated endocytosis (CME) 
 CME is by far the most important route for nutrient uptake and is critical in 
regulation of receptor recycling55,56. It is also the most common route utilized by 
viruses to gain entry inside the cells76,77. The first stage of CME involves receptor-
ligand clustering to form ‘coated pits’ on plasma membrane 78,79. These pits are 
composed of polygonal cages made primarily by self-assembly of clathrin. The 
coated pits then invaginate and pinch off from the plasma membrane to form 
endocytic vesicles80-82. The size of cargo delivered via CME ranges from 50- 200 nm 
in diameter83. However, recent studies have challenged the current dogma of 200 
nm size limit showing that Listeria and latex beads requires clathrin for their 
uptake84-86. 
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Caveolae mediated endocytosis 
 Caveolae are 50 -80 nm large flask shaped invaginations present on plasma 
membrane of eukaryotic cells73. They are recognized for controlling many cellular 
functions including cell signaling, lipid and vesicular transport. The primary protein 
that provides shape to caveolae is a dimeric protein caveolin87. Non-enveloped 
viruses such as simian virus 40 enter the cell by caveolae mediated uptake88-90. The 
upper size limit for entry by this pathway is considered to be 80 nm73. 
 
Macropinocytosis 
 Macropinocytosis involves the uptake of large quantities of fluid by formation 
of waving extensions of plasma membrane over the cargo generating 
macropinosome of size 500 nm or larger91,92. Plasma membrane ruffles, depending 
on the cell type, can be planar folds92,93, cup shaped (circular ruffles)94-96 and 
blebs91. The molecules and dynamics of this process are still not clearly understood.  
 
Clathrin-and caveolae-independent endocytosis 
 In this pathway cholesterol rich microdomains, that lack caveolin, are formed 
on plasma membrane. These domains are called lipid rafts ranging from 50-200 nm 
in diameter. The small rafts can be contained within an endocytic vesicle rich in 
glycosyl phosphatidylinositol (GPI)-anchored protein. This pathway is further divided 
into Rho97,98, CDC4299, ARF6100 and Flotillin mediated pathways101-104. 
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Mimicking pathogens for rational design of adjuvants 
Immune Response to Pathogens 
The body’s immune response to pathogenic microorganism infections is a 
complex process that can vary drastically between different infectious agents. 
However, for most acute infections the immune response can be broken into stages 
starting with the initial infection exposure which is often countered by the innate 
immune response in which germline-encoded receptors are used to identify foreign 
invaders. Some of these innate mechanisms such as pattern recognition receptors 
(PRRs) on immune cells can identify molecules on the surface of pathogens such as 
pathogen associated molecular patterns (PAMPs) (lipopolysaccharide (LPS), CpG 
DNA, dsRNA, flagellin, etc.) which then cascades towards the adaptive immune 
response stage105,106. Pathogenic infections, in terms of antigen available to the 
immune system, often peaks at a later time point after the initial inoculation when the 
pathogen is replicating (Figure 4). The adaptive immune response, towards the 
presented antigen, results in the activation of cytotoxic T cells, effector T cells, 
antibodies, and memory T and B cells. The memory T cell and B cell populations are 
critical for the immune response to respond in a timely manner against a similar 
pathogen at a later time. That peak antigen then decreases when the adaptive 
immune response is able to control the pathogen infection with the remaining 
pathogens feeding the adaptive immune response until no antigen is left. This is a 
basic representation of pathogen infections as pathogens are constantly evolving to 
evade, manipulate, and subvert the immune response but the idea of recreating the 
antigen peaks and valleys helps to improve rational vaccine design.   
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Innate Effects 
Innate Immune Response 
Following initiation of the innate immune response, once bacterial replication 
or antigen quantity is sufficient; signaling to the adaptive immune response begins. 
Professional APCs are immune cells responsible for bridging the innate and 
adaptive immune response. The APCs engulf the pathogenic organisms or their 
products, process and present their antigens on their surface which enables 
activation of B and T cells. Pathogen research has pushed molecular discovery of 
innate immune receptors located on the cell surface, within cytoplasmic vesicles of 
the cell, and within the cytoplasm of the cell. Conserved molecular patterns found 
associated with pathogens, PAMPs, ligate innate immune receptors found on nearly 
all cells of the mammalian cells. Ligation of these receptors leads to a signaling 
cascade event leading to proinflammatory transcription factors being produced 
resulting in production of proinflammatory cytokines and chemokines. These 
cytokines and chemokines provide the signal to bystander cells to act in defense and 
recruit immune effector cells to the site of infection. The innate signaling leads to 
antigen presentation to cells of the adaptive immune system, T cells and B cells.   
This innate signaling leading to adaptive immune response can often result in 
pathological damage due to immune cell infiltrate due to the immune system trying 
to control the amount of pathogen either at the site of infection or systemically. One 
of the main conundrums of vaccine research is try to replicate the pathogenic 
infection mechanism to create immune memory without the immune mediated 
damage at the site of inoculation or systemically. Early vaccines accomplished this 
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by using inactivated pathogens. Inactivated pathogens maintain the PAMPs but lack 
the ability to replicate. Furthermore, inactivated vaccines are often not safe even 
though the pathogens are unable to replicate because there can still be immune 
mediated damage at the injection site. Purified antigens of pathogens avoid the 
immune mediated damage of inactivated vaccines but often lack the immunogenicity 
to elicit the innate signaling and adaptive responses, effector or memory. This is why 
combining antigens of vaccines with adjuvants, non-specific immune stimulators, 
helps to cross this chasm of poor immunogenicity.   
 
Adjuvants  
Adjuvants provide an innate danger signals that signal inflammation which, in 
turn, leads to an adaptive immune response mounted against the antigen. These 
inflammatory danger signals, while effective in eliciting immune responses towards 
the antigen, are often considered a double edged sword due to their adverse side 
effects such as pain, swelling, and cell death. Advances in molecular research have 
led to insights into mechanisms of common adjuvants which often signal through 
PRRs. PRRs are specialized innate structures located on the surface and 
intracellular spaces of cells that PAMPs. Aluminum salt (Alum) is one of the most 
widely used adjuvants in human and veterinary vaccines. It provides 
immunostimulatory effects through Nalp3 inflammasome activation in dendritic cells, 
the professional antigen presenting cells (APCs) of the immune system107,108. This 
process is initiated by uric acid production within the endosome of APCs that lyses 
the endosomal membrane which causes ligation of the Nalp3 inflammasome within 
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the cytosol. This ligation leads to transcription of inflammatory cytokines which 
enables recruitment of inflammatory DCs, potent inducers of CD4+ T cells. This 
finally results in an increased humoral response 109. Agonists for other PRRs are in 
various stages of development for use in human vaccines. A detoxified bacterial LPS 
product, monophosphoryl lipid A (MPLA), ligates toll like receptor (TLR) 4 110,111. The 
ligation leads to APC activation, cytokine secretion, and subsequent T cell and B cell 
adaptive responses. This response is especially pronounced when combined with 
Alum 112,113.  
Polymeric biomaterials are another class of adjuvants currently being 
investigated for their immunosimulatory, pathogen mimicking abilities. 
Polyanhydrides and polyesters are two classes of polymer adjuvants which have 
demonstrated the ability to stimulate expression of cell surface markers and 
production of cytokines. Polyesters such as poly(lactic-co-glycolic acid) (PLGA) have 
demonstrated the ability to enhance expression of CD86 and secretion of IL-6 and 
TNFα114-116. Further studies have reported MPLA-loaded PLGA particles to enhance 
expression of CD40, CD86, and MHC II and the secretion of TNF, IL-6 and IL-12p70 
in dendritic cells117,118. However, these immunostimulatory, ‘pathogen mimicking’ 
capabilities are likely attributed to the MPLA loaded into the PLGA particles and not 
the inherent properties of the particles themselves.  
Another polymeric material with surprising immunomodulatory, pathogen 
mimicking characteristics are polyanhydrides composed co-polymers based upon 
sebacic acid (SA), 1,6-bis-(p-carboxyphenoxy)hexane (CPH), and 1,8-bis-(p-
carboxyphenoxy)-3,6-dioxaocatane (CPTEG). Studies have shown enhanced 
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activation profiles of dendritic cells and macrophages which show an increased 
expression of MHC I, MHC class II, B7 costimulatory molecules, CD40, and CD209 
(C-type lectin that is involved in migration and binding of glycoproteins containing 
high amounts of mannose) in vitro119-123. The expression patterns and levels are 
chemistry dependent and reach similar activation levels as compared to positive 
control, LPS. Particles rich CPTEG or SA resulted in the highest simulation of these 
markers. Furthermore, these particles enhance the secretion of cytokines including 
TNFα, IL-12p40, and IL-6 but at levels much lower than that induced by LPS. The 
moderate phenotype of activation is favorable because the particles appear to be 
less inflammatory. This lack of inflammatory response leads to a favorable safety 
profile in the context of the particles themselves. More recent work has revealed 
similar activation patterns specifically between 50:50 CPTEG:CPH polyanhydride 
nanoparticles and the pathogen molecule, LPS. These similarities arise in the double 
positive populations of DCs for expression of MHC II, CD86 and CD40 and secretion 
of IL-6 and IL-12p40122. Further similarities in internalization patterns were identified 
between pathogens and the polyanhydride nanoparticles. Like many pathogens, 
MHC II and CD86 expression were independent of particle internalization whereas 
CD40, IL-6 and IL-12p40 were dependent upon particle internalization. Informatics 
analysis indicated alkyl ether, % OH endgrope, backbone O, and hydrophobicity as 
the primary contributors to this pathogen mimicking behavior. Work by Ulery et al. 
has reported further evidence of the pathogen mimicking characteristics of 50:50 
CPTEG:CPH polyanhydride nanoparticles in their ability to persist within intracellular 
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vesicles, similar to Y. pestis and E. coli as well as revealed similar activation 
patterns as LPS123. 
 
Importance of uptake by innate immune cells 
The encounter of pathogen with immune cells of the body especially myeloid 
phagocytes (macrophages and DCs) shapes the direction of the immune response 
against the pathogen. These cells can identify many cues from pathogens and then 
generate and transfer the information to other immune cells of the body in the form 
of costimulatory signals and cytokines. Recent studies have shown that 
internalization process itself can have a huge impact on the resultant immune 
response. APCs can collect physical information of their targets such as size during 
the process of phagocytosis by membrane ruffling and pseudopodia extension. This 
information later decides the fate of those targets inside APCs, for example different 
fate of viruses versus bacteria. In similar context, size and chemistry of the 
polymeric particles define their mechanism of uptake, delivery of antigen and the 
resultant immune response. Direct comparative studies of the method of uptake 
between Salmonella and polyanhydride nanoparticles showed that both of them 
were internalized by similar cellular process that required actin and was temperature 
dependent124.  Additional studies utilizing various inhibitors of cellular uptake 
pathways showed the requirement of clathrin in the uptake of polyanhydride 
nanoparticles and microparticles. This is in parallel to uptake pathways of many 
pathogens such as Listeria and Yersinia85,125.  
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Pathogens possess various virulence factors to target different cells of the 
host. This targeting strategy can be used for vaccine delivery by attaching ligands to 
the antigen or the delivery vehicles that can interact with receptors present on APCs 
and facilitate the uptake of vaccine. One such approach is targeting C-type lectin 
receptors (CLRs) present on APCs. Pathogens ranging from mycobacteria, viruses 
to fungi are recognized by CLRs. Once recognized they mediate multiple steps in 
DC response including internalization, processing, presentation and maturation39. 
Targeting antigen-loaded liposomes to a CLR DEC-205 using monoclonal antibody 
anti-DEC-205 induced a potent T cell response and marked protection from tumor 
growth. Recently, two studies explored use of sugar (di-mannose and galactose) 
functionalization of nanoparticles to target mannose receptors on DCs and 
Macrophages126. The results showed functionalization with sugars, increased the 
expression of activation markers and secretion of proinflammatory cytokines from 
DCs and alveolar macrophages compared to non-functionalized controls. Thus, 
targeting vaccines to APCs is an efficient method to increase the efficacy of the 
vaccine. 
Immune cells recognize pathogens by not only the presence of PAMPs but by 
their location and cellular context also. For example, PAMPs- flagellin and DNA can 
stimulate the cells only when they are in cytosol and not from the cell surface. 
Presence of extracellular or endosomal TLR ligands leads to NF-κB mediated 
response whereas cytosolic PRRs stimulate the inflammasome pathway. Thus, 
particulate vaccines are also studied in the context of their cellular location inside 
APCs. Danger signals are included in the delivery platforms to stimulate extracellular 
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and intracellular pattern recognition pathways. PLGA particles have shown to 
rupture lysosomes, leading to activation of inflammasome pathway127. Similarly di-
mannose functionalized polyanhydride nanoparticles induced secretion of IL-1β, a 
cytokine secreted after inflammasome activation suggesting a dual hit model of first 
engaging cell surface PAMPs and then cytosolic PRRs.  
 
Adaptive Effects  
Adaptive Immune Response 
Antigens are delivered to the cell surface and presented by major 
histocompatibility complexes I or II (MHC I or II). Most viruses and certain bacteria 
often replicate in the cytosol and are presented to CD8+ T cells via the MHC I 
receptor on APCs, whereas, most bacteria and some parasites replicate in 
lysosomes and endosomes and are presented to CD4+ T cells via the MHC II 
receptor on APCs. The CD8+ T cells function to kill infected cells and CD4+ cells 
function to activate other adaptive immune cells. These immune cells include 
antibody secreting B cells which are activated by a Th2 subclass of CD4+ cells and 
macrophages targeted to eliminate pathogens residing in their intravascular 
compartments which are activated by a Th1 subclass of CD4+ cells. Prolonged 
antigen persistence and exposure enables robust activation of these adaptive 
immune responders and prolonged immunological memory. Surprisingly, the poor 
immunogenicity of many current vaccination components fail to establish this 
memory and often times require a multiple dose vaccine regimen. Here we will 
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discuss current pathogen mimicking approaches used to establish prolonged 
immunological memory against infectious diseases. 
 
Adjuvant Depot, Size, and Administration Route Effects 
The most effective way to design and deliver a vaccine is by mimicking that of 
the natural infection while avoiding the negative side effects. Adjuvants are non-
specific immunological activators that can help achieve this robust immune response 
with limited problems. While non-specific simulation of the innate immune system is 
an integral first step to initiate the immune response, other important factors in the 
design and delivery of vaccine adjuvants include administration route, depot effect, 
and size. The administration route will influence the spread of the antigen and 
development of immunological memory in the various lymphoid tissues. This could 
also affect the persistence or residence time of the antigen and its ability to establish 
long lived immunological memory. Depot effect and size are two other properties 
that influence the immune response by controlling antigen exposure to immune cells 
and the ability of the adjuvant/antigen complex to be internalized by immune cells. 
Through administration via the route of infection, persistence and the ability to be 
internalized, vaccine design in a pathogen mimicking approach may lead to more 
effective disease prevention strategies. 
The main principal in the genesis of many polymers as biomaterials was the 
ability of the material to provide a controlled release (i.e. depot effect) of a payload 
encapsulated within the particle by a unique surface erosion mechanism. The 
erosion kinetics can be modified to fine tune erosion to increase or decrease release 
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of an encapsulated protein. Differences in size of proteins, chemistry of particles, 
and size of particles all lead to unique release effects from particles but the main 
principle of controlled release is maintained. While controlled release of an 
encapsulated antigen is integral for prolonged antigen exposure, we have 
discovered that an initial bolus of antigen appears to be important for maximizing the 
efficacy of vaccines using the polyanhydride platform. Free (soluble) antigen acts as 
a pathogen secretion or a virus in that the free antigen is rapidly trafficked to 
secondary lymphoid tissues within minutes post inoculation via size restricted 
conduit structures128,129. Particulate antigens take longer to reach secondary 
lymphoid tissues based on size and uptake by tissue resident DCs and the 
subsequent trafficking to lymph nodes 130,131. The initial bolus of free antigen allows 
for a rapid and lymph node directed initiation of the innate immune response by 
engaging lymph node resident DC’s lining the conduits 132,133. The encapsulated 
antigen in polyanhydride carriers then augments the free antigen by simultaneously 
providing a particulate structure in which resident DC’s and macrophages proximal 
to the inoculation site can ingest and traffic to the lymph nodes. This provides a 
prolonged, controlled release of intact antigen from particles embedded at the 
inoculation site. This extended antigen exposure mimics the process in which 
pathogens persist and interact with the immune system. Once a sufficient amount of 
antigen is built up, the adaptive immune response is initiated by effector cells. 
Pathogen or antigen persistence enables the immune system to develop and 
maintain immunological memory. In fact, the surface eroding polyanhydride particles 
which reside long enough at the inoculation site may mimic repeat infection of the 
 22 
same pathogen, enabling the immune system to develop an even more robust, long 
lived immune response. 
The main purpose of controlled release of antigen is to mimic a pathogenic 
infection by manipulating antigen presentable to the immune system. Encapsulation 
of antigen allows for adaptive immune maturation which is evident in the increased 
avidity of serum IgG using polyanhydride nanoparticles134-136. In vivo evaluation of 
immune responses depends on two major factors. The immunogenicity of the 
subunit antigen by itself is paramount. The response seen in all particle vaccinations 
appears to be predominantly humoral with antibody titers being sustained longer and 
exhibiting greater avidity as compared to other commercial adjuvants in single dose 
regimens 134,136. The magnitude of the antibody response is dependent on the 
immunogenicity of the antigen being examined but the antibody response kinetics 
appear to be similar regardless of antigen when a portion is encapsulated. 
Measurable antibody changes are seen at 2-4 weeks post injection. The antibody 
responses increase and are sustained for up to 36 weeks post vaccination or more. 
The efficacy of the vaccinations can be increased by administration of soluble 
antigen in conjunction with the particles at the time of vaccination. The exact ratio of 
amount of soluble antigen to amount encapsulated needs to be determined with 
each antigen being studied. In a plague challenge model using the F1-V antigen, 
protection from lethal challenge was maintained at 36 weeks post single intranasal 
vaccination with 80% of the protein being soluble and 20% encapsulated into 
nanoparticles123,137.   
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 Understanding how size affects pathogenicity directly effects research into 
preventative therapies. This increased focus on size has led researchers to examine 
its relationship with mechanisms of adjuvants action. Mineral oil emulsion adjuvants, 
such as the Freund’s adjuvants, have been common veterinary adjuvants and are 
often used as immune potentiators in the research sector. These mineral oil 
adjuvants create a water-in-oil (W/O) emulsion in which vaccine antigens are 
contained in water droplets within an oil phase 138. These antigenic particles usually 
range in size from 1-5 µm in size. Alum adjuvanted vaccines undergo a similar 
antigenic particle creation when antigens are adsorbed to the aluminum salts. Size 
of the antigen particles is often dictated by the size of antigen (killed bacteria versus 
soluble subunit protein) but relative particle size ranges from 0.5-5 µm.   
Using principles of biomaterials, it is possible to create particles that 
encapsulate subunit protein antigens that resemble the particle sizes of the most 
common adjuvants discussed previously. More importantly, these particle constructs 
are able to mimic the sizes of bacteria and larger viruses as well (Figure 5). 
Research has demonstrated that the size and chemistry of particles could also affect 
distribution of particles from the inoculation site allowing for distribution in different 
tissue environments 128,130-132,139. Polyanhydride microparticles (~5 µm in diameter) 
encapsulating an in vivo imaging fluorophore exhibited a traditional depot effect with 
little migration from the inoculation site as compared to nanoparticles (~0.5 µm in 
diameter) which demonstrate fluorescent peaks in sites distal from the inoculation 
site. Studies examining the distribution of other polyanhydride particle chemistries 
verify this distribution size effect with major peaks of fluorescence observed at the 
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site of inoculation with microparticles and an increased systemic fluorescence 
observed with the nanoparticles, which allow for greater uptake and systemic 
trafficking potential. Analysis of excised lung tissue after intranasal inoculation has 
revealed fluorescence intensity at one month post administration suggesting the 
ability of polyanhydride particles to reside at the sight of immunization to provide 
extended antigen exposure over long periods of time. Ex vivo analysis of spleen and 
lymph nodes also show increased fluorescence which suggests that the particles are 
trafficking to secondary lymphoid structures.  
Evidence of fluorescence from particles in typical blood mixing tissue sites 
(i.e. spleen and liver) is apparent when polyanhydride nanoparticles are 
administered via an intranasal route. Presumably, the access to a greater area of 
vasculature in the lungs and more phagocytic populations taking up particles and 
trafficking via lymph and the bloodstream contribute to this finding. Evidence of 
fluorescently conjugated antigen loaded polyanhydride particles has been identified 
at least 4 weeks post intranasal administration indicating a controlled release that 
mimics the antigen load of a chronic infection. A depot of fluorescently loaded 
polyanhydride particles was identified at a subcutaneous administration site up to 10 
weeks post administration dictated by chemistry with higher CPH content 
demonstrating longer in vivo detection times. Alternatively, particles administered at 
parenteral tissue sites demonstrate less trafficking to liver and spleen possibly due 
to the lack of distribution by resident dendritic cells and macrophages to different 
sites. Larger particles are also likely not able to move through the extracellular space 
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as effectively as smaller particles contributing to the differences in fluorescence 
distribution observed.  
The trafficking of particles to the liver and spleen mimics tissue distribution 
patterns of pathogenic infections of many different bacteria and viruses140-151. 
Heterogenous Salmonella infection with genetically tagged identification shows 
bacterial populations detected in the spleen and liver145. Inhalation of Bacillus 
anthracis spores causes a disseminated bacterial infection leading to viable bacteria 
evident in the spleen and draining lymph nodes151. Mouse models of Mycobacterium 
tuberculosis using an aerosol or intravenous route of administration demonstrate 
bacterial load in the lungs, spleen, and liver at 3-4 weeks post infection150. 
Pathogenic viruses present similar dissemination patterns. Highly pathogenic H5N1 
VN/1203 when administered intranasally in a mouse model shows pathogenic gene 
changes in lungs and spleens of infected mice 142. Parasites also exhibit 
disseminated phenotypes in mouse models.  Toxoplasma gondii infected dendritic 
cells display a hypermotile phenotype leading to spread of intracellular pathogen to 
secondary lymphoid structures rapidly post intraperitoneal infection 146,147. BALB/c 
mice infected with Leishmania major show viable parasites in the spleen and 
draining lymph nodes at 8 weeks post infection 152. Ex vivo analysis of spleen and 
liver tissues of mice infected with Trypanosoma brucei with bioluminescent reporter 
show detectable luminescence at day 20 post infection153.  
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Yersinia pestis  
Introduction 
Y. pestis, the causative agent for plague, is a non motile, gram-negative, 
facultative intracellular bacterium154,155. Rodents are the principal hosts for the 
bacteria, and the transmittance to rodents or humans is through infected flea 
vectors156,157. No other pathogen has affected mankind as drastically as Y. pestis 
causing three major pandemics that resulted in more than 200 million deaths 
worldwide. The first pandemic wave, known as Justinian plague, affected mainly the 
Byzantine Empire and lasted from 6th to 8th century. The second pandemic, “Black 
death” killed more than 25 million people during 14th to 16th century and culminated 
as the great plague of London. The third, Indo-China plague started during the war 
in the Yunnan province in mid 18th century killing 10 million people in India alone158-
163.  
The World Health Organization has categorized plague as a re-emerging 
infection and the possibility of fourth pandemic is real because of significant number 
of cases reported in Algeria, Congo, India and Zambia164,165,166. Plague is classified 
as a Category A select agent because of the potential to be used as a bioterror 
weapon. In fact, during the 13th century, the tartars catapulted corpses of plague 
victims to the city walls of Kaffa to make residents flee.  
The disease is manifested in three major forms depending upon the route of 
infection- bubonic (lymph nodes), septicemic (spread of bacteria to blood stream) 
and pneumonic plague (lungs)155,166-168. Bubonic plague is caused when Y. pestis is 
delivered by a flea bite. The bacteria travel to lymph nodes, replicate without a 
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measurable immune response and the disease symptoms are expressed between 2-
10 days. This long incubation period is required for bacteria to change the gene 
expression, suitable in flea vector (26 °C in flea gut), to that suitable in humans (37 
°C). Once sufficient number is reached, the bacteria enter the lymphatics and blood 
vessels leading to secondary septicemia. Symptoms are usually characterized by 
headache, fever and tender lymph nodes. The mortality rate is about 50-60% if left 
untreated169. 
Primary septicemic plague occurs after infection with high doses of Y. pestis 
in susceptible patients or in individuals in specialized professions such as 
veterinarians, where a direct transcutaneous infection from an infected mammalian 
host can occur. In the latter case, Y.pestis is already expressing the virulent factors 
required to infect a mammalian host, hence the disease spread is quick170,171.  
The third and the most lethal form is the pneumonic plague where the 
bacteria infect the lungs172. Flu-like symptoms are followed by cough with bloody 
sputum leading to cardiovascular dysfunction and coma. This form of disease is 
100% fatal if untreated and rapidly transmissible from person to person via 
respiratory droplets173,174. 
 
Treatment 
The standard treatment includes use of antibiotics such as streptomycin, 
tetracycline and sulfonamides, alone or in combination. Alternatively, gentamicin and 
fluoroquinolones may be used if the above mentioned antibiotics are not 
effective167,175-179. Treatment is successful only if antibiotics are administered within 
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24-36 hours of infection. Y. pestis has been shown to acquire antibiotic resistance 
naturally. Moreover, the prospects of genetically engineering the bacterium to make 
it multidrug resistant calls for developing alternate protective measures other than 
treatment with antibiotics180.  
 
Vaccines 
Vaccines can be used as a prophylactic measure against plague. A formaldehyde-
killed whole cell vaccine was available for military personnel, however, it was 
discontinued in 1999 because of multiple reasons: i) short-lived and variable 
protection, ii) high frequency of adverse effects and iii) protection against the 
bubonic form only and not the pneumonic plague181-186. Presently, there is no FDA 
approved vaccine against plague.  
Vaccines containing subunit antigens of Y. pestis have shown promises with 
the foremost candidates being Fraction 1 (F1) and Low calcium response V (LcrV) 
proteins. These two proteins are responsible for the anti-phagocytic activity and 
regulation of type three-secretion system (T3SS) of Y. pestis, respectively. Mice 
immunized with F1 were protected against aerosolized plague challenge187,188. 
However, F1-negative Y. pestis strains exist in nature and are fully virulent and so 
vaccines based solely on F1 antigen will be ineffective in case of weaponized F1 
mutant bacteria189-193. In contrast, LcrV is critical for the pathogenesis of Y. 
pestis154,194-199. Numerous studies in mice have shown vaccination with LcrV antigen 
protects mice against subcutaneous and aerosol challenge with Y. pestis. Of note is 
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that LcrV alone may not provide protection against weaponized LcrV variants 
because of failure to induce cross-protective immunity200. 
Vaccine based on recombinant F1-V protein provided better protection than 
F1 or LcrV alone201-204. Studies conducted on cynomolgus macaques at US Army 
Medical Research Institute of Infectious Diseases (USAMRIID) showed 80-100 
percent protection after vaccination with F1/LcrV protein. However, this antigen 
failed to produce sufficient levels of protection in African green monkeys. Because 
the antibody levels in response to the vaccine were similar in both the primates, the 
role of cell mediated immunity in plague protection was suggested205. Thus, taking 
steps to rationally design antigens and adjuvants that can enhance the humoral and 
cellular immunity in response to F1-V vaccine is required. 
 
Role of Humoral immunity 
Studies have shown that antibody response is important for protection but the 
mechanism of protection is unclear. Mice of four different haplotypes immunized with 
rF1 and rV antigens responded with high antibody titers and were protected against 
aerosol and subcutaneous challenge with Y. pestis. Mice passively immunized with 
sera of cynomolgus macaques that were immunized with F1-V showed protection 
against a lethal plague challenge174.    
 
Role of Cellular immunity 
Role of cell mediated immunity has received considerably little attention 
compared to its humoral counterpart. Guinea pigs challenged with live attenuated Y. 
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pestis were protected despite their low titers. In another study, antibody deficient 
µMT mice showed efficient protection against pneumonic plague challenge206. Gene 
deletion in Stat4 signaling pathway, which abrogates the Th1 response, resulted in 
significantly reduced protection in mice207.  All of these studies suggest that 
antibodies are not the only source of protection against plague, and that cellular 
immunity may play an important role too. 
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Figure 3. Different mechanisms of uptake in a typical eukaryotic cell. Reprinted from 
reference 73 
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Figure 4. Cartoon representation of antigen load during pathogenic infection and 
controlled delivery vaccine.  
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Figure 5. Size distribution of polyanhydride particles in comparison to pathogens. 
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Abstract 
 
Polyanhydride micro- and nanoparticles have emerged as delivery platforms 
due to the versatility to encapsulate drugs, immunogens, antibodies, or bioactive 
proteins. However, detailed studies on the effects of size and polymer chemistry on 
the interaction with cells are lacking. Studying the effects of physicochemical 
properties of polyanhydrides on their cellular interactions should allow for selection 
of particle chemistries to fit into specific applications. In the present study, the 
internalization, mechanism(s) of uptake, and intracellular fate of micro- and 
nanoparticles were evaluated. Polymer chemistry was based on 1,6-bis(p-
carboxyphenoxy)hexane (CPH), sebacic acid (SA) and 1,8-bis(p-carboxyphenoxy)-
3,6-dioxaoctane (CPTEG) chemistries. The results show that 20:80 CPH:SA and 
20:80 CPTEG:CPH nanoparticles had a significantly higher internalization compared 
to other chemistries. Further, cytochalasin-D treatment of cells inhibited uptake of all 
the particle groups indicating that actin-mediated uptake is the primary means of 
entry of polyanhydride particles. Based on this data, it was hypothesized that 
specific particle groups may enhance efficacy in treating intracellular infections. The 
value of this approach was demonstrated by the in vitro efficacy of doxycycline 
loaded particles against an intracellular pathogen Brucella. Together, this approach 
allows for rationally designing and choosing delivery platforms to meet needs of a 
spectrum of biomedical applications.  
Keywords: polyanhydrides, microparticles, nanoparticles, drug delivery, 
vaccine delivery 
 53 
Introduction 
Use of polymeric micro- and nanoparticles in biomedical applications is becoming 
very popular especially for the delivery of vaccines1, 2, drugs3, and genes4. They offer 
numerous advantages over other delivery modalities including high biocompatibility, 
subcellular size, and ease of manipulation to fit specific needs. Because of these 
reasons, they hold promise to overcome the challenges associated with traditional 
approaches of administering therapeutics5 such as increased antigen delivery to 
antigen presenting cells6, 7.  
Polyanhydrides, a class of biodegradable polymers, are extensively studied 
as delivery platforms in a range of applications such as vaccine and drug delivery. 
Studies have shown that in contrast to polyester-derived delivery platforms  
polyanhydride-based polymers exhibit surface erosion kinetics, providing more 
control over the release of the encapsulated drug or antigen. Further, as vaccine 
delivery agents, they provide a moderate pH microenvironment leading to stability of 
the encapsulated immunogen and maintenance of antigenic epitopes. Moreover, 
several studies have demonstrated the immunomodulatory properties of 
polyanhydride micro- and nanoparticles8-10. In order to meet the diverse spectrum of 
biomedical needs, physiochemical properties of polyanhydrides can be altered by 
varying the ratio of the polyanhydride monomers (i.e.,SA, CPH and CPTEG) used to 
synthesize a given copolymer. 
 In order to capture the full potential of the delivery platform technology, it is 
important to have a deep understanding of the interactions of the particles with host 
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cells and how physicochemical properties of the particle chemistry influence those 
interactions. Previous work has shown that the amount of internalization, mechanism 
of uptake and intracellular fate of particles is influenced by factors such as size, 
hydrophobicity, chemistry and their surface charge11, 12. The mechanisms by which 
these particles are internalized decide not only their fate but also of the host cell that 
harbors them. Multiple pathways have been elucidated for the uptake of particles, 
bacteria, viruses and drugs. Phagocytosis is primarily conducted by specialized cells 
such as macrophages, DCs and neutrophils. Other cells types including epithelial 
and endothelial cells may also exhibit some phagocytic activity but to a lower 
extent13. Clathrin mediated endocytosis (CME), the most common route of entry of 
viruses, involves receptor-ligand clustering to form ‘coated pits’ on plasma 
membrane. These pits are composed of polygonal cages made primarily by self-
assembly of clathrin. Caveolae mediated endocytosis involves formation of 
caveolae, 50 -80 nm large flask shaped invaginations on plasma membrane, made 
by different protein, mainly caveolin13. Cholera toxin and simian virus 40 are 
internalized by this mechanism. Macropinocytosis involves the uptake of large 
quantities of fluid by formation of waving extensions of plasma membrane over the 
cargo generating macropinosome of size 500 nm or larger. Although intracellular 
vesicles and their cargo resulting from these different uptake mechanisms can 
intersect similar intracellular compartments within the cell (i.e., endosomal and 
lysosomal compartments), mechanism of uptake does affects the fate of the 
internalized cargo.  
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To date, no mechanistic studies evaluating cellular mechanisms involving the 
uptake of polyanhydride particles have been performed. The aim of this study was to 
compare the internalization efficiency, mechanism of uptake and intracellular fate of 
polyanhydride micro- and nanoparticles. The insights were then used to test the 
ability of polyanhydride nanoparticles to intracellularly deliver doxycycline in an in 
vitro Brucella killing assay. Together, the results indicate that rational selection of the 
delivery platform(s) to fit a specific need has more potential than the “one size fits 
all” approach.  
 
Materials and methods 
Materials 
The synthesis of polyanhydride carboxylic diacid monomers required the use 
of 1, 6-dibromohexane (98.5%), 4-p-hydroxybenzoic acid (96%), 1-methyl-2-
pyrrolidinone anhydrous (99.5%), triethylene glycol (99%), FITC-Dextran purchased 
from Sigma Aldrich (St. Louis, MO); 4-p-fluorobenzonitrile (98%) purchased from 
Apollo Scientific (Stockport, Cheshire, England); and sodium hydroxide, sulfuric acid, 
acetonitrile, dimethyl formamide, toluene and potassium carbonate purchased from 
Fisher Scientific (Fairlawn, NJ). Chemicals needed for copolymer synthesis and 
nanoparticle fabrication included sebacic acid (99%), acetic anhydride, chloroform, 
heptane, petroleum ether, ethyl ether, methylene chloride and hexanes and were 
purchased from Fisher Scientific. The cell culture medium included RPMI 1640, 
glutamate, penicillin-streptomycin, gentamycin was acquired from Mediatech 
(Herndon, VA); heat inactivated fetal bovine serum was acquired from Atlanta 
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Biologicals (Atlanta, GA).  
 
Polymer synthesis and characterization  
CPH diacid, SA and CPH pre-polymers were synthesized as previously 
described14. Synthesis of CPH:SA and CPTEG:CPH copolymers with 20:80 and 
50:50 molar ratios was performed by melt polycondensation as previously published 
by Kipper, et al and Torres, et al14, 15. The obtained polymer was characterized by 1H 
nuclear magnetic resonance spectroscopy and gel permeation chromatography 
(GPC). Polymer properties evaluated were consistent with accepted ranges14.   
 
Microparticle fabrication 
1% (w/w) FITC-Dextran- loaded microparticles were fabricated out of 20:80 
and 50:50 CPH:SA and CPTEG:CPH copolymers by a cryogenic atomization 
procedure, as described elsewhere16, 17. For the fabrication of FITC-Dextran-loaded 
nanoparticles, an antisolvent nanoencapsulation method adapted from Ulery et al 
was performed18. Briefly, polymer was dissolved in cold methylene chloride (15 
mg/mL) and FITC-Dextran was homogenized by sonication in the polymer solution. 
The polymer-dye mixture was rapidly poured into a bath of pentane held at -40 °C at 
an antisolvent to solvent ratio of 1:80 and 1:150 for CPH:SA and CPTEG:CPH, 
respectively. Micro and nanoparticles were collected by vacuum filtration and dried 
under vacuum overnight. Scanning electron microscopy (SEM) (JEOL 840 A, JEOL 
Peabody, MA) was used to evaluate particle morphology. Microparticle size 
distribution was obtained using ImageJ image analysis software (National Institutes 
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of Health, Bethesda, MD) with an average of 200 particles per image analyzed. 
Average nanoparticle diameter was obtained by quasi-elastic light scattering (QELS, 
Zetasizer Nano, Malvern Instruments Ltd., Worchester, U.K.). 
 
Uptake experiments  
To quantify uptake parameters such as percent of cells positive for 
internalized particles, average number of particles per cell, and mean fluorescent 
intensity (MFI) multispectral imaging flow cytometry (MIFC) was employed based on 
previously published protocol with minor modifications19. Briefly, RAW 264.7 cells 
were seeded at a density of 0.5 x 106 cell per well in complete RPMI 1640 (RPMI 
1640, 10% heat- inactivated fetal bovine serum (FBS), 2 mM Glutamax) of a twenty 
four well culture dish and incubated at 37°C, 5% CO2. After an over night incubation 
period, micro- or nanoparticles were added to separate cultures of RAW 264.7 cells 
at 200 µg/mL and these cultures were incubated for 45 min at 37°C in 5% CO2. 
Following the incubation period, cultures were harvested by gentle scrapping and 
transferred into siliconized microcentrifuge tubes (Sigma). Cells were then washed 
and fixed in 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS, pH 
7.4). Samples were analyzed for particle uptake using ImagestreamX (Amnis 
corporation, Seattle) with 488 laser. For each sample, 5000 cells were acquired for 
analysis. Images were analyzed for the presence of internalized particles using 
IDEAS 4.0 software (Amnis corp, Seattle). This assay can differentiate between 
internalized versus surface bound particles and only cells with internalized particles 
were calculated as particle positive cells. 
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Inhibition of particle uptake  
RAW 264.7 cells were established as described above. Next day, the cells 
were washed once with PBS and treated in separate wells with cytochalasin-D (1 h, 
5 µg/mL), genistein (1 h, 200 µM), rottlerin (30 min, 2 µM), methyl-β-cyclodextrin 
(MβCD) (15 min, 5 mM), or chlorpromazine (CPZ) (15 min, 10 µg/mL). Following the 
treatment with the inhibitors, micro- and nanoparticles (200 µg/mL) were added to 
the monolayers and incubated for additional 45 min in the presence of inhibitors. 
Negative controls (i.e. cells treated with 1 % DMSO v/v) were also performed in 
parallel. After incubation with particles, cells were harvested and processed as 
described above. The incubation time and concentrations of the inhibitors used were 
carefully titrated and the concentrations used are consistent with those reported to 
be non- toxic 20, 21. Additional confirmation of cell viability was obtained by Trypan 
blue staining and lactate dehydrogenase assay, after treatment with inhibitors for the 
indicated time points (data not shown). 
 
Colocalization of particles within Lysosomes  
RAW 264.7 cells were cultured as described above. After an over night 
incubation, 1% FITC-dextran loaded micro- or nanoparticles were added to the 
cultures at 200 µg/mL and the cells were incubated for another 24 h at 37°C in 5% 
CO2. Following the incubation, cultures were washed with PBS, harvested by gentle 
scrapping and transferred into siliconized microcentrifuge tubes. Cells were washed, 
fixed, and permeabilized in Cytofix/Cytoperm (BD Biosciences) solution for 20 min. 
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Samples were then washed and incubated with 10 µg/mL of AF-647conjugated rat 
anti-mouse CD107b antibody (e-Bioscience) for 40 min, followed by washing and 
fixing the cells in 1 % PFA.  Intracellular colocalization was measured using 
ImagestreamX (Amnis corporation, Seattle) with 488 and 658 laser. A minimum of 
5000 cells were acquired for each sample. Images were analyzed IDEAS 4.0 
software. The threshold ( x%) mask of the AF647 image, which covers the lysosome 
area was used to calculate the ratio of the intensity of the particles inside the 
lysosome mask divided by the total intensity of the particles for each cell. The cells 
were then gated into three population based on the obtained ratio as high, medium 
and low colocalized. The median ratio is reported as the co-localization index.  
 
THP-1 and Brucella culture 
The human THP-1 monocytic cell line was used for these studies and was 
differentiated into adherent cells by supplementing the cRPMI 1640 medium with 5 
nM phorbol myristic acid (PMA) for 24 hours followed by an additional 24 hours in 
fresh cRPMI without PMA prior to use in infectious assays22.  
All research with live Brucella abortus were conducted in University, State 
and Federally approved BSL3 facilities at Iowa State University College of Veterinary 
Medicine. Virulent B. abortus laboratory strain 2308 cultures were grown on 
Trypticase Soy agar (Difco) supplemented with 5% bovine blood (BA) (Gemini 
Bioproducts) under 5%CO2 at 37oC. A GFP-expressing derivative of B. abortus 2308 
was constructed in prior studies by introducing the plasmid pBBR1MCS6-Y encoding 
GFP expression downstream of the constitutively active promoter for aph3A-derived 
 60 
from pBlueKS+Kan (Stratagene)(Bellaire 2005). GFP positive Brucella were 
maintained in culture using a concentration of 6 µg/ml chloramphenicol.  
 
Intracellular viability assay description.  
Diluted bacteria were opsonized with hyper-immune, rabbit anti-Brucella 
immunoglobulin (Difco) for 20 min at 37 °C. Bacteria were added to cultures of THP-
1 cells at defined MOI 100:1 and then the cultures were centrifugated at 1000 rpm 
for 10 minutes at 4 °C.  After centrifugation, uptake of bacteria was allowed to 
proceed at 37 °C for 20 min under 5% CO2. After internalization period, monolayers 
were washed once with PBS to remove extracellular bacteria and culture medium 
supplemented with 1:1000 gentamicin was added to the monolayer. After 24 h, 
monocytes were treated with either soluble doxycycline alone (10 µg/mL) or with 
doxycycline-loaded nanoparticles (equivalent doxycycline 10 µg/mL). Following 
another 48 h incubation period, the THP-1 cells were washed once with PBS and 
then lysed with 0.1% deoxycholate to release intracellular bacteria. Serial dilutions of 
the culture lysates were plated onto TSA blood agar plates in triplicate to enumerate 
viable intracellular bacteria.. 
 
Statistical analysis 
The statistical software JMP 9 was used to analyze the internalization data. 
One-way ANOVA and Tukey’s HSD were used to determine statistical significance 
among treatments and p< 0.05 was considered significant. For the inhibition studies 
treatment groups were compared to the vehicle controls utilizing Student’s one tail t 
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test and p < 0.05 was considered significant.  
 
Results 
Characterization of micro and nanoparticles 
SEM microphotographs for both micro or nanoparticle chemistries showed 
spherical shape with smooth surfaces (data not shown). Size distribution analysis of 
both micro and nanoparticles is presented in Supplementary Information (SI) Figure 
1. Slight bigger microparticles are obtained out of the CPH:SA co-polymers (i.e., 
10.2 ± 5.5 µm and 9.6 ± 6.1 µm for 20:80 CPH:SA and 50:50 CPH:SA, respectively) 
compared with microparticles made of CPTEG:CPH (i.e., 9.7 ± 4.8 µm and 7.9 ± 3.1 
µm for 20:80 and 50:50 CPTEG:CPH particles, respectively), as shown in SI 1A-1D. 
The same trend was observed for polyanhydride nanoparticles with average 
diameters of 378 ± 94 nm and 311 ± 52 nm for 20:80 CPH:SA and 50:50 CPH:SA 
nanoparticles (SI 1E and 1F), while 20:80 CPTEG:CPH and 50:50 CPTEG:CPH 
showed an average diameter of 323 ± 85 nm and 265 ± 52 nm, respectively (SI 1G 
and 1H). For both micro and nanoparticles, higher polydispersity is observed for 
CPH:SA particles.  
 
Internalization analysis of micro and nanoparticles 
The therapeutic potential of particle based delivery depends upon their 
internalization by target cells.  A chemistry and size dependent effect was observed 
on the uptake parameters evaluated for 20:80 CPH:SA, 50:50 CPH:SA, 20:80 
CPTEG:CPH and 50:50 CPTEG:CPH micro and nanoparticles. Within the 
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microparticles groups, 20:80 CPTEG:CPH particles were internalized the most (8% 
cells) whereas the other three chemistries had similar levels of uptake (Figure 1A). 
The cells that had taken up particles were further evaluated for average number of 
particles internalized. There were significantly less (p ≤ 0.05) 50:50 CPH:SA 
particles (~2.5/cell) internalized compared to the other three chemistries (~ 4/cell) 
(Figure 1B). Furthermore, the MFI values of the cells that were particle positive were 
quantified as a measure of amount of particles internalized per cell. No differences 
were observed for 20:80 CPH:SA, 20:80 CPTEG:CPH and 50:50 CPTEG:CPH 
microparticles, however, 50:50 CPH:SA had significantly lower mean intensity 
(Figure 1C).  
Nanoparticles also exhibited a chemistry dependent effect on uptake. 20:80 
CPH:SA and 20:80 CPTEG:CPH nanoparticles were internalized by ~45% cells; 
however, less than 5 % of the cells internalized 50:50 CPH:SA and 50:50 
CPTEG:CPH nanoparticles (Figure 1D). For the 20:80 CPH:SA chemistry, not only 
higher percent of cells were particle positive but more nanoparticles were 
internalized per cell. While more cells internalized 20:80 CPTEG:CPH  nanoparticles 
than microparticles, there was no increase in the number of nanoparticles per cell 
(Figure 1E). The MFI values for 20:80 CPH:SA were significantly higher than the 
other three chemistries (Figure 1F).  
Previous work has shown a size dependent effect on internalization, that 
nanoparticles are internalized more readily compared to microparticles23. For the 
20:80 CPH:SA and 20:80 CPTEG:CPH chemistries, significantly higher number of 
cells took up the 20:80 nanoparticles compared to microparticles of the same 
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chemistry. However, no significant enhancement in uptake was observed for the two 
50:50 nanoparticle chemistries over their microparticle counterparts. Together, this 
data shows that chemistry and size play an important role in the internalization of 
particles.  
 
Role of phagocytosis and actin in particle uptake 
Cells can internalize extracellular substances by multiple mechanisms and 
the method by which substances are internalized, decides their subsequent 
intracellular fate24. In order to investigate the mechanism of entry of polyanhydride 
micro- and nanoparticles, known biochemical inhibitors were used to block specific 
internalization pathways such as phagocytosis, macropinocytosis, clathrin-mediated 
endocytosis, and caveolae-mediated endocytosis. Cytochalasin-D, which blocks 
polymerization of F-actin filaments and inhibits phagocytosis and 
macropinocytosis23, blocked the internalization of both micro- and nanoparticles of 
all chemistries by more than 50% compared to the respective vehicle controls. 
Cytochalasin-D had the most profound impact on uptake of 50:50 CPH:SA 
microparticles as evidenced by 93% inhibition of uptake.  
Rottlerin, a more specific inhibitor of macropinocytosis than is cytochalasin-D, 
was utilized to evaluate the relative contribution of this pathway in particle uptake25. 
Only the uptake of 50:50 CPTEG:CPH nanoparticles was significantly reduced (p ≤ 
0.05) after treatment with rottlerin while the uptake of none of the other micro- or 
nanoparticles was affected.  
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Role of caveolae and clathrin mediated uptake 
Recent studies have shown actin requirement in endocytic pathways 
including caveolae and clathrin-mediated endocytosis (CME)23, 26. Because 
cytochalasin-D has an indirect role in these pathways, inhibitors were used to 
specifically block caveolae- and clathrin-mediated endocytosis. Genistein and methyl 
β cyclodextrin (MβCD) block caveolae-mediated uptake by inhibiting a tyrosine 
kinase and depleting cholesterol rich lipid rafts, respectively23. Treatment with these 
inhibitors only altered the internalization of 50:50 CPH:SA microparticles (~45% 
inhibition) and 20:80 CPTEG:CPH nanoparticles (~27% inhibition) (Figures 3A, 3B, 
3D and 3E).  
Next, involvement of clathrin-mediated endocytosis pathway was studied by 
using the amphipathic drug, chlorpromazine, that blocks clathrin monomers from the 
binding the plasma membrane to prevent the formation of clathrin-coated pits20, 27. 
The internalization of 50:50 CPH:SA and 50:50 CPTEG:CPH for both micro- and 
nanoparticles was reduced (~50% inhibition) as a result of chlorpromazine 
treatment. In contrast, no influence on the uptake of 20:80 CPH:SA and 20:80 
CPTEG:CPH micro- and nanoparticles was observed. Together, these data indicate 
a chemistry dependent effect on the mechanism of internalization of micro and 
nanoparticles.   
 
Intracellular trafficking to lysosomes 
Studying intracellular trafficking of polymeric micro- and nanoparticles is 
important for both drug delivery and vaccine delivery application as the therapeutic 
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outcome is dependent upon the fate of particles inside the cells. Further, mechanism 
of internalization also influences the subsequent intracellular fate of particles24. In 
this regard, we investigated the localization of polyanhydride micro- and 
nanoparticles within lysosomal vesicles. Interestingly, 50:50 CPTEG:CPH micro- and 
nanoparticles had significantly less colocalization with lysosomes compared to other 
chemistries (Figures 4A and 4B).  
 
Enhanced killing of Intracellular B. abortus with doxycycline loaded nanoparticles 
The drug delivery capabilities of the polyanhydride nanoparticles were tested 
using an in vitro Brucella infection model. Opsonized B. abortus survives and 
replicates within macrophages in a specialized LAMP-1+ compartment22. We 
hypothesized that nanoparticle chemistries that targeted more macrophages i.e. 
20:80 CPH:SA and 20:80 CPTEG:CPH (see Figure 1D) and can enter LAMP-1+ 
vesicles will show enhance killing of Brucella compared to nanoparticle chemistries 
with a lower uptake efficiency (50:50 CPH:SA and 50:50 CPTEG:CPH). Monocytes 
were infected with B. abortus to establish intracellular residence and after 24 h, 
cultures were treated with either soluble doxycycline alone or with doxycycline-
loaded nanoparticles. Following an additional 48 h incubation, the THP-1 cells were 
lysed to release intracellular bacteria and the numbers of surviving bacteria were 
enumerated. The data in Figure 5 demonstrates that the uptake of doxycycline 
loaded 20:80 CPH:SA and 20:80 CPTEG:CPH nanoparticles resulted in a significant 
reduction in viable intracellular bacteria compared to soluble doxycycline.  
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Discussion 
Polyanhydride micro- and nanoparticles have been evaluated for their 
potential as vaccine delivery vehicles2, 28 as well as in drug delivery applications29-32. 
The fact that three polyanhydride chemistries, CPH, SA and CPTEG, can be mixed 
in different combinations provides more flexibility for modulating physiochemical 
properties of the particles. In this work, we sought to seek how chemistry and size 
influence the interactions of phagocytic cells with polyanhydride particles. 
A critical step for particulate delivery system is their internalization by specific 
cell types depending on the application. Size of the particles have a pronounced 
effect on uptake and studies with poly(ethylene glycol) particles have shown that 
nanoparticles are more efficiently internalized compared to microparticles23. The 
results presented herein show that particle chemistry influences the size-dependent 
uptake of polyanhydride particles. Specifically, chemistries rich in SA (in the CPH:SA 
formulation) and CPH (in the CPTEG:CPH formulation) had a dramatic improvement 
in uptake when comparing micro- to nanoparticles (Figures 1A and 1D). However, 
this enhancement was not observed for the 50:50 CPH:SA and 50:50 CPTEG:CPH 
chemistries. In contrast to a previous study reported by Petersen et al where 20:80 
CPTEG:CPH nanoparticles exhibited poor internalization in DCs, this study showed 
much better internalization of those nanoparticles33. These differences may be 
attributed to the difference in cell types (DCs versus macrophages) and time points 
(48 h versus 45 min) used in the two studies. For some applications of drug delivery 
that involve intracellular mechanisms and/or where the drug itself does not 
effectively cross the cellular membrane, it may be beneficial to have cells internalize 
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the delivery vehicle to increase the therapeutic outcome of the treatment. In this 
regard, nanoparticles may provide better efficacy than microparticles, specially the 
two 20:80 nanoparticle chemistries.  
Further analyses revealed the effect of chemistry on the number of particles 
entering per cell. For the microparticles, 50:50 CPH:SA had a lower average number 
of particles per cell compared to the remaining three chemistries (Figure 1B). With 
respect to the uptake of nanoparticles, significantly more particles were observed 
per cell for 20:80 CPH:SA compared to other three chemistries (Figure 1E). This 
data is important, as having a higher number of drug delivery vehicles per cell 
should enhance the ability to target the niches occupied by the pathogen. 
Intracellular pathogens such as Brucella and Mycobacterium reside and replicate in 
specific intracellular niches inside macrophages22, 34-36. Surprisingly, for the 20:80 
chemistries, where changing the size of the particles from micro to nano had a major 
influence on number of cells internalizing particles, minimal, if any, impact was 
observed for average number of particles per cell for those chemistries (Figure 1B 
and 1E). The combination of higher number of cells internalizing 20:80 CPH:SA 
nanoparticles and increase in the numbers of nanoparticles per cell increases the 
likelihood that this chemistry may have superior ability to treat diseases associated 
with intracellular pathogens.  
The interplay of size and chemistry in context of mechanism of internalization 
of biomaterials is poorly understood23. Studies using polyethylene glycol hydrogel 
nanoparticles of specific size showed that multiple endocytic pathways are involved 
in the uptake of these particles. Data from the present study demonstrate that actin-
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mediated uptake is the primary means of entry of polyanhydride particles and no 
size-dependent effect was observed (Figure 2).  These results are in contrast with a 
previous study where strong inhibition in internalization of 200 nm but not of 1 µm 
particles was observed after cytochalasin–D treatment23. A possible explanation 
could be the differences in the chemistry of particles and the cell types used in the 
two studies. The size range of objects entering cells by macropinocytosis is 
considered to be ≥ 1 µm. Inhibition of macropinocytosis by rottlerin had no effect on 
the uptake of the microparticles. Interestingly, 50:50 CPTEG:CPH nanoparticles had 
a significant reduction in their uptake after rottlerin treatment of cells (Figure 2D). 
This may be due to the fact that 50:50 CPTEG:CPH particles have a low glass 
transition temperature (Tg=8 °C) and would be rubbery at room temperature, which 
may make phagocytosis more difficult compared to macropinocytosis where the cell 
has to extend the cell membrane around the particles instead of having close 
specific interactions as in phagocytosis. Many pathogens such as Legionella, 
Salmonella, Shigella and Vaccinia virus exploit macropinocytosis to enter the host 
cell37. Upon entering they can either escape the macropinosome by disrupting the 
membrane as seen for Vaccinia virus or reside in non-degradative organelles 
(Legionella)37. 50:50 CPTEG:CPH nanoparticles may thus be a suitable carrier to 
treat infections caused by pathogens that reside within intracellular compartments 
derived from macropinocytic uptake.  
The four chemistries used in this study were hydrophobic and may have an 
affinity to interact with the lipid raft present on the cell membrane. To test if the 
particles were internalized by lipid raft/caveolae mediated endocytosis, genistein and 
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MβCD inhibitors were utilized. Interestingly, internalization of only 50:50 CPH:SA 
microparticles and 20:80 CPTEG:CPH nanoparticles was significantly reduced 
(Figure 3A, 3B, 3D and 3E) while other chemistries were not affected. 
Inhibiting clathrin-mediated endocytosis (CME) by chlorpromazine had a 
major impact on internalization of 50:50 CPH:SA and 50:50 CPTEG:CPH micro- and 
nanoparticles. Recently, the dogma related to the effect of size limit (i.e., ≤ 120 nm) 
on the uptake of particles by CME was challenged when it was shown that 
pathogenic Listeria and Yersinia (<1 µm) can exploit this pathway to gain entry into 
host cells38, 39. To the best of our knowledge, this is the first study showing 
microparticles (i.e. ~3 µm) similar in size to many bacteria can utilize CME. Indeed, 
50:50 CPTEG:CPH nanoparticles were found to be pathogen-mimicking in terms of 
their cellular interactions, when compared to Yersinia pestis28. 
Studying lysosomal trafficking of the particles is important in both vaccine and 
drug delivery. 50:50 CPTEG:CPH micro- and nanoparticles showed the least 
tendency to be localized within lysosomes which may be attributed to the fact that 
they utilize multiple mechanisms to enter inside the cells including phagocytosis, 
macropinocytosis and CME (Figure 4).  
Finally, the in vitro Brucella killing assay demonstrated the superior 
capabilities of polyanhydride nanoparticles as drug delivery vehicle by improving 
doxycycline efficacy through particle encapsulation. It is of note that the two 
nanoparticle chemistries which showed the highest amount of internalization (20:80 
CPH:SA and 20:80 CPTEH:CPH) also proved to be the best in delivering 
doxycycline to the intracellular compartments and effectively reducing the 
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intracellular Brucella  burden (Figure 5). In contrast, 50:50 CPH:SA and 50:50 
CPTEG:CPH provided no additional benefits in reducing the intracellular bacterial 
burden over soluble doxycycline alone (Figure 5).  
Together, these data exemplify the effect of physiochemical properties on 
biomaterial interactions with cells. Varying the size and chemistry of polyanhydride 
particles affects their internalization efficiency and the mechanism of uptake.  This 
allows for rationally choosing the right size and chemistry to fit the specific needs of 
a given application including drug and vaccine delivery.   
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List of Figures 
 
 
 
 
Figure 1. Effect of size and chemistry on internalization of polyanhydride micro- 
(open bars) and nano (closed bars) particles by macrophages. Cells were incubated 
with micro- or nanoparticles for 45 min, harvested, and analyzed by multispectral 
imaging flow cytometry to determine: percentage of cells internalizing micro (A) or 
nanoparticles (D). Average number of microparticles (B) or nanoparticles (E) per 
cell. Mean fluorescent intensity (MFI) of micro- (C) and nanoparticles (F). Data are 
expressed as the mean ± SEM of three independent experiments. Different letters 
indicate statistically significant differences between the groups at p < 0.05. 
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Figure 2. Effect on macrophage internalization of polyanhydride micro- and 
nanoparticles by inhibitors of phagocytosis and macropinocytosis. RAW 264.7 cells 
were incubated with cytochalasin-D (cyto-D, A and C) or rottlerin (B and D) for 45 
min prior to the addition of particles. Uptake of the micro- or nanoparticles was 
allowed to proceed for 45 minutes in the presence of the indicated inhibitor and then 
the macrophages were harvested and analyzed as described in Methods. Data are 
reported as percent uptake of particles relative to the uptake of particles by RAW 
264.7 cells cultured in medium. Data are expressed as the mean ± SEM of three 
independent experiments. * indicates significant reduction in uptake compared to 
vehicle control at p < 0.05. 
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Figure 3. Effect of caveolae and clathrin mediated endocytosis inhibitors on the 
internalization of polyanhydride micro- (open bar) and nanoparticles (closed bar) by 
macrophages. Cells were preincubated with the specific inhibitors for 45 min, 
followed by 45 min exposure to micro- or nanoparticles in the presence of inhibitors 
genistein, methyl β cyclodextrin (MβCD) and chlorpromazine (CPZ) then harvested 
and analyzed as described in Methods. Data are reported as percent of cells that 
have internalized particles relative to cells treated with medium alone. Data are 
expressed as the mean ± SEM of three independent experiments. * indicates 
significant (p < 0.05) reduction in uptake compared to vehicle control. 
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Figure 4. Lysosomal colocalization analysis of micro- (A) and nanoparticles (B). 
Cells were incubated with particles for 24 h, fixed, stained for LAMP-2, and analyzed 
by MIFC. Data are expressed as the mean ± SEM of three independent experiments. 
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Figure 5. Killing of intracellular Brucella abortus 2308 is enhanced by using 
nanoparticles loaded with antibiotic. THP-1 monocytes were infected with virulent B. 
abortus 2308 to establish a productive intracellular infection. At 24 h, infected 
cultures were supplemented with 10 µg/mL of either soluble doxycycline or 
encapsulated into polyanhydride particles. Following additional 48 h incubation, non-
treated and drug treated cells were washed and lysed to release intracellular 
bacteria. The lysate was subsequently serially diluted and plated on solid agar 
medium. Mean counts of bacteria for untreated cells were 1.8 x 106 CFU/mL. Data 
are representative of three independent experiments. * indicates significant 
reduction in bacterial CFU compared to monocyte cultures treated with soluble 
doxycycline at p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
so
lub
le 
do
xy
20
:80
 C
PH
:S
A
50
:50
 C
PH
SA
20
:80
 C
PT
EG
:C
PH
50
:50
 C
PT
EG
:C
PH
0
2000
4000
6000
C
FU
/m
L
* *
 78 
 
 
 
SI Figure 1. Size distribution of: (A) and (E) 20:80 CPH:SA, (B) and (F) 50:50 
CPH:SA, (C) and (G) 20:80 CPTEG:CPH, and (D) and (H) 50:50 CPTEG:CPH 
microparticles and nanoparticles, respectively. For microparticles, distribution curves 
were obtained from analysis of representative scanning electron microphotographs 
using ImageJ software. Quasi-elastic light scattering was utilized to obtained size 
distribution curves of nanoparticles. Data presented is representative of five 
independent experiments.  
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Functionalization of Polyanhydride Microparticles 
Influences their Uptake and Intracellular Fate in Dendritic 
Cells 
 
 
 
 
 
 
 
Yashdeep Phanse1, Brenda R. Carrillo-Conde2, Amanda E. Ramer-Tait1, Rajarshi 
Roychoudhuri 3, Nicola L.B. Pohl3, Balaji Narasimhan2*, Michael J. Wannemuehler1*, 
and Bryan H. Bellaire1* 
 
 
 
 
 
 
 
1Department of Veterinary Microbiology and Preventive Medicine, Iowa State 
University, Ames 
2Department of Chemical and Biological Engineering, Iowa State University, Ames 
3Department of Chemistry, Iowa State University, Ames, IA, 50011 
 
 
 
Manuscript to be submitted to Acta Biomaterialia 
 
 
 
 
*To whom correspondence should be addressed 
E-mail: bbella@iastate.edu; Phone: (515) 294-1006, mjwannem@iastate.edu; 
Phone: (515) 294-3534 and nbalaji@iastate.edu; Phone: (515) 294-8019  
 
 
 80 
Abstract 
A critical need exists to design protective, single dose vaccines. 
Polyanhydride microparticles are promising vaccine delivery vehicles due to their 
ability to stabilize antigens, provide tailored release kinetics, and adjuvant properties. 
A major obstacle with the use of microparticle-based vaccines is the less than 
optimal uptake by dendritic cells (DCs). In this study, we have functionalized the 
microparticle surface with di-mannose in order to target C-type lectin receptors 
(CLRs), such as mannose receptor (MR), CIRE, and/or Dectin-1 on DCs. 
Coincubation of di-mannose-modified microparticles upregulated the expression of 
CLRs (e.g., CIRE and MR) on DCs. More critically, di-mannose modification 
increased the uptake of microparticles by 10-20 fold. Both di-mannose-functionalized 
and non-functionalized particles trafficked to lysosomes. The combination of 
lysosomal localization and enhanced uptake of di-mannose modified microparticles 
increased the likelihood that more APCs would be available to present antigen via 
MHC II to CD4+ T cells following in vivo administration of these particles. Together, 
these studies demonstrate that employing rational vaccine design principles, such as 
the use of modifications that target CLRs on APCs, can enhance delivery of 
encapsulated antigens and potentially induce a more robust adaptive immune 
response. 
 
Keywords: polyanhydride, microparticles, C-type lectin receptors, uptake, targeted 
vaccines, di-mannose 
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Introduction 
Vaccines have played a critical role in improving public health in the last 
century. Traditional vaccine strategies, including killed or live attenuated organisms 
and subunit fragments or recombinant proteins have proven to be successful in 
prevention of multiple diseases [1]. However, their high reactogenicity, multiple 
immunizations, and/or parenteral administration made researchers seek alternative 
strategies. In this regard, the use of novel biomaterials as vaccine delivery platforms 
has emerged as a rational alternative to address the above mentioned concerns [2, 
3]. Microparticles composed of biomaterials offer several advantages over traditional 
vaccines. They can be formulated to tailor the release of the encapsulated 
immunogens over time providing antigen persistence, which in turn allows for 
developing single dose vaccines. The encapsulated protein is protected from 
degradation that allows for using lower antigen doses. Microparticles comprised of 
polyanhydrides possess the above mentioned qualities and are also 
immunomodulatory [4-9].  
One of the challenges in microparticle vaccine development is to efficiently 
target antigen-presenting cells (APCs) such as dendritic cells (DCs) where the 
encapsulated antigen can be released, degraded and presented via major 
histocompatibility complex molecules (MHC). Increasing the number of APCs that 
internalize the antigen-loaded microparticles would increase the presentation of 
antigen via MHC II to CD4+ T cells. 
C-type lectin receptors (CLRs) are a type of pattern recognition receptor 
(PRR) that recognizes pathogen-associated molecular patterns (PAMPs). 
 82 
Pathogens such as Yersinia pestis and Mycobacterium tuberculosis that display 
conserved carbohydrate structures on their cell surface like mannose are detected 
by CLRs [10, 11].  Previous studies have shown successful targeting of CLRs on 
APCs by functionalizing particles or antigen with mannoproteins [12], antibodies [13, 
14], or glycans [15]. For example, carbohydrate modification of a model antigen 
ovalbumin resulted in a 50-fold increase of antigen presentation to CD4+ T cells [14]. 
However, detailed studies on the effect of functionalization on uptake, intracellular 
trafficking, and persistence of microparticles were not reported.  
The aim of this study was to determine if surface modification of 
microparticles with linker or di-mannose could increase their cellular uptake through 
targeted interactions with cells, especially by C-type lectin receptors engagement of 
di-mannose particles. Polyanhydrides based on sebacic acid (SA), 1,6-bis (p-
carboxyphenoxy)hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane 
(CPTEG) were used in this study. The results showed that functionalization of 
microparticles with di-mannose markedly increased the number of DCs that had 
internalized microparticles. Further, functionalization did not alter the intracellular 
trafficking of microparticles as all of the microparticles trafficked to lysosomal 
compartments. However, the intracellular fate as measured by morphometric 
analysis showed that degradation of the linker functionalized microparticles was 
faster than non-functionalized or di-mannose functionalized particles. Lastly, the 
uptake of di-mannose functionalized microparticles was not dependent on mannose 
receptor mediated pathway. 
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Materials and Methods  
Materials 
Sebacic acid (99%), p-carboxy benzoic acid (99+%), and 1-methyl-2-
pyrrolidinone, anhydrous (99+%) were purchased from Aldrich (Milwaukee, WI); 4-p-
hydroxybenzoic acid, 1,6-dibromohexane, 1-methyl-2 pyrrolidinone, tri-ethylene 
glycol, and FITC-Dextran were purchased from Sigma Aldrich (St. Louis, MO); 4-p-
fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); potassium 
carbonate, dimethyl formamide, toluene, sulfuric acid, acetic acid, acetonitrile, acetic 
anhydride, methylene chloride, pentane, and petroleum ether were purchased from 
Fisher Scientific (Fairlawn, NJ). All the mentioned chemicals were utilized for 
monomer synthesis and polymerization, as well as for microparticle fabrication.  
 
Polymer synthesis and microparticle fabrication 
CPH and CPTEG monomers were synthesized in our laboratory as previously 
[16, 17] described. Copolymers containing 50:50 molar ratio of CPH:SA and 
CPTEG:CPH were synthesized by melt polycondensation as described [5] 
previously. The chemical structure was characterized with 1H NMR and the 
molecular mass was determined using gel permeation chromatography (GPC).  
Microparticles were fabricated out of 50:50 CPH:SA and 50:50 CPTEG:CPH 
copolymers by a cryogenic atomization procedure, as described elsewhere [17, 18]. 
Briefly, 100 mg of copolymer was dissolved in methylene chloride. For FITC-
Dextran-loaded microparticles, 1 mg of the fluorescence payload was added to the 
dissolved polymer and dispersed by sonication at 40 Hz for 30 s. Pumping of the 
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polymer solution was performed through an 8700-1200 MS ultrasonic atomizing 
nozzle (SonoTek Corporation, Milton, NY) into 200 mL of frozen ethanol (with an 
excess of liquid nitrogen). This procedure was performed at 4 ºC. After storage at -
80 ºC for 24 h, 200 mL of cold ethanol was added to reduce particle aggregation; the 
solutions were stirred at 300 rpm for 15 min and placed back in the freezer at -80 ºC 
for extra 48 h. After these three days, vacuum filtration was used to collect the 
microparticles and finally they were drying overnight under vacuum. Scanning 
electron microscopy (SEM) (JEOL 840 A, JEOL Peabody, MA) was used to observe 
the morphology of the microparticles. The particle size distribution was obtained 
from SEM images using ImageJ image analysis software (National Institutes of 
Health, Bethesda, MD). 
 
Microparticle functionalization and characterization 
Synthesis of carboxylated di-mannose was performed as previously 
described [19, 20]. Glycolic acid linker and di-mannose were conjugated on the 
surface of polyanhydride microparticles by a two-step amine-carboxylic acid coupling 
reaction [19, 20]. For the first step, microparticle suspensions (100 mg/mL) were 
incubated with 10 equivalents of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC), 12 equivalents of N-hydroxysuccinimide (NHS), and 10 
equivalents of ethylene diamine in distilled water. Reagents equivalents are related 
to the average concentration of carboxylic groups on the surface of the polymeric 
concentration; such as concentration was determined as 6.7 x 10-4 mmol COOH/mg 
of non-functionalized microparticles and was calculated by theoretical approach 
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using the end group quantification from 1H NMR spectra. The first reaction was 
carried out at 4 ºC for 9 h with end-over-end rotation. After completion of the first 
attachment reaction, particles were centrifuged at 10,000 rpm for 10 min and the 
supernatant was discarded. A wash step with cold distilled water was then 
performed in order to remove unreacted reagents. The second attachment reaction 
involved the incubation of microparticles with 12 eq. of EDC, 12 eq. of NHS and 10 
eq. of di-mannose or glycolic acid in distilled water, using constant end-over-end 
rotation for 9 h at 4 °C. After reaction completion, microparticles were collected by 
centrifugation (10,000 rpm, 10 min), washed twice with cold water and dried under 
vacuum for at least 2 h.  
SEM was utilized to analyze the morphology and size of functionalized and 
non-functionalized microparticles. Quasi-elastic light scattering (QELS, Zetasizer 
Nano, Malvern Instruments Ltd., Worchester, UK) was used to determine the ζ-
potential of non-functionalized and functionalized microparticles in order to 
determine successful surface modification. To determine the surface composition of 
functionalized and non-functionalized particles, X-ray photoelectron spectroscopy 
(XPS) (PHI 5500 Multi-technique system, Physical Electronics, Inc., Chanhassen, 
MN) was used. Deconvolution of high-resolution carbon peaks (C1s) using 
CasaXPS software (RBS Instruments, Bend, OR) was performed to identify the main 
carbon bound classes on microparticle surfaces. Finally, an optimized high 
throughput version of a phenol-sulfuric acid assay [19] was used to approximate the 
amount of sugar attached to microparticles.  
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Mice 
C57BL/6 mice were purchased from Harlan Sprague-Dawley (Indianapolis, 
IN) and mannose receptor deficient (MR -/-) B6 mice were a generous gift from Dr. 
Mary Ann McDowell of the University of Notre Dame. All animal procedures were 
conducted with the approval of the Iowa State University Institutional Animal Care 
and Use Committee. Mice were housed in pathogen-free conditions with bedding, 
feed, and caging sterilized prior to use. 
 
DC culture 
Bone marrow DCs were derived from tibia and femurs of C57BL/6 mice and 
cultured in vitro in the presence of murine granulocyte macrophage colony 
stimulating factor (GM-CSF) for 8 days [8]. At day 8, the harvested DCs were > 90% 
positive for CD11c and were transferred to 24-well plates in non-GM-CSF containing 
media.  
 
Uptake analysis 
To quantitate the percent of cells internalizing microparticles multispectral 
imaging flow cytometry (MIFC) was employed based on previously published 
protocol with minor modifications [21]. Briefly, Day 8 DCs were incubated with the 
1% FITC encapsulated non-functionalized or functionalized microparticles at 200 
µg/mL for 48 h at 37 C, 5% CO2. Following the incubation, DCs were harvested by 
gentle scraping and transferred into siliconized microcentrifuge tubes (Sigma). Cells 
were then washed and fixed in 4% paraformaldehyde in phosphate buffered saline 
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(PBS, pH 7.4). Sample acquisition was performed using ImagestreamX (Amnis 
corporation, Seattle) with 488 laser. Images were analysed using IDEAS 4.0 
software (Amnis Corp, Seattle).  
 
Fluorescence microscopy analysis 
To evaluate microparticle interaction with DCs, cells were pulsed with 200 
µg/mL 1% FITC encapsulated microparticles for 2 h [4, 22]. Cells were washed with 
PBS to remove non-adherent or loosely adherent microparticles and continued to be 
incubated for 46 h. Following the incubation cells were fixed with 4% PFA in PBS for 
10 min. To visualize if the microparticle traffic to lysosomal compartment, cells were 
stained with anti- lysosomal associated membrane protein (LAMP-1) antibody ID-4B 
(University of Iowa) for 1 h in PBS containing 0.1% saponin and 1% bovine serum 
albumin (BSP). Cells were then washed three times in BSP and incubated with anti-
mouse secondary antibody for 1 h. Coverslip containing stained cells were washed 
and mounted on glass slide using Pro-Long with DAPI (Molecular Probes, 
Invitrogen). Epifluorescence and confocal microscopy were performed using an 
inverted Olympus FluoviewTM 1000 laser scanning microscope. Intracellular 
trafficking analysis and final images were prepared using Image J v1.36b (NIH, 
Bethesda,MD) software. 
 
Flow cytometry analysis 
Flow cytometric analysis of surface molecule expression was performed as 
previously described [4]. Antibodies used included FITC mouse CD206 (MR, clone 
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MR5D3) and the isotype control antibody FITC rat IgG2a k (clone RTK2748) 
purchased from BioLegend (San Diego), and biotin anti-mouse CD209 (CIRE, clone 
5H10) purchased from eBioscience (San Diego, CA). Samples were acquired on a 
Beckton-Dickinson FACS Canto flow cytometer (San Jose, CA) and the data 
analyzed using FlowJo (TreeStar Inc., Ashland, OR). 
 
Statistical analysis 
The statistical software JMP 9 was used to analyze the internalization and cell 
surface marker data. One-way ANOVA and Tukey’s HSD were used to determine 
statistical significance among treatments and p < 0.05 was considered significant. 
 
Results 
Polymer Synthesis 
The purity of the copolymers was verified using 1H NMR, obtained spectra 
showed agreement between the molar feed ratio and the actual composition of the 
copolymer (data not shown). The CPH:SA copolymer had a Mw of 15,000 g/mol with 
a polydispersity index of 1.8 and CPTEG:CPH had a Mw of  8,000 g/mol with a PDI 
of 1.8. These values are consistent with previously published data [6]. 
 
Functionalization and Characterization of Microparticles 
Size of functionalized or non-functionalized particles was analyzed using 
scanning electron microscopy (SEM). The mean diameter of 50:50 CPH:SA and 
50:50 CPTEG:CPH were 8 ± 5 and 6 ± 4.5 µm respectively, which is consistent with 
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previous work. Functionalization did not affect the diameter of the particles (Table 1). 
Particle morphology was analyzed by SEM and both the chemistries regardless of 
functionalization had smooth surfaces (data not shown).  
Surface charge of particles as measured by ζ-potential was determined by 
QELS analysis. Non-functionalized 50:50 CPH:SA and 50:50 CPTEG:CPH had a net 
negatively charged surface with a ζ-potential of -23 and -20 mV, respectively (Table 
1). Functionalization of microparticles by linker [glycolic acid] or di-mannose resulted 
in a net positively charged surface with ζ-potential ranging from +20 mV to +33 mV, 
respectively (Table 1). No significant differences in ζ-potential were observed 
between linker and di-mannose modified particles. This change in ζ-potential is 
attributed to the presence of the diamine linker on the surface of the particles [19].  
Further characterization of particles by XPS revealed an increase in nitrogen 
to carbon (N/C) ratio on the surface of polyanhydride microparticles after 
functionalization. As the diamine linker contains two nitrogen groups per molecule, 
this data demonstrated the successful conjugation of the ethylenediamine linker to 
the microparticles (Table 2). Deconvolution of high-resolution C1s peaks into four 
main components based on their characteristic binding energies (aliphatic 
hydrocarbon at 285.0 eV (C1), ether and amine groups at 286.5 eV (C2), carbonyl 
and amide groups at 288.2 eV (C3), and ester and carboxylic acid groups at 289.1 
eV (C4)), was performed in order to corroborate the attachment of di-mannose or 
glycolic acid to the linker molecules on the surface of the polyanhydride 
microparticles (Table 3). An increase in the average percentage area of the C2 
component from non-functionalized to functionalized microparticles was observed for 
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both particle chemistries, this increment was higher for di-mannose functionalized 
particles. This increase (e.g., 13.6% for non-functionalized 50:50 CPH:SA to 22.1% 
for di-mannose functionalized 50:50 CPTEG:CPH) demonstrated the presence of 
both amine and ether groups on the surface of functionalized particles; while the 
increase in amine groups is directly related with the ethylenediamine linker used for 
sugar attachment, ether groups are characteristic mainly of carbohydrate structures.  
From this carbon peak fitting data, a decrease in the carboxylic acid content (C3 
component) from non-functionalized to functionalized microparticles is also observed 
(Table 3), which may corroborate the reduction of the free-carboxylic acid groups on 
the particle surface as a consequence of the binding with ethylenediamine linker 
molecules.  
The amount of di-mannose conjugation to particles was quantified by phenol-
sulfuric acid assay. Both 50:50 CPH:SA and 50:50 CPTEG:CPH showed similar 
levels of sugar density 10.1 to 12.1 µg/mg particles (Table 1). Further 
characterization of particles by XPS revealed an increase in nitrogen percent from 0 
to 10 after functionalization. As the diamine linker contains two nitrogens per 
molecule, this increase shows the successful conjugation of linker to the particles.  
 
Enhanced Internalization of Functionalized Microparticles by DCs 
 It has been observed that a low percentage of DCs internalize microparticle 
regardless of the polyanhydride chemistry employed (personal data). In order to 
evaluate if surface modification with either linker or di-mannose improves the ability 
of DCs to internalize functionalized microparticles, multi-spectral imaging flow 
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cytometry was utilized. This technique can differentiate between microparticles that 
are internalized (Figure 1C and 1D) versus those that are cell bound [21]. The effect 
of functionalization on the uptake of particles was chemistry dependent. For 50:50 
CPH:SA, functionalization, regardless of linker or di-mannose, increased the 
internalization of microparticles by 800 -1000% (10 to 17 %) compared to non-
functionalized group for which only 0.83% cells were positive for internalized non-
functionalized particles (Figure 1A). In contrast, only the di-mannose modification of 
50:50 CPTEG:CPH microparticles significantly improved the internalization of 
microparticles by DCs (Figure 1B). Linker functionalized 50:50 CPTEG:CPH 
microparticles had similar internalization levels (2.5%) as that observed for non-
functionalized microparticles (1.35%). Together, this data shows that surface 
functionalization of polyanhydride microparticles with di-mannose significantly 
improved their internalization by DCs.  
 
Intracellular fate of particles  
 Lysosomal localization of exogenous particles is important for antigen 
presentation of the associated antigen on MHC II [23, 24]. To evaluate if 
functionalization of particles change their intracellular localization within DCs, 
particles were co-incubated with DCs for 48 h and assessed for their localization 
within the lysosomal compartment by staining for lysosomal marker LAMP-1. 
Regardless of functionalization, 50:50 CPH:SA microparticles displayed a similar 
trafficking pattern where at 48 h, they were located within LAMP-1+ vesicles (Figure 
2A). 50:50 CPTEG:CPH linker and di-mannose modified microparticles also 
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trafficked to lysosomal compartments; however, for the non-functionalized particles, 
a minor portion were not co-localized to LAMP-1+ vesicles (Figure 2B). This is 
consistent with previous studies where a small fraction of 50:50 CPTEG:CPH 
nanoparticles are were observed to be outside of a lysosomal compartment [4].  
 
Persistence of particles 
 To evaluate the effects of surface modification on the degradation of the micro 
particles after internalization, their area distribution was evaluated at 48 h. The 
majority of non-functionalized or functionalized 50:50 CPH:SA microparticles were in 
the area range of 10-40 µm2 (Figure 3A). For the same chemistry, it was observed 
that linker modified microparticles presented with a second smaller peak in the sub-
micron region (Figure 3A). 50:50 CPTEG:CPH non-functionalized and di-mannose 
particles also followed a similar size distribution in the 10-40 µm2 area range. 
However, the microparticles functionalized with the linker alone showed a very 
different size profile with the majority in the sub-micron range suggesting more rapid 
degradation (Figure 3B). Together, this data indicate that polyanhydride 
microparticle degradation kinetics is affected by surface functionalization.  
 
DC activation 
Previous work has shown that di-mannose functionalized nanoparticles 
upregulated surface expression of C type lectin receptors such as mannose receptor 
(MR/CD206) and CIRE (CD209) in macrophages [19]. To evaluate if di-mannose 
microparticles also exhibit similar activation profiles in DCs, flow cytometry was used 
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to measure the expression levels of MR and CIRE. The results show that di-
mannose functionalization of 50:50 CPH:SA increased the surface expression of 
both MR and CIRE (Figure 4A and 4C); however, di-mannose modified 50:50 
CPTEG:CPH only increased MR expression (Figure 4B and 4D). DCs exposed to 
linker modified microparticles did not up-regulate MR compared to non-
functionalized particles indicating that upregulation is di-mannose dependent. DCs 
incubated with non-functionalized particles had similar levels expression of MR and 
CIRE compared to non-stimulated cells (data not shown). As previously reported, 
the addition of soluble di-mannose to the DC culture did not induce MR or CIRE 
expression suggesting the need for an ordered or structured presentation of di-
mannose that would cross link the MR [22].  
 
Enhanced uptake of di-mannose functionalized particles is not MR mediated. 
The internalization data presented in Figure 1 showed that di-mannose 
modification increased the uptake of both 50:50 CPH:SA and 50:50 CPTEG:CPH 
particles. Furthermore, di-mannose functionalization also increased the expression 
of MR on DC surface. To evaluate if these effects are due to internalization of di-
mannose functionalized particles by MR, DCs derived from MR deficient mice (MR-/-) 
were cultured and incubated with NF or di-mannose particles. Interestingly, no 
significant reduction in internalization of di-mannose modified particles of either 
chemistries in MR-/- DCs was observed compared to WT DCs (Figure 5). 
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Discussion 
Biodegradable microparticles have been evaluated extensively as vaccine 
delivery systems for the delivery of antigen or DNA [25-27]. The surface properties 
of the particles influence their interaction with DCs and in turn the resultant immune 
response. Several strategies including surface modification of particles have been 
studied to target the various receptors on DCs [28]. In this work, we describe a novel 
approach to enhance the internalization of microparticles by functionalizing their 
surface by a specific carbohydrate, di-mannose.  
Our data demonstrate an enhancement in uptake of microparticles as a result 
of functionalization that was chemistry dependent (Figure 1). Previous work has 
shown that cationic particles are internalized better [29-31] than negatively charged 
or neutral particles which provides an explanation for enhanced uptake of linker 
functionalized 50:50 CPH:SA microparticles. However, this increase was not 
observed in 50:50 CPTEG:CPH linker functionalized particles, although both of them 
possessed a net positive ζ-potential. This data indicate that positive charge may 
improve microparticle uptake but is not sufficient to enhance the internalization of 
particles. As hypothesized, di-mannose functionalization significantly improved the 
uptake of both CPH:SA and CPTEG:CPH particles compared to non-functionalized 
particles. Here too, a chemistry dependent effect was observed where di-mannose 
functionalized CPH:SA showed ≈20 fold increase compared to non-functionalized 
CPH:SA whereas di-mannose CPTEG:CPH had only ≈10 fold increase. These 
results are consistent with previous work where polyanhydride chemistry of the 
particles played a crucial role in internalization by APCs [32]. 
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Despite the enhanced level of internalization, the particles trafficked to 
(LAMP-1) lysosomal compartments at 48 h (Figure 2). This is an important finding, 
as efficient antigen presentation via the MHC II pathway is facilitated by trafficking of 
exogenous antigen to lysosomal vesicles that in turn fuse with the MHC II loading 
compartment [33-35]. As the intracellular fate of particles is dependent upon the 
mechanism by which they are taken up, lysosomal trafficking of all particles 
suggests that both non-functionalized and functionalized particles are internalized by 
similar uptake pathway. Additional experiments in our laboratory are underway to 
confirm the uptake mechanism by which functionalized particles are internalized by 
DCs. The combination of lysosomal localization and enhanced uptake of di-mannose 
functionalized particles increases the likelihood that more DCs would be available to 
present antigen via MHC II to CD4+ T cells following in vivo administration of these 
particles.  
The activity profile of DCs is influenced by the intracellaur fate (i.e., 
aggregation and degradation) of the internalized particles [4]. Previous work from 
this laboratory has shown that within a population of DCs there is evidence for 
simultaneous agglomeration and degradation of polyanhydride nanoparticles after 
internalization by DCs. To study the effect of functionalization on the fate of the 
particles, morphometric evaluation of particle size at 48 h was performed. As the 
initial size of all the particles was similar (Table 1) any change observed at 48 h can 
be attributed to differential rates of aggregation or degradation. In fact, we observed 
both agglomerated and degraded particles for all the particles groups. Non-
functionalized and di-mannose functionalized CPH:SA and CPTEG:CPH particles 
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had majority of particles in 10-40 µm2 size range (Figure 3C and 3D) indicating 
degradation. In contrast, linker functionalized particles had a major peak under the 
sub-micron range indicating much faster degradation rate compared to non-
functionalized or di-mannose functionalized microparticles. A possible explanation 
for this phenomenon can be the presense of linker particles in lysosomal 
compartments with higher pH. As the degradation of polyanhydride particles is base 
catalyzed, the presence of the linker on the surface of the microparticles would be 
expected to accelerate the particle degradation in a neutral or basic environment 
compared to acidic lysosomes. Futhermore, only few if any di-mannose 
functionalized particles were present in the sub-micron range indicating a slower 
degradation activity. The persistence of all the chemistries at 48 h may provide for 
sustained antigen release and continued stimulation to the DCs. This data also 
confirms that the particle surface plays a crucial role in that various aspects of 
particles-cell interactions are affected by a given modification . 
C-type lectin receptors such as MR and CIRE play a vital role in sensing 
pathogens, internalizing antigen and promoting DC migration [28, 31, 36, 37]. Given 
their important role in helping DCs orchestrate the immune response, the expression 
levels of MR and CIRE were evaluated. At 48 h, di-mannose functionalized CPH:SA 
particles significantly enhanced expression of CIRE as well as MR compared to NF 
or linker particles. However, di-mannose CPTEG:CPH particles increased 
expression of only MR and not CIRE. Several CLRs can be internalized and 
recycled back to plasma membrane based on activation status of DCs [38, 39]. 
Moreover, a positive self-regulation of CLRs as a result of ligand recognition has 
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been reported as well [20]. To assess if the di-mannose functionalized microparticles 
are internalized via interactions with MR, uptake studies utilizing DCs derived from 
MR-/- mice were performed. Surprisingly, no significant differences were observed in 
the uptake of di-mannose functionalized particles between MR-/- and wild type (WT) 
mice. This data suggests that di-mannose functionalized particles may be entering 
the cells by mechanisms independent of MR engagement..  
In summary, these studies indicate that functionalization of particles is an 
effective strategy in enhancing the internalization of microparticles. Functionalization 
of particles did not alter their intracellular trafficking to lysosomal compartment, a 
requirement for efficient antigen presentation on MHC II molecules. Moreover, 
differential degradation of functionalized particles may also allow for selecting the 
delivery vehicle rationally to get a faster (linker) or slower (di-mannose) release of 
antigen intracellularly. Collectively, this data indicate that microparticle 
functionalization is a viable strategy to enhance the delivery capabilities that in turn 
may allow for developing more effective vaccination regimen. 
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Figure 1. Functionalization of microparticles enhanced their internalization by 
dendritic cells (DCs). Cells were incubated with 1% FITC-dextran encapsulated 
nonfunctionalized  (NF) or functionalized (Linker or Di-mannose) microparticles for 
48 h, harvested and analyzed by multispectral imaging flow cytometry to determine 
percentage of cells internalizing (A) CPH:SA or (B) CPTEG:CPH particles. For each 
sample, 5000 events were collected. Representative images of cells that internalized 
(C) CPH:SA or (D) CPTEG:CPH particles. Data are expressed as the mean ± SEM 
of three independent experiments. Treatments with different letters are significantly 
different from one another at p < 0.05. 
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Figure 2. Intracellular localization of microparticles to lysosomes of dendritic cells 
(DCs) at 48 h post-incubation. Monolayers were incubated for with 1% FITC-loaded 
(A) CPH:SA or (B) CPTEG:CPH microparticles (MP, green) for 48 h, were stained 
with anti-LAMP-1 antibody (red). DAPI (blue) was used to stain the nucleus. 
Photomicrographs shown are representative of results obtained from three 
independent experiments.  
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A       B 
 
Figure 3. Morphometric analysis of microparticles at 48 h postincubation. Data points 
were ordered based on size (smallest to largest) on horizontal axis and percentage 
of total particles on the vertical axis. (A) CPH:SA or (B) CPTEG:CPH microparticles. 
Results were compiled from morphometric analysis performed on epifluorescent 
photomicrographs for each treatment group with five fields-of-view per treatment.  
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Figure 4. Di-mannose-functionalized microparticles enhanced dendritic cell (DC) 
expression of C-type lectin receptors (CLRs). DCs were stimulated with (A and C) 
CPH:SA or (B and D) CPTEG:CPH microparticles for 48 h, harvested and analyzed 
by flow cytometry for the surface expression of CIRE or Mannose Receptor (MR). 
Data are expressed as the mean ± SEM of four independent experiments performed 
in triplicate. Treatments with different letters are significantly different from one 
another at p < 0.05.  MFI = mean fluorescence intensity. 
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A       B 
 
 
Figure 5. Enhanced uptake of Di-mannose functionalized microparticles by dendritic 
cells (DCs) is not mediated by MR. Percent of wild type (open bar) and MR deficient 
(MR-/-, closed bar) DCs that internalized (A) CPH:SA or (B) CPTEG:CPH 
microparticles after 48 h. To determine the percent of cells internalizing non-
functionalized (NF) or functionalized (Linker and Di-mannose) microparticles, DCs 
were fixed and analyzed by multispectral imaging flow cytometry (ImageStreamX, 
Amnis Corp). For each sample, 5000 events were collected. Data are expressed as 
the mean ± SEM of three independent experiments.  
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List of Tables 
 
Table 1. Microparticle characterization. 
 
Chemistry Type *Average 
Particle 
Diameter 
(µm) 
**Average 
Particle ζ-
Potential 
(mV) 
***Sugar 
Density 
(µg/mg of 
particle) 
50:50 
CPH:SA 
NF 8 ± 5.0 -23 ± 2.5 ---- 
 Linker 10 ± 6.4 20 ± 2.7 ---- 
 Di-mannose 10 ± 5.5 33 ± 5.9 10.1 ± 3.5 
50:50 
CPTEG:CPH 
NF 6 ± 4.5 -20 ± 0.6 ---- 
 Linker 9 ± 4.0 21 ± 1.5 ---- 
 Di-mannose 9 ± 5.7 28 ± 3.2 12.1 ± 3.6 
 
Size and ζ-potential of non-functionalized (NF) and functionalized microparticles 
(Linker and Di-Mannose) were characterized by QELS. *Particle size determined by 
dynamic light scattering and data is presented as the mean value ± standard 
deviation (SD) of data collected in three independent experiments. ** data represent 
the mean value ± SD of three independent readings. ***Sugar density was 
determined by a phenol-sulfuric acid assay as described in M&M. Amount of sugar 
was determined relative to standard curves; data is presented as mean± SD of four 
independent experiments.  
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Table 2. X-ray photoelectron spectroscopy (XPS) analysis of atomic percentages 
and ratios of elements present on nonfunctionalized and functionalized 
microparticles. 
Chemistry Type % Ca % Na % Oa O/Cb N/Cb 
50:50 
CPH:SA 
NF 76.4 ± 0.5 0 ± 0.0 23.2 ± 2.0 0.310 0.000 
 Linker 74.2 ± 0.9 8 ± 2.5 18.1 ± 3.8 0.244 0.108 
 Di-mannose 74.6 ± 1.3 10 ± 3.4 15.3 ± 2.5 0.210 0.138 
50:50 
CPTEG:CPH 
NF 75.3 ± 1.1 0.3 ± 1.7 24.3 ± 1.5 0.320 0.039 
 Linker 74.2 ± 3.5 5.7 ± 2.4 18.9 ± 2.2 0.258 0.077 
 Di-mannose 72.2 ± 2.1 5.9 ± 4.7 21.6 ± 3.5 0.300 0.082 
 
aAtomic percentage data is reported as the mean ± standard deviation of four 
independent experiments performed in triplicate. bRatio of the two elements as 
indicated. 
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Table 3. Average percentage areas of aliphatic hydrocarbon (C1), ether and amine 
groups (C2), carbonyl and amide groups (C3), and ester and carboxylic acid groups 
(C4). Obtained from XPS high-resolution C1s fitted spectra. 
   
Chemistry Type C1 C2 C3 C4 
50:50 CPH:SA NF 
58.6 ± 3.2 13.6 ± 1.1  10 ± 3.2 2.3 ± 0.5 
 Linker 
59.3 ± 0.6 17.4 ± 2.4 7.6 ± 2.3 0.9 ± 0.8  
 Di-mannose 
59.0 ± 1.7 22.1 ± 2.9 5.6 ± 4.6 1.0 ± 0.2 
50:50 CPTEG:CPH NF 
59.1 ± 3.2 24.2 ± 2.2 8.9 ± 0.5 1.4 ± 0.3 
 Linker 
59.7 ± 1.5 26.4 ± 1.2 7.2 ± 1.4 0.1 ± 0.3 
 Di-mannose 
58.3 ± 2.2 27.5 ± 1.5 7.0 ± 2.5 0.4 ± 0.2 
 
Increased surface presence of ether, amine and hydroxyl groups corroborated 
microparticle functionalization. Data reported as mean ± standard deviation of four 
independent experiments performed in triplicate. 
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Abstract 
An imminent need exists to design improved adjuvants and vaccines to 
control emerging and re-emerging diseases. An ideal vaccine will mimic the way by 
which a naturally occurring infection induces a robust immune response yet avoids 
the undesirable effects of the disease. To accomplish this, new adjuvants must 
engage pattern recognition receptors on antigen presenting cells (APCs) such as 
dendritic cells (DCs). In this work, novel strategies are employed to enhance the 
adjuvanticity of polyanhydride nanoparticles composed of sebacic acid (SA) and 1,6-
bis(p-carboxyphenoxy) hexane (CPH), mixed in equimolar ratio (50:50 CPH:SA), by 
decorating their surfaces with either glycolic acid linker or di-mannose to confer 
“pathogen-like” properties co-incubation of linker-modified nanoparticles with DCs 
elicited significant increases in surface expression of MHC I, MHC II, CD86 and 
CD40and secretion of IL-6, IL-12p40, and TNFα. An 800% increase in uptake of 
linker and di-mannose modified polyanhydride nanoparticles was also observed. 
Together, our data show that DCs incubated with linker-functionalized polyanhydride 
nanoparticles demonstrated similar patterns of uptake, intracellular fate, persistence 
and activation, as did DCs exposed to pathogenic Y. pestis or E. coli. The innovative 
combination of polyanhydride nanoparticles and selected surface modification 
provides insight into the properties required for next-generation adjuvants to safely 
mimic the immune stimulating activities of bacterial pathogens. 
 
Keywords: polyanhydride, nanoparticles, pathogen-mimicking, uptake, targeted 
vaccines   
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Introduction 
Use of vaccines has had a profound impact on public health and medicine in 
the last 100 years. Traditional vaccines comprised of whole killed or live attenuated 
organisms took advantage, not by design, of the fact that pathogens possess 
various innate molecular signatures such as pathogen associated molecular patters 
(PAMPs) that are recognized by the innate immune response and enhances the 
host’s response to vaccination. However, these types of vaccines had several 
disadvantages such as the need for multiple immunizations, high reactogenicity, 
and/or reversion to virulence (1). Recent advances in immunology and 
biotechnology have allowed for development of subunit vaccines that provide a 
better safety profile than afforded by whole cell vaccines. However, the minimal 
immunogenicity of subunit antigens compared to traditional vaccines requires the 
use of adjuvants to stimulate innate immunity and, in turn, generate a robust 
adaptive immune response (2).   
Traditionally, adjuvants can be divided into two subclasses comprising 
immunostimulatory compounds and antigen delivery vehicles (3), both exclusive of 
each other. In this regard, it will be advantageous to design delivery agents which 
themself contain innate pathogen mimicking signatures thus avoiding use of any 
additional excipients. Although, multiple nanoparticle delivery systems have been 
evaluated as vaccine delivery systems, polyanhydride nanoparticles have emerged 
as excellent candidates due to their chemical properties which promote superior 
antigen stability, release kinetics and immune modulatory effects (4-8). 
Previously, we have identified similarities in specific molecular descriptors 
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between pathogens and biodegradable amphiphilic polyanhydrides indicating that 
polyanhydride particles have immune stimulatory properties (9). In this work, 
nanoparticles were functionalized with linker or di-mannose to enhance their 
pathogen-like molecular properties and target them to dendritic cells (DCs). A 
multidisciplinary approach that included cell biology, host-pathogen interactions, 
innate immune responses, biomaterials, and informatics analysis has provided a 
toolbox to delineate complex patterns observed during host-pathogen interactions 
and facilitated a direct comparison between nanoparticle and bacterial pathogens, Y. 
pestis and E. coli. These results demonstrate that functionalization improved the 
cellular internalization, enhanced activation of DCs, and made nanoparticles more 
pathogen-mimicking. Together, functionalization of nanoparticles is an attractive 
strategy to design the next generation adjuvants systems to combat emerging and 
re-emerging infections.  
 
Materials and Methods 
Materials 
Carboxylic diacid monomer synthesis required the use of 1, 6-dibromohexane 
(98.5%), 4-hydroxybenzoic acid (96%), 1-methyl-2-pyrrolidinone anhydrous (99.5%), 
triethylene glycol (99%) purchased from Sigma Aldrich (St. Louis, MO); 4-p-
fluorobenzonitrile (98%) purchased from Apollo Scientific (Stockport, Cheshire, 
England); and sodium hydroxide, sulfuric acid, acetonitrile, dimethyl formamide, 
toluene and potassium carbonate purchased from Fisher Scientific (Fairlawn, NJ). 
Sebacid acid anhydride was purchased from Sigma Aldrich (St. Louis, MO). 
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Chemicals needed for polymerization and nanoparticle fabrication include acetic 
anhydride, chloroform, petroleum ether, ethyl ether, methylene chloride, heptane 
and hexanes all of them were purchased from Fisher Scientific (Fairlawn, NJ). DC 
culture medium included RPMI 1640, HEPES buffer, L-glutamate, penicillin-
streptomycin, gentamycin acquired from Mediatech (Herndon, VA); heat inactivated 
fetal calf serum acquired from Atlanta Biologicals (Atlanta, GA); and GM-CSF 
acquired from PeproTech (Rocky Hill, NJ). Materials used in flow cytometry included 
fixative buffer (BD Bioscience); mouse serum; anti-mouse CD16/32 FccR purchased 
from eBioscience (San Diego, CA); β-mercaptoethanol and unlabeled rat 
immunoglobulin purchased from Sigma Aldrich; E. coli lipopolysaccharide (LPS) was 
acquired from Sigma Aldrich.  
 
Polymer Synthesis, Nanoparticle Fabrication, and Characterization 
CPH diacid, SA and CPH pre-polymers were synthesized as previously 
described (10). Synthesis of CPH:SA polymer with a 50:50 molar ratio was 
performed as previously published by Kipper et al (10). The obtained polymer was 
characterized by 1H nuclear magnetic resonance spectroscopy and gel permeation 
chromatography. Polymer properties evaluated were consistent within accepted 
ranges (10).   
An anti-solvent nanoprecipitation method adapted from Ulery et al was 
utilized to fabricate both FITC-dextran loaded and blank nanoparticles (11). 
Scanning electron microscopy (SEM, JEOL 840A, JEOL Ltd., Tokyo, Japan) was 
used to observe particle morphology, which showed a consistent spherical shape. 
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Quasi-elastic light scattering (QELS, Zetasizer Nano, Malvern Instruments Ltd., 
Worchester, U.K.) was employed to determine the average particle diameter and 
zeta potential of the fabricated particles. Finally, nanoparticles were tested for 
endotoxin levels using a Limulus Amebocyte Lysate (LAL) QCL-1000 test kit 
(Cambrex, Walkersville, MD) indicating that all the tested formulations were 
endotoxin free.  
 
Nanoparticle Functionalization and characterization 
Carboxylated di-mannose was synthesized as previously described (13). 
FITC-loaded or blank 50:50 CPH:SA nanoparticles were surface functionalized 
following a two-steps carbodiimide coupling reaction. Reaction conditions to 
complete these amine-carboxylic acid reactions were adjusted from previously 
described protocols in order to achieve sugar conjugation while maintaining 
nanoparticle morphology (13). Briefly, after activation of available carboxylic acid on 
nanoparticles by the addition of 10 equivalents (eq.) of 1-ethyl-3- (3-
dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and 12 eq. of N-
hydroxysuccinimide (NHS), ethylene diamine (10 eq.) was conjugated to the surface. 
After 9h of incubation at 4°C with end-over-end rotation, particles were washed with 
cold distilled water and collected by centrifugation at 10,000 rpm for 10 min. 
Ethylene diamine-modified particles were incubated with 12 eq. of EDC, 12 eq. of 
NHS, and 10 eq. of either di-mannose or glycolic acid (linker control for covalently 
attachment) for 9h at 4°C for the second reaction. After washing twice, particles 
were collected by centrifugation and dried under vacuum.  
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After functionalization, nanoparticle morphology and size were analyzed by 
SEM and QELS, respectively. QELS was also utilized to evaluate changes in ζ-
potential. X-ray photoelectron spectroscopy (XPS, PHI 5500 Multi-technique system, 
Physical Electronics, Inc., Chanhassen, MN) was used to evaluate surface 
composition of non-functionalized and functionalized nanoparticles. A high 
throughput phenol-sulfuric acid assay was applied for sugar identification on 
nanoparticle surface (13).  
 
Mice 
C57BL/6 mice were purchased from Harlan Sprague-Dawley (Indianapolis, 
IN). All animal procedures were conducted with the approval of the Iowa State 
University Institutional Animal Care and Use Committee. Mice were housed in 
pathogen-free conditions with bedding, feed and caging sterilized prior to use. 
 
Dendritic Cell Culture 
Bone marrow was obtained from tibia and femurs of C57BL/6 mice and 
cultured in vitro in the presence of murine granulocyte macrophage colony 
stimulating factor (GM-CSF) for 8 days to generate bone marrow derived dendritic 
cells (DCs) (7). At day 8 of culture, the cells were > 90% positive for CD11c and 
were transferred to 24-well plates in non-GM-CSF containing media. 
Internalization of polyanhydride nanoparticles  
To quantify the percent of cells internalizing nanoparticles, multispectral 
imaging flow cytometry (MIFC) was employed as previously described with minor 
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modifications (12). Briefly, in vitro derived DCs were harvested on day 8 and were 
incubated with the 1% FITC-dextran encapsulated non-functionalized or 
functionalized 50:50 CPH:SA nanoparticles at 200 µg/mL or green fluorescent 
protein (GFP)-expressing E. coli HB101 or Y. pestis ∆pgm at a multiplicity of 
infection (MOI) of 100 for 48 h at 37°C in an atmosphere of 5% CO2. Following the 
incubation, cultures were harvested and transferred into siliconized microcentrifuge 
tubes (Sigma). Cells were then washed and fixed in 4% paraformaldehyde in 
phosphate buffered saline (PBS, pH 7.4). Sample acquisition was performed using 
ImagestreamX (Amnis corporation, Seattle) with 488 laser. Images were analysed 
using IDEAS 4.0 software (Amnis corp, Seattle). 
 
Intracellular Colocalization and Morphometry 
To evaluate the intracellular trafficking of nanoparticle within DCs, cells were 
pulsed with 200 µg/mL 1% FITC-dextran loaded 50:50 CPH:SA nanoparticles or live 
GFP-expressing E. coli HB101 or Y. pestis ∆pgm at MOI 100 for 2 h (11, 13). Cells 
were washed with PBS to remove non-adherent or loosely adherent nanoparticles or 
bacteria and incubation continued for 46 h. Following the incubation period, cells 
were washed with phosphate buffered saline and then fixed with 4% PFA in PBS for 
10 min. To visualize the intracellular localization of the nanoparticles of bacteria, 
cells were stained with anti-lysosomal associated membrane protein antibody ID-4B 
(University of Iowa) or calnexin for 1 h in PBS containing 0.1% saponin and 1% 
bovine serum albumin (BSP). Cells were then washed three times in BSP and 
incubated with anti-mouse secondary antibody for 1 h. Coverslips containing stained 
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cells were washed and mounted on glass slides using Pro-Long with DAPI 
(Molecular Probes, Invitrogen). Epifluorescence and confocal microscopy were 
performed using an inverted Olympus FluoviewTM 1000 laser-scanning microscope. 
Intracellular trafficking analysis and final images were prepared using Image J 
v1.36b software (NIH, Bethesda,MD). 
 
Cell Activation Analysis 
Flow cytometric analysis of surface molecule expression was performed as 
previously described (14). DCs were stimulated and assessed for cell surface 
markers with 125 µg/mL of 50:50 CPH:SA nanoparticles or 200 ng/mL of LPS. 
Antibodies and staining protocols used to measure the expression of MHC I, MHC II, 
CD86 and CD40 were described previously (13). Samples were acquired on a 
Beckton-Dickinson FACS Canto flow cytometer (San Jose, CA) and the data 
analyzed utilizing FlowJo (TreeStar Inc., Ashland, OR). 
 
Cytokine Secretion Assessment 
Supernatants were collected after incubation of DCs with non-functionalized 
or functionalized nanoparticles and assayed for IL-10, TNF-α, IL-6, and IL-12p40 
using multiplex cytokine assays in conjunction with a Luminex 100 System 
(Flowmetrics, Austin, TX). 
 
Informatics Analysis 
Principle component analysis (PCA) operates on the equation of: X = T*PT, 
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where X is the input data matrix, T is the scores matrix, and P is the loadings matrix. 
The loadings define the new axes as a linear combination of the descriptors of X, 
and T is the axial values of the original data in this new dimensional space. Based 
on ranking the eigenvalues associated with P, a limited number of descriptors are 
sufficient. Three different PCAs were performed: one with input data based on 
intracellular fate, another with data based on DC activation, and a final data set 
based on internalization. The criterion for selection of axis representing the data set 
is that a majority of the variance in the data was captured. One axis was selected 
from each PCA, and using these axes a mapping system for similarity between 
conditions was developed. 
 
Statistical Analysis 
The statistical software JMP 9 was used to analyze the internalization, 
average intracellular area occupied by nanoparticles, cell surface marker, and 
cytokines secretion data. One-way ANOVA and Tukey’s HSD were used to 
determine statistical significance among treatments and p < 0.05 was considered 
significant.  
 
Results  
Functionalization and characterization of nanoparticles 
As reported in Table 1, the average size and zeta potential of the non-
functionalized (NF) 50:50 CPH:SA was 248 ± 45 nm and -20 ± 3.5 mV, respectively. 
A slight increase in the average diameter of linker and di-mannose functionalized 
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particles was observed (i.e., 289 ± 18 nm and 302 ± 38 nm). Moreover, 
functionalization of particles with linker (i.e., glycolic acid) or di-mannose resulted in 
a net positively charged surface with ζ-potential ranging from +20 mV to +33 mV, 
respectively (Table 1). The presence of free amine groups, from the diamine linker, 
derived from the incomplete surface coverage with di-mannoside or glycolic acid 
groups may be responsible for the observed positive surface charge after 
functionalization.   
The increase on surface nitrogen content after nanoparticle functionalization 
was corroborated with the analysis of surface elemental atomic percentages by 
XPS. A significant increase in the nitrogen to carbon (N/C) ratio (i.e., from zero in NF 
particles to more than 0.07 in functionalized particles) was obtained (Table 2). The 
resulted increase of nitrogen content on nanoparticles provide pathogen-like 
properties to 50:50 CPH:SA nanoparticles since high content amine-containing 
compounds have been identified as main constituents of the outer surface of some 
bacteria pathogens (15).  
 
 Enhanced uptake of Linker and Di-mannose functionalized nanoparticles by DCs 
Internalization of pathogens by DCs is an important step for presentation of 
antigens and activation of the immune machinery. Similarly, vaccine delivery 
vehicles should also be internalized in order to efficiently deliver the antigen to APC. 
To evaluate the effect of functionalization on the uptake of nanoparticles, DCs were 
incubated with non-functionalized or functionalized 50:50 CPH:SA nanoparticles, E. 
coli or Y. pestis. Multispectral imaging flow cytometry was utilized to determine the 
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percentage of DCs that internalized nanoparticles or bacterial cells. An advantage of 
this technique over flow cytometry is that it can differentiate between particles which 
are attached to the exterior surface of the cell versus those that are internalized (12). 
The data in Figure 1 shows that functionalization of 50:50 CPH:SA nanoparticles 
resulted in a significant increase in the percentage of cells that internalized 
nanoparticles (~60%) compared to non-functionalized particles (~7%). No additional 
advantage of di-mannose modification was observed compared to linker 
functionalization, in terms of internalization. No significant differences were observed 
between functionalized nanoparticles and pathogens (i.e., E. coli and Y. pestis). The 
presented data support the hypothesis that functionalization of polyanhydride 
nanoparticles is a viable strategy to enhance their uptake by DCs. 
 
Trafficking of polyanhydride nanoparticles to lysosomal compartment  
For nanoparticle-based vaccines, intracellular trafficking of the particles 
directly influences antigen presentation by DCs. Moreover, co-existence of danger 
signals and antigen within endo/lysosomal compartments helps antigen presenting 
cells (APCs) to differentiate between the level of threat posed by a pathogenic 
versus a harmless foreign body (16). Therefore, confocal microscopy was utilized to 
assess the intracellular localization of the 50:50 CPH:SA polyanhydride 
nanoparticles in the context of surface functionalization. Consistent with previous 
work, non-functionalized 50:50 CPH:SA nanoparticles trafficked to lysosomal 
compartments within 48 h after addition to the DC cultures (Figure 2) (9). Similarly, 
majority of linker and di-mannose functionalized nanoparticles that were internalized 
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were present within LAMP-1+ compartments. Unexpectedly, some of the linker 
functionalized particles were not localized to lysosomes and may be present within 
cytosol or other cell organelles (Figure 2). The trafficking patterns of 50:50 CPH:SA 
nanoparticles were similar to those observed for E. coli and Y. pestis since both the 
organisms were found with lysosomes. This data shows that nanoparticles are 
present in an optimal location of antigen release much like that by bacteria.  
 
Linker functionalized nanoparticles trafficked to endoplasmic reticulum (ER)  
Next, in order to determine the location of linker modified 50:50 CPH:SA 
nanoparticles that were not colocalized to lysosomes. Trafficking of particles to 
cytosol and ER may provide an opportunity for cross presentation of antigen via 
MHC I molecule (17-19). To assess ER localization of 50:50 CPH:SA nanoparticles, 
separate cultures of DCs were incubated with non-functionalized and linker 
functionalized nanoparticles and stained for calnexin, an ER specific protein. Indeed, 
a portion of linker modified 50:50 CPH:SA nanoparticles colocalized within 
membrane compartments positive for calnexin (Figure 3). None of the non-
functionalized particles colocalized within calnexin positive compartments.  
 
Influence of functionalization on intracellular fate of nanoparticles 
The intracellular fate of pathogens (i.e., degradation, agglomeration) inside 
APCs shapes resultant innate and adaptive immune response. In order to evaluate 
the effect of functionalization on the intracellular fate of 50:50 CPH:SA nanoparticles, 
we morphometrically compared the average area of non-functionalized and 
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functionalized particles at 48 h. Non-functionalized 50:50 CPH:SA nanoparticles 
were found to occupy the greatest average area within DCs (Figure 4). In contrast, 
linker functionalized nanoparticles had a lower area which was not statistically 
different from average area of E. coli and Y. pestis (Figure 4). 
 
Linker functionalized nanoparticles enhanced expression of DC activation markers 
Flow cytometry was utilized to evaluate the ability of functionalized 
nanoparticles to activate DCs. DCs stimulated with non-functionalized or di-mannose 
functionalized 50:50 CPH:SA nanoparticles failed to enhance the expression of MHC 
I  MHC II CD40 or CD86 over that observed for non-stimulated DCs (Figures 5A, 5B, 
5C and 5D). In contrast, linker functionalized particles significantly (p ≤ 0.05) 
increased surface expression of CD40, CD86, MHC I and MHC II on the surface of 
DCs. Moreover, as observed in Figure 5B, the enhancement of MHC II expression 
was greater than that induced by LPS. 
 
Linker functionalized particles enhanced pro-inflammatory cytokines secretion from 
DCs 
DCs stimulated with non-functionalized or di-mannose functionalized 50:50 
CPH:SA nanoparticles did not enhance the secretion of pro-inflammatory cytokines 
IL-12p40, TNF-α and IL-6 compared to non-stimulated DCs (Figures 6A, 6B and 
6C). Linker functionalized 50:50 CPH:SA nanoparticles significantly (p ≤ 0.05) 
increased the secretion of all three pro-inflammatory cytokines in comparison to non-
stimulated DCs. However, the cytokines levels were much lower than those obtained 
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after stimulation with LPS. IL-10 was not detected in the culture supernatants from 
any of the treatment groups (data not shown), consistent with previous work from 
our laboratory (20, 21).  
 
Informatics analysis identified that linker functionalized nanoparticles affected DCs in 
a fashion similar to bacteria.  
Informatics analysis was employed to quantitatively define similarity between 
particles and pathogens in terms of intracellular fate, DC activation and 
internalization. To accomplish this task, a dimensionality reduction technique and 
specifically principal component analysis (PCA) combined these different data types 
to map the relationships (Figure 7). A dimensionality reduction approach is needed 
because three different data measurements were included in the analysis and the 
ability to quantitatively identify trends associated across all three data was 
challenging due to the number of descriptors. By converting a high-dimensional and 
multi-type data set to three axes, the relationships between how DCs interact with 
the 50:50 CPH:SA nanoparticles and bacterial cells can be defined. 
Four systems were plotted in this reduced dimensional space: non-
functionalized (NF), di-mannose functionalized, linker functionalized, and pathogen.  
Similarity between systems is defined by proximity between points.  As the DC 
interactions with pathogen generated large positive values for each of the three 
axes, the objective is to identify nanoparticle groups that have increased PC values 
for all three axes.  Based on these criteria, the addition of either di-mannose or linker 
makes the 50:50 CPH:SA nanoparticles significantly more pathogen-like.  Moreover, 
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the attachment of the linker made the 50:50 CPH:SA behave more “pathogen-like” 
than the incorporation of di-mannose molecules.  
 
Discussion  
Designing next generation vaccines necessitates development of novel 
adjuvants that can deliver purified antigens to DCs as well as activate them. These 
agents should not only stimulate and sculpt the immune response in a manner 
similar to the natural infection but should be non-toxic and safe (1). In this work, we 
functionalized the surface of polyanhydride nanoparticles to assess their ability to 
enhance the activation of APCs.  
The internalization process in and of itself can deliver signals to the engulfing 
cell that can subsequently shape the resultant immune response (22). For example, 
ovalbumin (Ova) delivered via 560 nm liposomes is phagocytosed by macrophages 
and efficiently presented via MHC II, while delivery of Ova in 155 nm liposomes that 
are endocytosed, resulted in poor presentation (23). Moreover, the amount of 
antigen delivered to DCs is also dependent on the efficiency of internalization of the 
delivery vehicle. Therefore, the effect of functionalization on internalization of 50:50 
CPH:SA nanoparticles was evaluated. Consistent with previous work, imparting 
positive surface charge to the nanoparticles resulted in significant increase in 
percent of DCs internalizing linker functionalized 50:50 CPH:SA nanoparticles 
compared to non-functionalized control nanoparticles (Figure 1). This can be 
attributed to the interactions between positively charged linker molecules on the 
surface of the nanoparticles and the negatively charged cell membrane. Although, 
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di-mannose particles were similarly internalized compared to linker functionalized 
50:50 CPH:SA nanoparticles (Figure 1), the cell activation patterns were marked 
different between the two groups (Figure 5 and 6). A possible explanation could be 
that di-mannose residues are internalized by targeted binding to CLRs such as 
mannose receptors (24), present on DCs as opposed to electrostatic attractions. 
This targeting can be analogously compared to invasion strategies utilized by many 
pathogens to infect APCs, for example, Mycobacterium contains mannose residues 
on its surface that facilitates attachment with mannose receptors present on 
macrophage surface.  
Once the particle or pathogen is engulfed, the subcellular localization 
influences the fate of both the pathogen and the host cell. Further, for a particulate 
vaccine, reaching the optimal antigen processing compartments is important. Figure 
2, shows that similar to E. coli and Y. pestis, all non- functionalized and di-mannose 
functionalized particles localized to lysosomal compartments consistent with 
exogenous pathway of antigen uptake and processing. The majority of linker 
functionalized 50:50 CPH:SA nanoparticles also reached lysosomes, however, a 
minor but notable fraction did not localized with LAMP-1+ vesicles. Additional studies 
revealed ER localization of linker functionalized 50:50 CPH:SA nanoparticles 
showing their entry into the cross- presentation pathway (Figure 3). Whether some 
of the linker-modified nanoparticles entered cells by first reaching direct translocation 
through the plasma membrane or if they first reached endo/lysosomal compartments 
and then escaped is a question for future studies. Trafficking of linker functionalized 
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50:50 CPH:SA nanoparticles to ER and lysosomes may result in antigen processing 
and presentation via both MHC I and MHC II, respectively (25, 26).   
Studies have shown aggregation and degradation of pathogens after 
internalization by DCs (8). These dynamic interactions are a result of the replication, 
persistence, and death of bacteria inside DCs (9). As one of the parameters to 
compare the pathogen-mimicking characteristics of 50:50 CPH:SA nanoparticles 
with that of internalized E. coli or Y. pestis, aggregation and degradation 
characteristics were morphometrically compared by measuring the average particle 
area at 48 h. As shown in Figure 4, non-functionalized nanoparticles had the highest 
average area followed by di-mannose functionalized particles suggesting 
agglomeration of nanoparticles. On the other hand, average area of linker 
functionalized particles at 48 h, was much lower compared to other particle groups 
and was not statistically significant to E. coli and Y. pestis. This may be attributed to 
the higher degradation of linker functionalized particles as all the nanoparticle 
groups, non-functionalized or functionalized, had a similar size prior to the addition 
to the DC cultures (Table 1). Considering that the degradation of polyanhydride 
nanoparticles is base-catalyzed, trafficking of linker-functionalized nanoparticles to 
the ER, which has a higher pH than lysosomes, may accelerate particle degradation 
in the ER. 
To continue with the evaluation of the pathogen-mimicking properties of 
polyanhydride nanoparticles, the adjuvant properties of particles were measured by 
the expression of DC activation markers and the secretion of pro-inflammatory 
cytokines. Interestingly, linker functionalized 50:50 CPH:SA nanoparticles enhanced 
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the surface expression of molecules responsible for antigen presentation (i.e., MHC I 
and MHC II) compared to non-stimulated cells (Figures 5A and 5B). Moreover, 
increased expression of T cell costimulatory molecules CD40 and CD86, were also 
observed for DCs stimulated with the linker functionalized 50:50 CPH:SA 
nanoparticles(Figures 5 C and 5D). In contrast, non-functionalized and di-mannose 
functionalized particles did not enhance the expression of any surface marker 
studies. Along with surface expression of activation markers, the secretion of 
cytokines by DCs is also a required signal for a further robust T cell activation. In this 
sense, linker functionalization significantly increased the secretion of pro-
inflammatory cytokines such as IL-6, IL-12p40 and TNF-α as compared to non-
stimulated DCs (Figure 6). Levels of cytokines secreted from DCs stimulated with 
non-functionalized and di-mannose particles were comparable to that of non-
stimulated DCs.  
Finally, pathogenic properties measured by multiple experiments were directly 
compared with those exhibited by the three-nanoparticle formulations using 
informatics analysis. The generated 3-dimensional rendering of the multi-
dimensional dataset identified linker functionalized particles as the nanoparticle 
formulation that interacted with DCs in a manner that most closely resembled the 
interactions between DCs and the pathogens (Figure 7). The di-mannose 
functionalized 50:50 CPH:SA nanoparticles also positively affected DC activation but 
in a less robust manner. This evaluation has important implications in designing, 
engineering and screening adjuvant candidates that can provide the dual work of 
antigen delivering along with immunostimulation; an attribute that is not present in 
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the existing adjuvant and delivery systems. Together, these studies suggest that 
functionalization of nanoparticles have beneficial effects on the immunostimulatory 
potential of 50:50 CPH:SA nanoparticles providing insights that may be pivotal for 
the rational design of next generation vaccines. 
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Figure 1. Enhanced uptake of functionalized nanoparticles by dendritic cells. 
Dendritic cells (DCs) were co-incubated with 1% FITC-dextran encapsulated 
50:50 CPH:SA nanoparticles or green fluorescent protein (gfp) expressing live 
bacteria for 48 h. To determine the percent of cells internalizing non-
functionalized (NF) or functionalized (Linker and Di-mannose) nanoparticles or E. 
coli HB 101 or Y. pestis ∆pgm, DCs were fixed and analyzed by multispectral 
imaging flow cytometry (ImageStreamX, Amnis Corp). For each sample, 5000 
events were collected. Data are graphed as mean ± SEM of three independent 
experiments. Groups identified with different letters are statistically different 
between them with a significance of p < 0.05. 
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Figure 2. Trafficking of nanoparticles to the lysosomal compartment after 
internalization. Dendritic cells (DCs) were co-incubated with 1% FITC-dextran 
encapsulated 50:50 CPH:SA nanoparticles or green fluorescent protein (gfp) 
expressing live bacteria (E. coli HB 101 or Y. pestis ∆pgm) (shown in green) for 48 
h. Intracellular fate was analyzed via confocal microscopy by staining the DCs with 
an anti-lysosomal associated membrane protein-1 (LAMP-1) antibody shown in red. 
Photomicrographs shown are representative of results obtained from five 
independent experiments (scale bars = 5 µm). DAPI (blue) was used to stain the 
nucleus.  
  
 133 
 
 
 
Figure 3. Linker functionalized nanoparticles trafficked to endoplasmic reticulum 
(ER). Dendritic cells were incubated with 1 % FITC-dextran loaded nanoparticles 
and stained with anti-calnexin, an ER specific antibody, and visualized by confocal 
microscopy. Arrow indicates co-localization of particles and ER. (Scale bar=5 µm). 
Data are representative of two independent experiments. DAPI (blue) was used to 
stain the nucleus.  
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Figure 4. Linker functionalized nanoparticles occupy less intracellular area 48 h after 
internalization. Dendritic cells (DCs) were co-incubated with 1% FITC-dextran 
encapsulated 50:50 CPH:SA nanoparticles or green fluorescent protein (gfp) 
expressing live bacteria (E. coli HB 101 or Y. pestis ∆pgm) for 48 h. Results were 
compiled from a morphometric analysis performed on replicate, epifluorescent 
photomicrographs for each treatment group. All nanoparticles (NF, linker and Di-M) 
were of similar size at t=0 (See table 1). * and # represent groups that are 
significantly different (p< 0.05) from E. coli or Y. pestis, respectively. 
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Figure 5. Linker functionalized nanoparticles enhanced co-stimulatory marker 
expression. Dendritic cells were co-incubated with 125 µg/mL of non- functionalized 
(NF) or functionalized (Linker and Di-mannose) nanoparticles for 48 h. 
Lipopolysaccharide (LPS) (200 ng/mL) stimulated and medium only (Non Stim) cells 
were used as positive and negative controls respectively. DCs were harvested, and 
analyzed for (A) MHC I (B) MHC II (C) CD40 (D) CD86 via flow cytometry. Data are 
graphed as mean ± SEM of the mean fluorescent intensity (MFI). * and # represent 
groups that are significantly different (p< 0.05) from the non-stimulated or LPS 
treated DCs, respectively.  
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Figure 6. Linker functionalized nanoparticles enhanced pro-inflammatory cytokine 
secretion. Dendritic cells were co-incubated with 125 µg/mL of non functionalized 
(NF) or functionalized (Linker and Di-mannose) nanoparticles for 48 h. 
Lipopolysaccharide (LPS) (200 ng/mL) stimulated and medium only (Non Stim) cells 
were used as positive and negative controls respectively. Supernatants were 
collected at 48 h and evaluated for (A) IL-6 (B) IL-12p40 and (C) TNF-α using a 
multiplexed bead assay as described in M&. Data are presented as mean ± SEM of 
the concentration of each cytokine per mL of culture supernatant. * and # represent 
groups that are significantly different (p< 0.05) from the non-stimulated or LPS 
treated DCs, respectively.  
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Figure 7. Informatics analysis identified that linker functionalized nanoparticles are 
perceived by dendritic cells in a pathogen-mimicking manner. Principal component 
(PC) analysis was performed using specific molecular descriptors to define the 
relationship between pathogens and nanoparticle formulations.  
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List of Tables 
 
Table 1. Nanoparticle Characterization 
 
Chemistry Type 
Particle 
Diameter 
(nm) 
Particle ζ-
Potential 
(mV) 
Sugar Density** 
(µg/mg of 
particle) 
 NF 248 ± 45* -20 ± 3.5**  ---- 
50:50 CPH:SA Linker 289 ± 18 25 ± 2.7  ---- 
 Di-mannose 302 ± 38 31 ± 3.6  14.6 ± 2.5*** 
 
Size and ζ-potential of non-functionalized (NF) and functionalized nanoparticles 
(Linker and Di-Mannose) were characterized by QELS. *Particle size determined by 
dynamic light scattering and data is presented as the mean value ± standard 
deviation (SD) of data collected in three independent experiments. ** Data represent 
the mean value ± SD of three independent readings. ***Sugar density was 
determined by a phenol-sulfuric acid assay as described in M&M. Amount of sugar 
was determined relative to standard curves; data is presented as mean± SD of four 
independent experiments.  
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Table 2. X-ray photoelectron spectroscopy (XPS) analysis of atomic percentages 
and ratios of elements present on the surface of non-functionalized and 
functionalized 50:50 CPH:SA nanoparticles 
 
Chemistry Type % Ca % Na % Oa O/Cb N/Cb 
 NF 77.5 ± 1.7 0 ± 0.0 22.4 ± 2.3 0.289 0.000 
50:50 
CPH:SA Linker 69.6 ± 3.8 5.4 ± 1.4 23.8 ± 4.8 0.342 0.077 
 Di-mannose 76.5 ± 2.3 5.6 ± 0.5 21.3 ± 1.2 0.278 0.073 
 
aAtomic percentage data is reported as the mean ± standard deviation of four 
independent experiments performed in triplicate. bRatio of the two elements as 
indicated. 
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Abstract 
Innovative vaccine platforms are needed in order to develop effective single-
dose vaccines to control emerging and re-emerging infectious diseases. These 
platforms should be able to direct antigen internalization and promote immunogenic 
responses by antigen presenting cells, as well as prevent rapid degradation of 
antigen, all these in order to augment, modulate and extend immune responses. In 
this work, a transdisciplinary approach was utilized to evaluate vaccines against 
Yersinia pestis by combining two novel platforms, αGalactose-modification of the 
vaccine antigen (i.e., F1-V) and use of polyanhydride nanoparticles as vaccine 
delivery vehicles, which results in the induction of a robust immune response. 
Vaccine regime containing soluble αGal-F1-V and encapsulated F1-V induced a high 
titers, high avidity antibody response with broad epitope recognition of F1-V 
peptides. This formulation also enhanced proliferation of F1-V specific CD4+ T cells. 
By combining peptide arrays with informatics analysis, we have introduced a novel 
strategy in understanding antigen-antibody interactions, generating information that 
allows for the rational selection of antigen (i.e., αGal-modification)- and adjuvant (i.e., 
polyanhydride nanoparticles)-based platforms for the design of efficacious vaccines. 
 
 
 
 
 
Keywords: αGal modification, polyanhydride nanoparticles, epitope mapping, 
nanovaccine, Yersinia pestis, informatics 
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Introduction 
Yersinia pestis, the causative agent of pneumonic plague, is an antibiotic-
resistant organism1,2, that is easy to weaponize, and can significantly affect 
susceptible populations, making the development of an effective vaccine highly 
desirable3. A robust humoral response is critical for protection against Y. pestis; 
however, recent studies indicate that CD4+ T cells may also contribute to immunity 
against plague4-7. Previous studies have shown that immunization with the fusion 
protein, F1-V, provides protection in mice8 and cynomolgus macaques9; however, 
this antigen failed to produce sufficient levels of protection in African green monkeys 
and other non-human primates and in human trials10,11. Thus, rational design of 
vaccines that can enhance the humoral and cellular immunity in response to F1-V is 
a major need.  
Sustained exposure to antigen can be achieved by utilizing nanoparticle-
based platforms; indeed, several biodegradable polymers including polyesters12 and 
polyethers13, have been studied as vaccine delivery vehicles. However, these 
vehicles generally require the addition of exogenous immunostimulatory molecules, 
like Toll-like receptor agonists14, to induce an efficacious immune response. In 
contrast, polyanhydride particles possess intrinsic adjuvant properties and have 
demonstrated the ability to provide sustained release of protein antigens, to activate 
antigen presenting cells (APCs), and modulate immune responses15-26. Moreover, 
amphiphilic polyanhydride particles made of 1,6-bis(p-carboxyphenoxy)hexane 
(CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) were able to 
stabilize the F1-V antigen15 and a nanovaccine formulation based on this copolymer 
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induced long-lived protection (i.e., 23 months) against Y. pestis in mice26. Recent 
work also shows that CPTEG:CPH nanoparticles mimic characteristics attributed to 
pathogens (i.e., Y. pestis) in terms of cellular uptake, intracellular fate, and activation 
of immune responses without inducing toxicity or disease as would a pathogen27. 
These properties allow for designing safe and efficacious vaccines that can induce 
long-lived immune responses.  
It is well known that humans and old world monkeys lack α-1,3 galactosyl 
transferase (αGal) genes and the functional glycosylation enzyme responsible for 
attaching αGal residues on cell surfaces28,29. Thus, αGal residues are treated as 
foreign by the immune system and the constant exposure to αGal residues provided 
by the gut microbiota leads to secretion of anti-αGal antibodies, which represents 
1% of the total serum IgG30-35. These anti-αGal antibodies can be used to target 
αGal-modified antigen to dendritic cells (DCs). In addition, αGal modification has 
been shown to substantially increase the immunogenicity of proteins as diverse as 
bovine serum albumin (BSA)36, viral hemagglutinin37, and HIV gp12032.  In this work, 
we describe a novel antigen design strategy that exploits the naturally occurring anti- 
αGal immune response to enhance immunity of the F1-V antigen. The idea is that 
functionalizing antigen with αGal will lead to reduced antigen dose and more 
efficacious immunization protocols, resulting in cost-effective vaccines. 
Previous work in our laboratories has shown the necessity of delivering 
soluble antigen together with the encapsulated antigen to provide the initial 
stimulation of immune cells required to efficiently prime the immune system and 
induce a robust immune response26.  As soluble doses of protein can be rapidly 
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cleared from the body, we exploited the αGal technology to increase its recognition 
by the immune system via opsonization to maximize the potential to prime the 
immune system. Targeting Fcγ receptors (FcγR) present on a variety of APCs (i.e., 
DCs, Langerhans cells, and macrophages) is an effective mechanism by which 
APCs identify and internalize antigens in the form of antigen-antibody 
immunocomplexes to induce an effective immune response38.  
This study outlines a novel and rational approach to design a single-dose 
vaccine against Y. pestis by combining the polyanhydride nanoparticle-based 
platform with αGal-modified F1-V protein. It was hypothesized that the combination 
of these two approaches would result in a synergistic effect, augmenting and 
accelerating antigen-specific immunity leading to the development of a cost-effective 
vaccine that can reduce the need for multiple injections and result in greater patient 
compliance. Specifically, in this work, the F1-V antigen was modified with αGal 
epitopes and in order to mimic the relevant human immune characteristics to the 
αGal pathway, an α1,3GT gene knockout (KO) mouse model, which lacks αGal 
epitopes and can produce anti- αGal similarly to humans, was used to evaluate the 
magnitude and quality of the resultant immune response. Our results show that mice 
immunized with a vaccine formulation composed of soluble αGal F1-V and 
unmodified F1-V encapsulated in polyanhydride nanoparticles induced higher titer 
and higher avidity anti-F1-V antibodies along with a robust CD4+ T cell recall 
response. Moreover, the antibodies showed a broader pattern of reactivity to peptide 
epitopes of F1-V compared to antibodies derived from mice immunized with 
unmodified F1-V adjuvanted with monophosphoryl lipid-A (MPLA).  
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Materials and Methods 
Materials 
Chemicals needed for monomer synthesis and polymerization, as well as for 
nanoparticle fabrication, including sebacic acid (99%), p-carboxy benzoic acid 
(99+%), and 1-methyl-2-pyrrolidinone, anhydrous (99+%), were purchased from 
Aldrich (Milwaukee, WI); 4-p-hydroxybenzoic acid, 1,6-dibromohexane, 1-methyl-2 
pyrrolidinone, and tri-ethylene glycol were purchased from Sigma Aldrich (St. Louis, 
MO); 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); 
potassium carbonate, dimethyl formamide, toluene, sulfuric acid, acetic acid, 
acetonitrile, acetic anhydride, methylene chloride, pentane, and petroleum ether 
were purchased from Fisher Scientific (Fairlawn, NJ). Goat anti-mouse IgG (H+L)-
AP was purchased from Jackson ImmunoResearch (West Grove, PA). Phosphatase 
substrate was purchased from Aldrich (St Louis, MO). Polyacrylamide 4–20% Tris–
Glycine pre-cast gradient gels, unstained protein standards, pre-stained broad range 
molecular weight standards, and Flamingo Gel Stain were purchased from Bio-Rad 
Laboratories (Richmond CA). Bicinchoninic acid (BCA) and micro-BCA protein assay 
kits were obtained from Pierce Biotechnology Inc. (Rockford, IL). 
 
Antigenic Modification of F1-V 
Recombinant F1-V obtained from NIH Biodefense and Emerging Infections 
Research Resources Repository (BEI, Manassas, VA) was antigenically modified by 
chemical addition of αGal epitopes at lysine residues. Chemical addition of αGal 
epitopes to this vaccine antigen was performed at BioProtection Systems, Inc. 
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(Ames, IA) using an efficient chemo-enzymatic synthesis of the αGal trisaccharide 
and conjugation39. The modified F1-V was characterized by SDS-PAGE and western 
blot. αGal modified and unmodified F1-V were loaded on a 12% Tris-Glycine pre-
cast gels and run for 90 min at 100 V. 5 µL of protein standard was used a control. 
Gels were electroblotted to PVDF membrane for 1h at 120 V. Then, the membrane 
was blocked with 1% fish skin gelatin in TBST buffer overnight at 4 °C. The following 
day membranes were washed three times in TBST and incubated with αGal (+) sera 
from α1,3GT KO mice, which was obtained after three intraperitoneal injections with 
rabbit red blood cells to induce production of anti-αGal antibodies, diluted 1:1000 in 
TBST for 2 h. Membrane was then washed three times with TBST and incubated 
with alkaline phosphatase conjugated goat anti-mouse IgG diluted in TBST (1:1000) 
for 2 h. Bands were detected with SIGMA FAST Fast Red TR/Naphthol AS-MX 
Phosphate tablets (Sigma Aldrich, St. Louis, MO).  
 
Polymer Synthesis and Characterization 
Synthesis of 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG) diacids was performed as described 
previously 23. 1H NMR and gel permeation chromatography (GPC) were utilized to 
confirm polymer chemical structure and to measure molecular weight, respectively.  
 
Nanoparticle Fabrication and Characterization 
F1-V encapsulated nanoparticles were fabricated by the anti-solvent 
nanoencapsulation method reported previously 26,27. Nanoparticle recovery was 
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>70% and antigen encapsulation efficiency was >95%. Scanning electron 
microscopy (SEM, JEOL 840A, JEOL Ltd., Tokyo, Japan) and quasi-elastic light 
scattering (QELS, Zetasizer Nano, Malvern Instruments Ltd., Worchester, UK) were 
employed to investigate particle morphology and size, respectively.   
 
Mice 
The α1, 3GT gene knockout (KO) mouse model on Balb/c background was 
used to stimulate immunity to αGal and mimic human immunity to this epitope. Mice 
were obtained from BioProtection Systems, Inc. and housed under specific 
pathogen-free conditions where all bedding, caging, and feed were sterilized prior to 
use. All animal procedures were conducted with the approval of the Iowa State 
University Institutional Animal Care and Use Committee. An intraperitoneal injection 
regimen of rabbit red blood cells (RRBCs) was performed prior to immunization to 
induce production of anti-αGal antibodies. Animals received three injections of 
RRBCs (3 x 108 RRBCs/injection) at 14-day intervals. Seven days after the final 
RRBC injection, whole blood was collected from mice via the saphenous vein and 
serum was assessed for anti-αGal specific antibodies. Only mice whose sera 
showed optical density values (OD405) higher than 5x background (PBS) were used 
in the study and animals were distributed randomly across the different immunization 
groups.  
 
Vaccination regimen  
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Mice were vaccinated subcutaneously with the regimens described in Table 1 
by suspension in pyrogen-free saline in a volume of 100 µL. Nanoparticles were 
sonicated briefly to disperse clumps prior to immunization using a 26 gauge needle. 
Control animals received 100 µL of saline alone. An antigenic challenge of 5 µg of 
unmodified F1-V was subcutaneously administered to all mice 37 days after 
immunization. Blood samples were collected from the left saphenous vein prior to 
immunization and prior to antigenic challenge (pre-challenge) at day 36. Five days 
after boosting (at 42 days), mice were euthanized and serum was collected by 
cardiac puncture (post-challenge). Serum was collected by centrifugation and stored 
at -20°C and assayed for anti-F1-V specific antibodies. Experiment was performed 
three times with an average of 6-8 mice each time. 
 
Anti-F1-V and anti-LcrV ELISA Titer 
High protein binding 96-well Costar microtiter plates (Corning Life Sciences, 
Lowell, MA) were coated overnight with 100 µl of phosphate buffer saline (PBS) at a 
pH of 7.4 containing 0.5 µg/mL of F1-V or LcrV (BEI, Manassas, VA). PBS 
containing 0.05% Tween 20 (PBS-T) and 2% (w/v) gelatin as a non-specific blocking 
agent (BD Biosciences, San Jose, CA) was used to block plates for at least 2 h at 
room temperature. After the blocking period, plates were heated at 37 ºC for 10 min 
in a dry oven to melt the gelatin, and rinsed three times to remove any unbound 
blocking reagent. Sera samples were diluted 1:100, then serially diluted two-fold in 
PBS-T with 1% (v/v) normal goat serum (NGS), and incubated overnight at 4ºC. 
PBS-T was used to wash the plates three times followed by the addition of 100 µL of 
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PBS-T (1% (v/v) NGS) containing alkaline phosphatase (AP)-conjugated goat anti-
mouse IgG(H&L) at a 1:1000 dilution. After 2 h of incubation at room temperature, 
the plates were washed four times with PBS-T and 100 µL of sodium carbonate (50 
mM) and magnesium chloride (2 mM) buffer (carbonate buffer, pH 9.3) containing 1 
mg/mL of phosphatase substrate was added. The plates were allowed to react for 20 
min at room temperature. Optical density (OD) of each well was measured at 405 
nm using a Spectramax 190 Plate Reader (Molecular Devices, Sunnyvale, CA). 
Endpoint titers were defined as the highest dilution with an OD value of at least 0.2, 
which was at least three times the background OD value. 
 
Antibody Avidity Assay 
Antibody avidity analysis was performed as described previously 26,27. Briefly, 
ELISA plates were coated overnight with 0.5 µg/mL F1-V in PBS. Plates were 
washed with PBS-T and blocked for two hours with 2% gelatin in PBS-T. Serum 
samples were diluted 1:500 in 1% NGS-PBS-T and incubated overnight at 4ºC. 
Plates were washed with PBS-T and 5M NaSCN diluted in 0.1M NaH2PO4 buffer 
was added to the first column and two-fold serially diluted to 9.76 mM leaving two 
columns containing 0M NaSCN (i.e., only PBS-T). The NaSCN was incubated for 15 
min and the plates were washed five times with PBS-T. AP-conjugated goat anti-
mouse IgG (H&L) diluted 1:1000 in 1% NGS in PBS-T was incubated for 2 h. Plates 
were washed and phosphatase substrate (1 mg/mL) in carbonate buffer (pH 9.3) 
was added. Changes in OD were measured at 405 nm using a spectrophotometer. 
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Avidity index was defined as the concentration of NaSCN necessary to reduce the 
OD by 50% compared to the wells treated with 0.1 M sodium phosphate.  
 
In vitro CD4+ T cell proliferation assay 
Antigen specific recall responses were measured by a protocol previously 
described 40. Single cell suspension of the draining lymph nodes (brachial and axial) 
was made using a glass homogenizer. Cells were stained with carboxyfluorescein 
diacetate succinimidyl ester (CFSE) dye and plated onto a 96-well U bottom plate at 
a density of 2.5 x 105 cells per well and incubated at 37ºC, 5% CO2 for 4 days in 
CTCM. Cells were stimulated with 10 µg/mL F1-V. Cells incubated with medium and 
CD3/CD28 were used as negative and positive control, respectively. Following the 
incubation, cell were harvested, washed and stained with PE-Cy7 labeled anti-CD4 
antibody, fixed and acquired on a Becton-Dickinson FACSCantoTM flow cytometer 
(San Jose, CA). Data were analyzed using the FlowJo (TreeStar Inc., Ashland, OR). 
 
Statistical Analysis 
JMP® software (SAS Institute, Cary, NC) was used to make comparisons 
between the various vaccine regimens using Tukey’s HSD with logaritmic 
transformation and p-values < 0.05 were considered significant.  
 
Epitope Mapping by Peptide Arrays 
For analysis of the binding specificity of the produced immune sera to F1 or V 
antigenic peptides, an ELISA assay was performed following a similar protocol to the 
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one described previously. Two sets of overlapping peptides, one panel covering the 
full length of the F1 antigen (27 peptides) and the other covering the full length of the 
V antigen (53 peptides), were obtained from BEI. Immunlon 2HB 96-well plates were 
incubated with the peptides (5 µg/mL) and incubated overnight at 4ºC. Plates were 
blocked for 2 h at room temperature with 2.5% skim milk in PBS-T. Sera samples 
were incubated at 1:200 dilution overnight at 4ºC and after three washing steps with 
PBS-T AP-conjugated goat anti-mouse IgG(H&L) at a 1:1000 dilution was added. 
Plates were allowed to react for 2 h with the phosphatase substrate buffer described 
before and changes in OD were determined at 405 nm.  
 
Informatics Analysis 
Hierarchical Clustering  
Cluster analysis was implemented in order to identify the peptides in the 
antigen under the different treatment conditions that are significant to induce higher 
immune response than others and to compare the immunization groups under study. 
In this hierarchical clustering method, the similarity between observations is 
accessed according to the relative proximity in the data space. Starting from the 
separate data points in the parameter space, RN (N=10 for the comparison of 80 
peptides, and N=80 for 10 different immunization groups), the Euclidean distance, 
dE, is calculated to make clusters. That is, the distance in the N-dimensional space is 
calculated according to the following equation. 
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!! = x! − y! !!!!!  
The color coding of a heat map indicates the relative distance among the 
data, and the corresponding tree structure, which is referred to as a dendrogram, 
shows the hierarchical grouping. 
 
Principal Component Analysis (PCA) 
The objective of this work was to mathematically capture differences in 
properties between antigens as a function of vaccine regimen, using principal 
component analysis (PCA). PCA is a classification method, which projects the 
spatial data onto a set of principal components (PC) and maps the data on a 
dimensionally reduced space. PC1, the PC capturing the most information, is 
associated with the eigenvector corresponding with the largest eigenvalue of the 
covariance matrix of the original dataset. All PCs are orthogonal to each other, and 
thus each captures unique information. The advantage of PCA is that typically a few 
PCs are sufficient for describing a system, and a dataset of n-dimensions can be 
reduced to a few dimensions with minimal loss of information.  
The input into the analysis is the conditions (i.e. antigens and their 
treatments) versus responses. The data is then decomposed into two plots: the 
scores, which describes the conditions and the loadings which describes the 
responses.  In the result, PC1 is the direction capturing the most variance in the 
data, while PC2 is the direction capturing the most information while being 
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orthogonal to PC1.  Between PC1 and PC2, over 90% of the information in the data 
set is captured. The degree of correlation in the results is indicated by proximity; that 
is, two points with similar PC values are highly correlated while two points with 
different PC values are less correlated. Therefore, 5 µg F1-V and 2.5 µg 
encapsulated/ 2.5 µg free are similar under same modifications, while a-gal modified 
and unmodified were found to be different. Encapsulation in 50:50 CPTEG:CPH 
causes a difference in the samples, making them similar to the control. 
To compare similarity of conditions with the control, a line drawn through the 
control and the origin (0,0) describes direction of the control, while any distance off 
of this line is unrelated to the control (because the PCs are described to be 
independent of each other). The projection (perpendicular) of the various points onto 
this line describes similarity to the control. Based on these interpretations, 
encapsulation in 50:50 CPTEG:CPH is most control-like, followed by mixed 
encapsulation/free, and then F1-V. In all cases, the a-gal modification makes the 
antigen less like the control. The power in PCA in finding these “hidden” 
relationships is due to the ability to describe the data in a form, which reduces the 
inter-correlations within the data. 
!
Results 
F1-V was successfully conjugated with αGal residues. 
Western blot analysis was performed to corroborate the conjugation of αGal 
residues to F1-V antigen. Both αGal-modified and unmodified F1-V were evaluated 
by immunoblot analysis using anti-αGal serum. As can be seen in lane 3 (Figure S1) 
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the only bands observed were those that corresponded to the αGal-modified F1-V 
protein further confirming the successful attachment of αGal epitopes.  
 
Polymer and nanoparticle fabrication and characterization 
1H NMR and GPC results showed that the 50:50 CPTEG:CPH copolymer had 
an average Mn of 8,500 Da and a PDI of 1.70, consistent with previous work15,23. 
Scanning electron photomicrographs of F1-V and αGal-F1-V loaded 50:50 
CPTEG:CPH nanoparticles are shown in (data not shown). Particles showed similar 
spherical morphology and size (147 ± 23 nm for F1-V loaded particles versus 169 ± 
16 nm for αGal-F1-V loaded particles), which was consistent with QELS analysis and 
with particle morphology and sizes observed in previous studies 16,22,26.  
 
Soluble αGal-F1-V and F1-V encapsulated nanoparticles work synergistically to 
generate high titer, high avidity antibodies 
Protection against plague has been primarily attributed to antibody-mediated 
immunity 41-44. We hypothesized that vaccine formulations consisting of soluble and 
encapsulated protein will induce a high titer humoral response and so anti-F1-V 
antibody titers at day 36 (pre-challenge) and day 42 (post-challenge) were 
evaluated.  
Treatment regimen containing soluble αGal-F1-V and encapsulated 
unmodified F1-V (SαGal + Eunmod) elicited a robust antibody response and the pre-
challenge titers were comparable to MPLA control groups (Figure 1A). On the other 
hand, delivery of 100% of unmodified antigen encapsulated in 50:50 CPTEG:CPH 
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nanoparticles generated very low antibody titers (<1000). From this data, it is clear 
that the combination of encapsulated and soluble antigen is critical to the induction 
of high antibody titers after a primary immunization, which is consistent with previous 
published data 26. Following an antigenic challenge (i.e., booster injection), all the 
immunized groups, except the group immunized with the nanoparticles regimen 
encapsulating 100 % of the unmodified F1-V, responded robustly showing that they 
were well primed (Figure 1A).  
Since it has been previously shown that the LcrV protein (V antigen) is the 
causative agent of plague 8,45,46, ELISAs were carried out to determine if antibodies 
produced after immunization with the various vaccine regimens recognize the V 
antigen. Results shown in Figure SI.2 demonstrated that all the vaccine formulations 
evaluated induced similar levels of anti-LcrV antibodies with the exception of the 
100% unmodified F1-V encapsulated group (Eunmod).  
In addition to the quantitative humoral response, quality of antibodies also 
plays an important role in mounting a protective response against pathogens like Y. 
pestis 26 and Streptococcus pneumoniae 47. As a measure of antibody quality, 
antibody avidity was evaluated by using the chaotropic reagent sodium thiocyanate 
to disrupt antigen-antibody binding (see Materials and Methods). At day 36, prior to 
antigenic challenge, mice immunized with SαGal + Eunmod produce antibodies with 
high avidity that were comparable to the MPLA+SαGal control (Figure 1B).  
Following antigenic challenge, avidity of all the groups, except MPLA+SαGal, 
was significantly enhanced (Figure 2). Moreover, treatment groups containing αGal-
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F1-V alone or in conjunction with nanoparticles had significantly higher avidity 
compared to the 100% unmodified encapsulated formulation.  
 
Enhanced F1-V specific CD4+ T cell proliferation in vitro was obtained with soluble 
αGal F1-V in combination with encapsulated unmodified F1-V  
Although humoral immunity plays a major role in host immunity against 
plague, evidence suggests that CD4+ T cells might also play an important role 
6,7,48,49. Moreover, role of CD4+ T helper cells is clearly established for providing help 
at various stages of humoral immune response 50,51. To investigate if any of the 
tested vaccine formulations induced T helper cell response, in vitro antigen specific 
CD4+ T cell proliferation was evaluated as a measure of a memory T cell recall 
response. At the termination of the experiment, draining lymph nodes were 
collected, single cell suspensions were prepared and, stained with CFSE, and 
stimulated in vitro with F1-V for 4 days. Cells stimulated with medium alone or with a 
combination of anti-CD3 and anti-CD28 antibody were used as negative and positive 
controls, respectively. Stimulation indices obtained for cells recovered from mice 
immunized with SαGal + Eunmod demonstrated highest (SI = 4.23) antigen-specific 
proliferation in comparison to the cell harvested from other groups of mice (Figure 
2). CD4+ T cells from both groups of mice immunized with antigen adjuvanted with 
MPLA showed no significant increase in proliferation over saline control.  
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Antibodies elicited by SαGal + Eunmod formulation showed enhanced and broader F1-V 
peptide recognition as determined by epitope mapping 
Many pathogens evade immune system recognition and thereby clearance by 
eliciting antibody responses to their non-protective epitopes. To characterize the 
binding of the serum antibodies to epitopes of F1-V protein in more detail, we 
examined the binding of the induced antibodies to two separate panels of 
overlapping peptides that covered the full-length of the F1 antigen (27 peptides) or a 
second panel that covered the full length of the V antigen (53 peptides).  
Implementation of cluster analysis (i.e., hierarchical clustering) and principal 
component analysis (PCA) on the generated data matrix allowed for identification of 
immunodominant peptides (Figures 3A and 4B). Results reveled that out of the 27 
F1 peptides only the F1-1 peptide reacted with all of the serum samples from 
immunized mice. Consistent with previous findings, the preponderance of the anti-
F1-V response was directed against the V portion of the protein and, in particular, 6 
of the 53 V peptides (Figures 3A and 3B). Specifically, those immunodominant 
peptides were identified as F1-1, V-2, V-14, V-19, V-20, V-27 and V-44. After 
removing the immunodominant peptides from the data analysis, it was demonstrated 
that there was a widespread antibody recognition of multiple F1 and V peptides by 
the serum generated from mice immunized with the SαGal + Eunmod formulation 
(Figure 3C, lane 5). Serum samples from mice immunized with F1-V plus MPLA 
showed weak reactivity to the vast majority of these remaining F1-V peptides 
indicating that most of the antibodies were directed against the immunodominant 
epitopes. 
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The peptide region spanning amino acids 196-225 of LcrV has been shown to 
be protective in mice 47,48. Six of the V peptides utilized in the peptide array, V-32, V-
33, V-34, V-35, V-36 and V-37, fall in this region. In order to evaluate the antibody 
response in the protective region of the V protein, we determined the increase in 
antibody reactivity over saline controls for these six V peptides. SαGal + Eunmod 
formulation showed high recognition with a fold change of at least 1.5 for five (V-32, 
33, 35, 36 and 37) out of the six peptides (Figure 3D). MPLA + SαGal group reacted 
strongly only with the V-33 peptide, while MPLA + Sunmod group showed a fold 
change of at least 1.5 for two out of the six peptides. Interestingly, the 100% 
encapsulated group serum samples reacted with four of these V region peptides. 
  
Use of informatics analysis to identify optimal vaccine formulations 
In order to draw inferences about the optimal vaccine formulation, PCA was 
used to analyze the immune response data including the antibody responses, T cell 
proliferation, and peptide array data. The use of PCA enabled the simultaneous 
investigation of the relationships between the multiple variables of the vaccine 
regimens used in this study, including αGal modification of the F1-V, use of 50:50 
CPTEG:CPH nanoparticles versus MPLA, and amount of soluble versus 
encapsulated protein. The input into the analysis is the conditions (i.e., vaccine 
formulations) versus responses. The data is then decomposed into two plots: the 
scores (Figure SI.3), which describe the conditions, and the loadings (Figure 4), 
which describes the responses.   
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Figure 4 depicts the vaccine formulations as assessed by PCA. In this figure, the 
distance along the direction (i.e., down and to the right) of the red arrow indicates 
improvement in vaccine efficacy compared to the saline treatment. Groups that are 
circled together in blue showed higher similarities in response between them. The 
responses induced by the 100% encapsulated unmodified and the 100% soluble 
unmodified antigen (i.e., Eunmod and Sunmod) are both located closer to the saline 
control, which indicate that the weakest immune response was obtained after 
vaccination with these groups. Having SαGal as part of the vaccine formulation has 
the largest impact in change from the control group. Based on this analysis, the SαGal 
+ Eunmod formulation was the best vaccine candidate as it is located further away 
from the saline control.  
 
Discussion 
The efficacy of vaccines to induce protective immune responses relies on 
their ability to mimic the immune pathways initiated by natural infections, including 
signaling to the innate immune system 13,22. Directing antigen internalization and 
promoting immunogenic responses by APCs, as well as preventing rapid 
degradation of antigen are key steps to augment and extend immune stimulation 
13,52. The data presented herein demonstrated the success of using multi-disciplinary 
approaches to rationally design vaccines against Y. pestis by combining two 
platforms, αGal-modification of the vaccine antigen (i.e., F1-V) and polyanhydride 
nanoparticles as vaccine delivery vehicles, which results in the induction of a robust 
immune response. 
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Characterization by SDS-PAGE and western blot analysis demonstrated 
successful conjugation of αGal-residues to F1-V (Figure SI 1). The presence of high-
titer anti-αGal antibodies provides an endogenous opsonin for αGal-expressing 
antigens 29,37 that would trigger several mechanisms that facilitate antigen uptake 
and presentation by APCs, including complement activation and FcγR-mediated 
endocytosis 30,32,52. Subsequent antigen processing and presentation by APCs may 
lead to the induction of a potent and specific T cell immune response that would 
include TFH cells. Experimental testing of this hypothesis showed that vaccine 
regimens containing αGal-F1-V induced higher antibody production as indicated by 
antibody titers prior to boosting (Figure 1A).  
The efficacy of vaccine regimes that include both soluble and encapsulated 
F1-V to induce protection after intranasal administration has been previously 
demonstrated 26. Higher production of antibodies was especially achieved when 
soluble αGal-F1-V was delivered together with encapsulated F1-V (Figures 1A). 
These observations demonstrate the efficacy of having the αGal-modified antigen at 
the “front end” of the vaccine formulation, which can be related to an enhanced initial 
antigen uptake by APCs mediated via FcγRs and induction of a primary immune 
response that is αGal-dependent followed by an antigen-specific response provided 
by the continuous antigen exposure controlled by nanoparticle degradation. 
The production of antigen-specific antibodies with high avidity is also 
important for protection against plague 26,53. High antibody avidity is usually achieved 
by continuous antigen exposure and is associated with affinity maturation of B cells 
53. Antibodies with higher avidity were produced after immunization with vaccine 
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formulations containing soluble plus encapsulated antigen (Figure 1B). Previous 
work from our laboratories has shown that amphiphilic 50:50 CPTEG:CPH 
nanoparticles are internalized by APCs at a slower rate than hydrophobic 
nanoparticles 22,27. Moreover, the amphiphilic nanoparticles persist within the body 
after subcutaneous administration acting as a depot (data not shown), which when 
combined with the slow antigen release dictated by nanoparticle degradation, allows 
for extended presence of antigen resulting in more avid antibodies. 
Conservation of antigenic epitopes during vaccine delivery is an important 
aspect for generating a protective immune response. In this regard, the amphiphilic 
50:50 CPTEG:CPH polyanhydride particles are effective delivery vehicles that have 
shown to stabilize the F1-V antigen, maintaining its primary, secondary, and tertiary 
structure in vitro 15, which may translate into conservation of epitopes in vivo. In this 
regard, to the best of our knowledge, this is the first study describing an 
enhancement in epitope recognition by a polymeric nanoparticle vaccine over 
vaccine containing traditional adjuvants. Applying informatics analysis tools (i.e. PCA 
and hierarchical clustering analysis) to data obtained from peptide array of F1-V 
protein showed one F1 (F1-1) and six V immunodominant peptides. An amino acid 
region in the F1 antigen that has been related with protection in passive 
immunotherapy is located at the amine-terminal end of the F1 antigen 44. It is well 
known that the V antigen is an effector protein and some of its epitopes have been 
identified as responsible for the contact-dependent Type III secretion system during 
infection 11,45,48,54-56. LcrV region spanning amino acid 135-275 57 and more 
specifically 196-225 58 is critical in antibody mediated protection against plague. 
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Here, we demonstrate that the SαGal + Eunmod vaccine formulation elicited more avid 
antibodies which not only bind to the peptides encompassing the protective region 
but were also able to bind to a greater array of the remaining F1-V peptides thus 
showing an increased epitope spread compared to other vaccine regimen. In case of 
a bioterror attack, this broad-spectrum antibody response could be very beneficial 
for protection against mutant or weaponized Yersinia pestis. Previous work has 
shown that antigen-antibody complex modulates humoral response by multiple 
mechanisms such as, masking of dominant epitopes by antibodies, better germinal 
center response, induction of somatic hypermutations and change in antigen 
processing59. Further, change in T cell epitopes have shown to affect the diversity 
and the spectrum of the resultant antibody response59. Moreover, the combination of 
F1-V display on nanoparticles and F1-V immunocomplexes, may facilitate the 
engagement of multiple B cells with different BCR receptor specificities contributing 
to the diverse epitope recognition observed in this study. Being able to induce the 
production of antibodies with broad-epitope recognition could lead to more 
efficacious vaccines for the treatment of diseases such as influenza where the 
induction of antibody to conserved epitopes may prove beneficial against pathogens 
that constantly mutate epitopes to evade the immune response.  
The efficacy of informatics tools such as PCA and cluster analysis for the 
interpretation of the multiparametric dataset obtained after antibody and cellular 
analysis was corroborated as it allowed the identification of optimal vaccine 
candidates. The hidden relationships among attributes embedded in a multitude of 
experimental results, due mainly to its multi-dimensional nature, have been 
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unraveled by using multivariate clustering and dimensional reduction algorithms in a 
high-throughput manner. Together, this study provides a proof-of-concept of the 
synergistic benefits that emerged when two independent technologies (i.e. immune-
complex mediated uptake of αGal antigen and pathogen-mimicking nanoparticles) 
were combined to design a novel vaccine delivery platform. Moreover, using peptide 
arrays in combination with informatics tools, we have developed a toolbox that will 
aid in the elucidation of antigen-antibody interactions, generating information that 
allows for the rational tailoring of antigen with naturally occurring haptens (e.g., α-
Gal-modification) and use of novel delivery platforms that will enable the induction of 
high titer, high avidity, and antibody responses with a broader repertoire respective 
to antigenic epitope recognition. 
 A transdisciplinary approach that combined material science, protein 
chemistry, immunology, and computational analysis was applied to rationally design 
a vaccine regimen and analyze the resulting robust immune response. The most 
efficacious vaccine formulation combined two technologies, αGal-modification of the 
immunogen and amphiphilic polyanhydride nanoparticles as vaccine delivery 
vehicles and adjuvants. Immunizing mice with a regimen consisting of soluble αGal-
F1-V and encapsulated unmodified F1-V resulted in the induction of high titer and 
high avidity antibody responses that were characterized by the ability to recognize a 
broad array of antigenic epitopes. The αGal-modification of antigen and amphiphilic 
polyanhydride nanoparticles technologies can function in tandem to design 
efficacious vaccine platforms for a wide range of pathogens.  
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List of Figures 
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Figure 1. Soluble αGal-F1-V and F1-V encapsulated nanoparticles work 
synergistically to generate high titers and high avidity antibody. Serum was collected 
at prior to antigenic challenge on day 36 (open bar) or after an antigenic challenge 
(closed bar) at day 42 and evaluated for (A) F1-V specific antibody response via 
ELISA measuring IgG (H+L) or (B) relative avidity of IgG (H+L) antibodies to F1-V 
using sodium thiocyanate as the chaotropic agent. Data is compiled from four 
independent experiments each comprising of 6-10 mice/group/experiment. Data is 
presented as the mean ± SEM. Alphabets represent statistical comparison between 
groups pre-challenge (smaller case) or post-challenge (upper case). Groups 
identified with different letters are statistically significant (p ≤ 0.05) from each other!
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Figure 2. Enhanced F1-V specific CD4+ T cell proliferation in vitro was obtained with 
soluble αGal F1-V in combination with encapsulated unmodified F1-V. Antigen 
specific recall responses were measured on single cell suspension of the draining 
lymph nodes (brachial and axial) as described in materials and methods. Cells were 
stimulated with 10 µg/mL F1-V or PBS for 4 days. Data is presented as the mean 
stimulation index ± SEM and is compiled from two independent experiment each 
comprising 6-10 mice/group/experiment. Groups identified with different letters are 
statistically significant (p ≤ 0.05) from each other!
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Figure 3. Antibodies elicited by SαGal + Eunmod formulation showed enhanced and 
broader F1-V peptide recognition as determined by epitope mapping. Differential 
epitope-recognition by antibodies elicited during immunization with the various 
vaccine formulations. α1,3GT KO mice were immunized with vaccine regimes 
presented in Table 1 and boosted 37 days post-vaccination. Sera collected five days 
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after antigenic challenge was assayed for epitope recognition using a peptide array 
for both the F1- and V-antigens. (A) Heat map of the responses of the 80 peptides 
after hierarchical clustering analysis implementation, which allows for grouping of 
peptides that showed relatively higher response than others. (B) Principal 
component analysis (PCA) of peptide arrays corroborates as outliers the same set of 
peptides identified by clustering analysis. The plot maps out high dimensional 
correlations permitting identification of significant responder from the peptide array 
data. (C) Broader peptide recognition by specific vaccination groups is illustrated by 
a heat map containing responses of antibodies elicited by the different vaccination 
regimens to the set of peptides that were not identified as outliners by the clustering 
analysis. (D) The increase in antibody reactivity over saline controls was used to 
determine antibody response in the protective region of the V protein (represented 
by peptides V-32, V-33, V-34, V-35, V-36 and V-37). For (A) and (C), peptides which 
show higher immune response for specific immunization groups are presented with 
red, yellow, or light blue color and vaccination groups are represented by numbers 
identifying each of the columns for the heat map: 1) control, 2) Sunmod, 3) SαGal, 4) 
Eunmod, 5) SαGal+Eunmod, 6) Sunmod + MPLA, and 7) SαGal + MPLA. Data are the 
average measurements for three pooled serum samples per vaccination group 
(samples from three or four mice were pooled) 
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 Figure 4. Informatics analysis is used to identify optimal vaccine formulations. 
Principal component analysis biplot of various vaccine regimens. The plot maps out 
high dimensional correlations permitting one to track the relative influences of 
varying the vaccine formulation. The distance along the direction of the red arrow 
indicates improvement in vaccine efficacy and groups that are circled together in 
blue showed higher similarities in response between them.  
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SI Figure 1. Western blot analysis of the unmodified F1-V and αGal-F1-V antigens 
confirms attachment of αGal epitopes. For SDS-PAGE, 1 µg of F1-V (lane 2) and 
αGal-F1-V (lane 3) was loaded per lane and the gel was run at 100 V for 90 min. 
Protein standard was loaded in lane 1. Gel was blotted to PVDF membrane and 
developed using anti-αGal sera, membrane was stained with SIGMAFAST™ Fast 
Red TR/Naphthol AS-MX tablets (Sigma Aldrich, St. Louis, MO). 
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SI Figure 2. Anti-LcrV IgG (H+L) antibody titers. Titers were determined by end-point 
ELISA 42 days after secondary vaccination. Data is presented as the mean ± SEM 
compiled from four independent experiments. Groups identified with different letters 
are statistically significant (p ≤ 0.05) from each other. 
 
!
Sunmod 
Eunmod 
Sal 
Eal 
MPLA 
+- -- -- +
-- -+ ++ -
-- +- -+ -
-- -- -- -
-- -- +- +
0
20000
40000
60000
80000
A
A
B
B
B B
B
A
nt
i L
cr
V 
Ig
G
 (H
+L
) 
Post-challenge
! 175 
 
SI Figure 3. PCA plot of the scores, which describes the variables, such as antibody 
titer and avidity, T cell proliferation and epitope mapping data, utilized to draw 
inferences about optimal vaccine formulations.  
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Table 1. Vaccination regimens. 
Group 
# 
Experimental 
Group 
Soluble F1-V 
(µg) 
Soluble αGal-
F1-V (µg) 
Encapsulated 
F1-V  
(µg) 
1 Control-Saline ----- ----- ----- 
2 Sunmod  5 ----- ----- 
3 SαGal ----- 5 ----- 
4 Eunmod ----- ----- 5 
5 SαGal + Eunmod ----- 2.5 2.5 
6 MPLA + Sunmod 5 ----- ----- 
7 MPLA + SαGal ----- 5 ----- 
 
*Quantities indicate the amounts of immunogen or adjuvant delivered to each mouse 
in the indicated group. S = soluble antigen; E = encapsulated antigen. Subscripts 
indicate amount of soluble or encapsulated antigen (in µg) administered per dose. 
500 µg of 50:50 CPTEG:CPH nanoparticles and 10 µg  of MPLA were used in 
formulations containing nanoparticles and MPLA as adjuvants. 
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CHAPTER 6 
 
Conclusions 
 
Vaccines and antibiotics have had a profound impact on human and animal 
health in the last century. Despite their success, there are several disadvantages 
associated with current regimens, including multiple immunizations that result in 
poor patient compliance, high reactogenicity, unpleasant side effects, and poor 
efficacy against intracellular pathogens. In this regard, innovative delivery platforms 
can facilitate the development of effective single-dose treatment regimens to control 
emerging and re-emerging infectious diseases. The work presented in this 
dissertation describes how concepts from immunology, microbiology, informatics, 
and nanotechnology can be employed in the rational design of targeted 
polyanhydride platforms for drug and vaccine delivery. 
 The work presented in Chapter 2 sought to define the influence of 
physicochemical properties on the cellular interactions of polyanhydride particles in 
order to rationally select formulations optimal for drug delivery applications. 
Nanoparticles composed of 20:80 CPH:SA and 20:80 CPTEG:CPH were more 
readily internalized by antigen presenting cells (APCs) as compared to 50:50 
CPH:SA and 50:50 CPTEG:CPH nanoparticles and microparticles of any formulation 
tested. Actin-mediated uptake was found to be the primary means of entry of all 
polyanhydride micro- and nanoparticle formulations tested. Detailed studies further 
revealed a chemistry and size dependent effect on the mechanism(s) of 
internalization. Intracellular trafficking studies demonstrated that 50:50 CPTEG:CPH 
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micro-and nanoparticles were least likely to colocalize with lysosomes than any 
other chemistry tested. Based on this observation, we hypothesized that other 
nanoparticle formulations (specifically, those made of either 20:80 CPH:SA and 
20:80 CPTEG:CPH) and loaded with an antibiotic would be more effective for 
treating intracellular infections in which the pathogen resides in LAMP-1+ vesicles. 
Indeed, the two 20:80 doxycycline loaded particle formulations facilitated enhanced 
killing of the intracellular pathogen Brucella in an in vitro model than the two 50:50 
polyanhydride formulations. 
To rationally expand the versatility of the nanoparticle platform from drug to 
vaccine delivery, a multidisciplinary approach combining cell biology, immunology, 
biomaterials engineering, carbohydrate chemistry, and informatics analysis was 
used to make polyanhydride nanoparticles behave in a manner that mimics the 
ability of pathogens to induce a robust immune response. One such approach is 
detailed in Chapter 3, where the surface of microparticles was functionalized with a 
specific carbohydrate to facilitate active targeting to C-type lectin receptors (CLRs) 
on APCs. Specifically, di-mannose modification increased the uptake of 
microparticles by 10-20 fold without altering their intracellular trafficking pattern. This 
finding is significant, as the combination of lysosomal localization with the enhanced 
uptake of di-mannose modified particles may increase the number of APCs capable 
of presenting antigen via MHC II to CD4+ T cells following in vivo administration of 
these particles. 
 In Chapter 4, the insights gained from surface functionalization of 
polyahnydride microparticles were then used to enhance the adjuvanticity of 50:50 
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CPH:SA nanoparticles by decorating their surface with glycolic acid linker or di-
mannose to confer “pathogen-like” properties. Co-incubation of linker nanoparticles 
with DCs elicited significant increases in surface expression of antigen presentation 
and co-stimulatory molecules and secretion of pro-inflammatory cytokines. An 800% 
increase in uptake of linker and di-mannose nanoparticles was also observed 
(Figure 1). Together, our data show that DCs incubated with linker-functionalized 
nanoparticles demonstrated similar patterns of uptake, intracellular fate, persistence 
and activation, as did DCs exposed to pathogenic Yersinia pestis or Escherichia coli. 
These findings provide important mechanistic insight into the properties required for 
next-generation adjuvants to safely mimic the immune stimulating activities of 
bacterial pathogens. 
 In Chapter 5, in vivo studies were performed to evaluate the effect of vaccine 
antigen functionalization in combination with the polyanhydride nanoparticle 
platform. A nanoparticle-based, single-dose vaccine against Yersinia pestis was 
rationally designed to include a modification of the plague antigen F1-V with α-
galactose (αGal). Immunization of mice with soluble αGal-modified F1-V in 
combination with unmodified F1-V encapsulated into polyanhydride nanoparticles 
induced a high titer, high avidity anti-F1-V antibody response along with a robust 
CD4+ T cell proliferative response. Moreover, the antibodies generated by this 
combination vaccine regimen displayed a broader pattern of recognition for F1-V 
epitopes associated with protection as compared to antibodies from mice immunized 
with unmodified F1-V adjuvanted with the traditional adjuvant monophosphoryl lipid-
A. Together, these results demonstrate how the integration of immunology, 
 180 
biomaterials engineering and informatics analyses can be used to rationally select 
antigens (i.e., αGal-modification) and adjuvants (i.e., polyanhydride nanoparticles) to 
deliver efficacious vaccines. 
In summary, the work presented in this dissertation outlines how a 
polyanhydride nanovaccine platform can be rationally designed to effectively mimic 
pathogenic microorganisms to induce potent and lasting immune responses similar 
to those induced following a natural infection. The current adjuvants approved for 
human use provide only a one-size-fits-all approach to vaccination that includes 
empirical trial and error, multiple immunizations and painful side effects (Figure 2). 
These off-the-shelf compounds cannot be tailored to differentially modulate the host 
immune response that may be needed to overcome mechanisms by which 
pathogens evade the host immune response. The transdiciplinary approach and 
rational design strategy employed in this work can be used to design vaccines that fit 
specific applications, thereby avoiding the “one size fits all” approach (Figure 3). This 
novel methodology will enhance patient compliance and deployment of therapeutic 
counter measures by reducing or eliminating the need to employ prime-boost 
immunization strategies. The continued refinement of tailored nanoadjuvant 
platforms will provide the basis for efficacious, protective vaccines and drug delivery 
vehicles for a variety of biodefense, emerging, and/or re-emerging pathogens with 
minimal adverse impact on humans and animals. 
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Figure 1. Cartoon model of the possible routes of entry of non-functionalizaed (NF) 
and functionalized, Linker or Di-mannose (Di-M) 50:50 CPH:SA nanoparticles. Inset 
depics the surface of CPH:SA nanoparticles after functionalization. The route of 
entry of NF nanoparticles is actin mediated and clathrin dependent (Chapter 2), 
possibly by receptors mediated endocytosis . Di-mannose nanoparticles are 
anticipated to be internalized by engaging C-type lectin receptors (CLRs). Linker 
functionalized nanoparticles are hypothesized to enter by engaging unknown cell 
receptors and by electorostatic interactions with the negatively charged plasma 
membrane. 
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Figure 2. Cartoon illustration of vaccine development using only traditional, empirical 
methods. In the absence of any multidisciplinary tools to enhance vaccine 
development efforts, the only results seen are those associated with trial or error 
methods that often lead to multiple immunizations, skewing of the immune response 
to a Th2 phenotype or reversions to pathogenic forms of the vaccine. 
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Figure 3. Cartoon illustration of vaccine development when rational vaccine design 
principles are utilized. The cloud seeded with tools from many different disciplines 
creates raindrops that bend the light (or efforts) associated with traditional vaccine 
development into new directions. These new directions allow us to see a rainbow of 
benefits associated with these new vaccine platforms, including enhanced safety, 
dose sparing capabilities, immunomodulation and single-dose delivery. 
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CHAPTER 7 
 
Future Work 
 
The long term goal of this research is to design innovative delivery platforms 
that can be utilized in multiple applications. The research presented in this 
dissertation has demonstrated the superior ability of polyanhydride particles as drug 
and vaccine delivery vehicles. While the effects of size and chemistry on 
internalization, mechanism(s) of uptake and intracellular fate were evaluated in this 
work, future studies on how shape of the particles influences their cellular 
interactions will be important to further enhance the efficacy of polyanhydride 
particles. Recent work has shown that PRINT particles that are cylindrical exhibit 
higher internalization rates compared to cubic particles. Moreover, increasing the 
aspect ratio of cylindrical particles further increases their uptake by HeLa cells. 
Methods to modulate shape of the particles can be applied to polyanhydride 
particles as well and the knowledge gained by studying the interplay among shape, 
size and chemistry will further propel the rational development of more effective 
vaccines and drug delivery agents. 
This work has identified surface functionalization of particles as a viable 
strategy to target antigen presenting cells (APCs). In this regard, linker or di-
mannose functionalized particles hold promise in drug delivery applications, 
specifically for the treatment of intracellular pathogens such as Mycobacterium 
tuberculosis and Brucella. The combination of functionalization and flexibility to 
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choose particles from different chemistries may allow for developing therapeutics 
tailored for a particular disease. Future work regarding surface functionalization of 
polyanhydride nanoparticles may include varying the length, stearic conformation 
and charge of linker molecules. Analyses of these properties can be achieved using 
dendrimers with amine end groups, diaminopropane or ethanolamine and comparing 
it to ethylenediamine. Further studies also require examination of the role of glycolic 
acid in the behavior of the functionalized nanoparticles. Alternatives such as 3-
hydroxypropionic or lactic acid can provide a better scope to the capabilities of 
surface functionalization of polyanhydride nanoparticles and its effects in cellular 
uptake and activation. 
The approach utilizing α-gal modification of F1-V along with unmodified F1-V 
encapsulated in amphiphilic nanoparticles for developing a plague vaccine showed 
induction of a robust immune response. However, in vivo challenge studies with live 
Yersinia pestis are required to compare the efficacy of the above mentioned 
formulation with that of other vaccines containing FDA approved adjuvants.  
 
! 186 
APPENDIX 1 
 
 
Analyzing Cellular Internalization of Nanoparticles and 
Bacteria by Multi-spectral Imaging Flow Cytometry 
 
  
 
Yashdeep Phanse1, Amanda E. Ramer-Tait1, Sherree L. Friend2, Brenda Carrillo-
Conde3, Paul Lueth1, Carrie J. Oster1, Gregory J. Phillips1, Balaji Narasimhan3, 
Michael J. Wannemuehler1, Bryan H. Bellaire1 
 
 
 
1Department of Veterinary Microbiology and Preventive Medicine, Iowa State 
University, 2Amnis Corporation, 3Department of Chemical and Biological 
Engineering, Iowa State University. 
 
 
A paper published in Journal of Visualized Experiments 2012 Jun 8;(64).  
 
 
 
 
 
Correspondence to: Balaji Narasimhan at nbalaji@iastate.edu, Michael J. 
Wannemuehler at mjwannem@iastate.edu, Bryan H. Bellaire at bbella@iastate.edu 
 
 
! 187 
Abstract:  
 Nanoparticulate systems have emerged as valuable tools in vaccine delivery 
through their ability to efficiently deliver cargo, including proteins, to antigen 
presenting cells1-5. Internalization of nanoparticles (NP) by antigen presenting cells is 
a critical step in generating an effective immune response to the encapsulated 
antigen. To determine how changes in nanoparticle formulation impact function, we 
sought to develop a high throughput, quantitative experimental protocol that was 
compatible with detecting internalized nanoparticles as well as bacteria. To date, two 
independent techniques, microscopy and flow cytometry, have been the methods 
used to study the phagocytosis of nanoparticles. The high throughput nature of flow 
cytometry generates robust statistical data. However, due to low resolution, it fails to 
accurately quantify internalized versus cell bound nanoparticles. Microscopy 
generates images with high spatial resolution; however, it is time consuming and 
involves small sample sizes6-8. Multi-spectral imaging flow cytometry (MIFC) is a 
new technology that incorporates aspects of both microscopy and flow cytometry 
that performs multi-color spectral fluorescence and bright field imaging 
simultaneously through a laminar core. This capability provides an accurate analysis 
of fluorescent signal intensities and spatial relationships between different structures 
and cellular features at high speed.  
 Herein, we describe a method utilizing MIFC to characterize the cell 
populations that have internalized polyanhydride nanoparticles or Salmonella 
enterica serovar Typhimurium. We also describe the preparation of nanoparticle 
suspensions, cell labeling, acquisition on an ImageStreamX system and analysis of 
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the data using the IDEAS application. We also demonstrate the application of a 
technique that can be used to differentiate the internalization pathways for 
nanoparticles and bacteria by using cytochalasin-D as an inhibitor of actin-mediated 
phagocytosis.  
 
Keywords: ImageStream, phagocytosis, nanoparticles, pathogen, bacteria, 
Salmonella, imaging, multi-spectral imaging flow cytometry. 
 
 
 
Protocol: 
 
1. RAW 264.7 cell culture: 
 
1.1 Harvest RAW 264.7 cells from their flasks when they reach confluency by 
scraping them gently with a cell scraper. Count and plate them into a 24-well 
cell culture dish at a density of 5 x 105 cells/well in 0.5 mL complete 
Dulbecco's Modified Eagle Medium!(cDMEM; 10% heat-inactivated fetal 
bovine serum (FBS), 2 mM Glutamax, and 10 mM HEPES) and incubate 
overnight at 37°C in a 5% CO2 incubator.  
 
2. Pathogenic Salmonella enterica serovar Typhimurium 14028 transformation 
and culture:  
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2.1 Introduce recombinant plasmids expressing green fluorescent protein (GFP) 
to S. Typhimurium by electroporation. First, prepare culture of Salmonella 
enterica serovar Typhimurium (ATCC 14028) in LB broth and incubate 
overnight at 37°C with aeration.  
2.2 Next day, pellet 1 mL of bacteria at maximum speed in a microcentrifuge. 
Wash the cells four times with 1 mL of cold MOPS/glycerol solution (1mM 
MOPS in 20% glycerol) by gently resuspending the pellet with a pipette 
between each wash9. After the final wash, resuspend the pellet in 50 µL of 
MOPS/glycerol into which ~0.5 µg of pAKgfp1 or pAKgfplux1 plasmid DNA 
has been added10. 
2.3 Transfer the cell suspension to a pre-chilled 1 mm gap electroporation cuvette 
and electroporate using the settings: 1800 V, 200 W, 25 mF. Immediately 
after pulse delivery, add 1 mL of LB broth and transfer the cell suspension to 
a new 15 mL tube. Allow the cells to recover at 37°C with aeration.  After one 
hour, concentrate the cells by centrifugation and resuspend in ~100 µL of 
remaining supernatant.  
2.4 Finally, plate the cells on LB plates containing 100 µg/mL ampicillin and 
incubate overnight at 37°C. Single colonies are purified by restreaking with 
antibiotic selection and expression of GFP is confirmed by illumination with a 
standard fluorescein isothiocyanate (FITC) filter set.   
2.5 Inoculate 10 mL of LB broth containing 25 µg/mL ampicillin (or appropriate 
antibiotic) with a loopful of Salmonella that has been transformed to stably 
express GFP. 
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2.6 Grow the bacteria overnight at 37°C. 
2.7 Dilute Salmonella 1:10 into a fresh culture tube containing 10 mL LB 
supplemented with ampicillin and incubate for 5 h at 37°C. 
2.8 Measure the absorbance of the culture at 600 nm (A600) and calculate the 
concentration of the Salmonella per mL using a previously establish growth 
curve. 
2.9 Dilute the Salmonella in cDMEM (0.5 mL/well) to obtain a multiplicity of 
infection (MOI) of 100 per RAW 264.7 cell.  
 
3. Preparation of nanoparticle suspension: 
      
3.1 Fabricate 1% FITC-loaded nanoparticles as described previously11. Briefly, 
particles are fabricated by polyanhydride anti-solvent nanoencapsulation, in 
which the polymer is dissolved in methylene chloride (4°C at a concentration 
of 25 mg/mL) and precipitated in pentane (-20°C at a ratio 1:200 methylene 
chloride: pentane). After evaporating any residual solvent, weigh the dried 
polyanhydride nanoparticles using sterilized weigh paper. 
3.2 Add 5 mg of nanoparticles to 0.5 mL of cold phosphate buffered saline (PBS, 
calcium and magnesium free, pH 7.4) in a 1.5 mL microcentrifuge tube and 
keep it on ice until the nanoparticles are added to the RAW 264.7 cells.  
3.3 Sonicate the nanoparticle suspension (while keeping on ice) using an 
ultrasonic liquid processor fitted with a microtip for approximately 25 s at 4 to 
6 joules.  
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4. Phagocytosis Assay: 
 
4.1 Pretreat a subset of RAW 264.7 cells with 5 µg/mL cytochalasin-D 1 h prior to 
introduction of NP or Salmonella by aspirating medium and replacing with 
fresh cDMEM supplemented with the inhibitor. Return the cultures to 37°C 
incubator.  
4.2 After the 1 h incubation with the inhibitor, remove the plates from the 
incubator, vortex the nanoparticle suspension, and add 10 µL to the 
appropriate wells.  
4.3 Vortex the Salmonella and infect the RAW 264.7 cells with an MOI of 100 by 
adding the bacteria to the appropriate wells.  
4.4 Tap the plate few times to mix and incubate at 37°C or 4°C (control) for 45 
min. 
4.5 Remove the plates from the incubator or refrigerator and place on ice. Wash 
the cells twice with ice cold PBS (without Ca2+ and Mg2+) by aspirating and 
discarding the old medium to remove unbound particles, Salmonella, and 
dead or detached RAW 264.7 cells.   
4.6 To harvest the RAW 264.7 cells after the second wash, add 250 µL of ice-
cold PBS and gently scrape the wells.  
4.7 Pipet the harvested cells into Clear-view® snap cap microcentrifuge tubes and 
keep them on ice.  
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4.8 Wash the cells by adding 1 mL of cold wash buffer (2% heat inactivated FBS, 
0.1% sodium azide in PBS) and centrifuge at 250 x g for 10 min at 4°C.  
4.9 Discard the supernatant and remove residual buffer by tapping the inverted 
microcentrifuge tube on paper towel. Resuspend the cell pellet by gently 
raking the microcentrifuge tube across a test tube rack.   
4.10 Fix the RAW 264.7 cells by adding 100 µL of 4% paraformaldehyde (PFA) in 
PBS and allow the cells to stand for 15 min at room temperature (RT). 
4.11 Wash the RAW 264.7 cells by adding 1 mL of Perm/Wash buffer (BD 
Biosciences) and centrifuge at 250 x g for 10 min at 4°C. 
4.12 Repeat step 4.9. 
4.13 Stain the RAW 264.7 cells for actin by adding 100 µl of Perm/Wash buffer 
containing Alexa Fluor phalloidin 660 (AF 660; 1:150 dilution) for 15 min at 
RT. Repeat steps 4.11 and 4.12. 
4.14 Resuspend RAW 264.7 cells in 50 µL of PBS containing 1% PFA and store 
them in the dark at 4°C until acquisition. 
 Tips & notes: 
• Single color fluorescence samples should be prepared at this step to be used 
as compensation controls while setting up the ImageStreamX instrument. The 
compensation controls included in this experiment were: RAW 264.7 cells 
(not labeled for actin) incubated with nanoparticles; RAW 264.7 cells (not 
labeled for actin) incubated with Salmonella; actin only labeled RAW 264.7 
cells.  
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• For the inhibitor studies, it is important to include the vehicle control in which 
the inhibitor was dissolved as a control. In this experiment, cytochalasin-D 
was dissolved in 100% DMSO. We, therefore, incubated cells in cDMEM 
containing DMSO and then evaluated the internalization of nanoparticles or 
Salmonella. We did not detect any significant difference between the medium 
group and DMSO control (data not shown).   
• The sample preparation guide available on the Amnis website 
(https://www.amnis.com/images/1__Sample_Prep_Guide_3L_-_0418081.pdf) 
is a good resource for checking the compatibility of fluorophores with the 
ImageStreamX. Users can login by making a free account on the website. 
 
5. Sample acquisition on the ImageStreamX: 
 
5.1    Power up ImageStreamX and launch INSPIRE™.  
5.2    Initialize Fluidics. At the end of this script SpeedBeads should be running. 
5.3 In the file menu, choose Load Default Template. 
5.4 In the Image Gallery view menu, select ALL and Press Run Setup to start 
imaging the beads. 
5.5 Adjust Core Tracking to center images laterally (if necessary). 
5.6 Select the Brightfield (BF) channel and click Set Intensity. 
5.7 Wait until the Flow Speed CV is consistently less than 0.2%. 
5.8 Calibrate the instrument daily. In the ASSIST tab, click Start All to run 
calibrations and tests and verify that all have passed. 
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5.9 Press Flush Lock and Load (FLL) to load the first sample. Load the brightest 
sample in the experiment that fluoresces with each fluorochrome used. It’s 
critical that you run this sample first to establish the instrument settings and 
then DO NOT change them for the entire experiment. 
5.10 Turn on each laser used in the experiment and set the Laser Power so each 
fluorochrome has max pixel values between 100 and 4000 counts, as 
measured in the scatter plots. 
5.11 Set Cell Classification criteria, to eliminate collection of unwanted objects. 
For collecting data from only the cells, select the Area Lower Limit in BF 
channel to 50 µm. Objects with area less than 50 µm will be considered 
debris and will not be acquired. Select channels to be collected. 
5.12 Enter the File Name, Destination Folder, set Sequence # to 1 and the 
Number of Events to acquire.  
5.13 Click Run Acquire to collect and save the first experiment data file. 
5.14 Click FLL and run the next experimental sample. Repeat until all 
experimental samples have been collected. 
5.15 Click Comp Settings (turns off brightfield and scatter laser and enables 
collection of all channels) and collect 500 positive cells from each single 
stained sample for each fluorophore in the experiment to develop a 
compensation matrix. 
 
To summarize, samples can be run in the following order: 
• Brightest sample first. 
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• Remaining test samples. 
• Compensation controls containing single color fluorescence. 
 
Tips & notes: 
 
• An INSPIRE template can be saved and reloaded to set the instrument 
settings. Once templates are saved, the autosampler can be used for 
unattended operation to run the experimental samples with one template and 
the compensation controls with a template for each single color control. 
• The ImageStreamX configuration for these experiments: 488 and 658 nm 
excitation lasers; 785 nm scatter laser; 40X (0.75 NA) objective, 6 channel 
system with a standard ISX filter stack. The autosampler option was used to 
allow unattended acquisition of the samples. 
• The following settings were used for the experiment. Nanoparticles were 
imaged with the 488 nm laser set to 10mW, the 658 nm laser set to 50 mW, 
the 785 nm laser set to 2 mW and BF in channel 1. Salmonella infected cells 
were imaged with the 488 nm laser set to 20 mW, 658 nm laser set to 50 mW, 
the 785 nm laser set to 2 mW, and BF in channel 1. Compensation controls 
were collected in the absence of BF and 785. At least 5000 events (i.e., cells) 
were imaged for each of the test samples.  
 
6. Image analysis:  
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6.1 Launch IDEAS and double-click on the Internalization wizard and load one 
of the test sample .rif files. 
6.2 Create a compensation matrix by clicking on ‘New Matrix’ in step 2. The 
compensation wizard is launched. Add files for the single color controls in 
the experiment. Click next through the wizard following directions until the 
compensation matrix file is saved and loaded into the box in step 2 of the 
Internalization wizard. 
6.3 Click Next and follow directions until a .daf file is generated. 
6.4 Set image display properties by selecting the image channels used during 
acquisition. Click on Ch 2 (FITC) and Ch 5 (AF 660). (BF and SSC are 
default selected). 
6.5 Select the image channel for making the cell boundary (CH01) and the 
channel in which nanoparticles or bacteria were collected (CH02). 
6.6 A scatter plot of Brightfield Area versus Brightfield Aspect Ratio of all of the 
cells is generated. Define the single cell population by clicking on individual 
dots and gating around singlets. Single cells have an aspect ratio of around 
1 and doublets around 0.5 (Fig 1A). 
6.7 A histogram of the Brightfield Gradient RMS (Root Mean Square) of the 
brightfield image is generated and the population view in the image gallery 
is set to selected bin (Fig 1B). Click on the bins to determine where cells in 
best focus begin and draw a line region to gate focused cells. The higher 
the Gradient RMS, the better focused. Skip the next step unless there are 
other stains you want to gate on. 
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6.8 A new scatter plot of Intensity of Channel 2 on the x-axis versus Max Pixel 
of Ch2 on the y-axis is generated (Fig 1C). Click on the dots and view the 
images to help you draw the region around the cells that are positive for 
nanoparticles or bacteria.  
6.9 A histogram of the Internalization feature is generated with a region that 
begins at 0, which should be adjusted by observing images (Fig 1D). The 
Internalization feature is a ratio of the intensity inside the cell to the 
intensity of the whole cell. It is scaled such that at a value of 0 about half of 
the intensity is inside. The wizard has created a region to designate the 
inside by making a mask that has used the cell image input from step 5 to 
find the cell surface and eroded this by 4 pixels. Note that this mask can be 
manually adjusted for different cell types when necessary. In this 
experiment, we manually adjusted the feature by creating an Object mask 
on the brightfield image first and eroded this by 4 pixels. The Internalization 
feature was then calculated based on this 4 pixel eroded Object mask. This 
feature allows us to distinguish internalized particles and bacteria, which 
have the majority of their fluorescence signal within the mask boundary, 
from surface bound particles and bacteria, which have the majority of their 
fluorescence signal outside the mask boundary (Fig 2). 
6.10 Create a new histogram with the new Internalization feature based on the 
eroded Object mask. Draw a region to gate on internalized cells by viewing 
the imagery in selected bin mode. In our experiments, we set this gate at 
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0.3. Cells with a score lower than 0.3 were considered surface bound 
particle positive cells. 
6.11 Finally, to eliminate the cells with background labeling and to identify 
specific internalized nanoparticles or bacteria, the IDEAS Spot Count 
feature was used. Spot count is a feature that counts the number of 
connected components or small masks in an image. The mask functions, 
Spot, Peak and Intensity were used to define the spots. The spot mask 
finds the bright details in an image that have a user specified radius and 
threshold above the local background, the mask is refined by breaking 
apart high intensities into individual spots using the Peak function and then 
spots above an intensity of 200 counts were included. See the Amnis spot 
masking guide for further information (Fig 1E). A statistics report template 
was generated by including various features in the Reports menu. 
6.12 This file was saved as template file to be used for batch analysis of all 
experimental files. 
6.13 In the IDEAS software, click Tools! Batch Data Files and input all the .rif 
files. Add the compensation matrix file  (.ctm) and the template file (.ast) in 
the corresponding sections. Submit the batch for processing. After the 
processing step, all the .rif files are analyzed and .daf files are generated 
for each of the individual raw files. A final report file is generated with 
statistics for all the samples. 
 
Tips & notes: 
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• Image analysis was performed using the IDEAS software version 4.0 and the 
Internalization wizard with some modifications. The wizard is self-instructive 
and the ouptput .daf file can be generated by following the instructions of the 
wizard.  
 
Representative Results: 
 The representative images in Figure 2 demonstrate that MIFC can be used to 
successfully distinguish between internalized (left panel) versus surface bound (right 
panel) NP (Fig 2A) or Salmonella (Fig 2B). Internalization of NP and Salmonella 
were reduced by both inhibiting actin and lowering the temperature to 4°C (Fig 3A). 
The percentage of cells positive for surface bound NP increased from approximately 
8% at 37°C to greater than 35% after either cytochalasin-D or 4°C treatment (Fig 
3B). In contrast, the percentage of cells with surface bound Salmonella was reduced 
from 35% to 15% following cytochalasin-D treatment. Incubation of RAW 264.7 cells 
with Salmonella at 4°C decreased internalization without an apparent increase in the 
amount of surface bound bacteria as compared to the 37°C control. Together, these 
data demonstrate that Salmonella and NP are internalized by a similar cellular 
process that requires actin and is temperature dependent. Moreover, the data 
indicate that sustained attachment of Salmonella to macrophages requires actin 
polymerization.  
 
Discussion:  
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 Studies have shown that biodegradable nanoparticles based on poly(lactic- 
co-glycolic acid (PLGA) or polyanhydrides can be used to deliver encapsulated 
antigens or drugs to target cells. Uptake of these nanoparticles by phagocytic cells is 
important for their effectiveness, thus making quantitative analysis of internalization 
critical in designing novel nanoparticle delivery systems. By using this method, 
differential uptake of nanoparticles by various cell types can be analyzed with ease. 
To date, conventional microscopy and flow cytometry have been used for quantifying 
particle uptake; however, their respective limitations with high throughput and 
resolution call for alternative approaches to study internalization. In this article, we 
perform MIFC analysis to characterize and compare how the biological process of 
phagocytosis differs between two types of targets- a bacterial pathogen and 
synthetic nanoparticles.  
 The MIFC phagocytosis assay was used to delineate differences in the 
mechanism underlying the uptake of Salmonella compared to nanoparticles. It 
should be noted that inhibitors can be cytotoxic depending on their incubation time 
and concentration; hence a prior cytotoxicity profiling (i.e., exposure time and 
concentration) is necessary before their use13,14. Depending on their chemical 
formulation, nanoparticles can have a glass transition temperature (Tg = 13°C) below 
RT, consequently, they form aggregates at RT15. To overcome the aggregation, we 
sonicated the particles and kept them on ice prior to addition to the cell cultures. 
Kinetic studies of nanoparticle uptake provide important information on the efficiency 
of these particles to deliver the encapsulated payload to antigen presenting cells. 
Care must be taken to keep cells on ice at the end of a given time point to inhibit 
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further cellular processes. To this end, we have noted variability in cellular uptake 
when cells were not placed on ice. One limitation of the method described above is 
that the experiment is performed on adherent cells that require scraping techniques 
to harvest the phagocytic cells.  This procedure could result in cell death, thus 
introducing some error in the data analysis. The procedure we describe herein could 
also be performed using cells that grow in suspension.    
 The incubation of macrophages with reactive dyes or immunolabeling 
reagents was optimized by reducing the amount of residual buffer present following 
fixation. The presence of residual buffer creates a dilution effect and can produce 
sample to sample variation among the multiple samples, thereby resulting in 
inconsistent mean fluorescence intensity values. Sample concentration (i.e., 
cells/mL) is also an important factor to consider during the acquisition step, as dilute 
samples result in longer run times. For a multi-parametric comparison between 
different experimental samples, it is important to keep the laser intensity constant.  
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Table of specific reagents and equipment: 
 
Name of the reagent Company Catalogue number 
Comments 
(optional) 
RAW 264.7 cell line American Type Culture Collection (ATCC) TIB-71  
Dulbecco's Modified 
Eagle Medium 
(DMEM) 
Cellgro 10-013-CV  
Fetal bovine serum Atlanta Biologicals S 11150 Premium Grade 
Glutamax Gibco 35050-061  
HEPES Gibco 15630-080  
24-well plate TPP 92024  
Cell culture Flasks TPP 90151  
Cell scraper TPP 99002 24 cm 
Salmonella enterica 
serovar Typhimurium ATCC 14028  
BTX ECM630 Electro 
Cell Manipulator BTX Harvard Apparatus   
MOPS Fisher Scientific BP308  
Phosphate buffered 
saline (PBS) Cellgro 21-040-CV  
Ultrasonic liquid 
processor Misonix S-4000  
Cytochalasin-D Sigma-Aldrich, C8273  
Formaldehyde Polysciences 04018  
Wash buffer 
2% heat inactivated 
FBS, 0.1% sodium azide 
in PBS. 
  
Perm/wash buffer BD Biosciences 554714  
Clear-view snap cap 
microtubes Sigma T4816  
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Alexa Fluor phalloidin 
660 Invitrogen A22285  
ImageStreamX Amnis Corporation 100200 Options: 658nm laser, autosampler 
Sodium azide Fisher Scientific S 227I-500  
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Figure 1. Schematic of the gating strategy utilized to determine internalized 
versus surface bound nanoparticles and Salmonella. (A) To limit the analysis to 
single cells, it is important to eliminate debris and multi-cellular events. Single cells 
and doublets were separated from multicellular aggregates using the IDEAS 
features area and aspect ratio of the brightfield image (M01). Area is the size of the 
image in square microns and aspect ratio is the minor axis divided by the major axis 
and therefore a measure of circularity (a perfect circle will have an aspect ratio of 1; 
doublets typically have aspect ratios of around 0.5 and multicellular aggregates are 
typically less than 0.5). A region was drawn to gate on single cell events (Step 6.6). 
(B) To gate on cells in-focus, the IDEAS feature Gradient RMS of the brightfield 
image is plotted in a histogram. The Gradient RMS feature measures the sharpness 
quality of an image by detecting changes of pixel values in the image. A higher 
Gradient RMS value indicates a more focused image (Step 6.7). (C) Green 
fluorescence positive cells were selected by gating on the cells with high Max Pixel 
values and Intensity in the green fluorescence channel (Step 6.8). (D) Cells with 
internalized NP or Salmonella were selected by choosing the cell population with an 
internalization score equal to or greater than 0.3. Cells receiving a score less than 
0.3 were considered to be surface bound (Step 6.9). (E) Cells in the “internalized” 
gate were further characterized based on the number of spots (NP or STM) because 
there were some cells with background staining that were counted as internalized 
but had a spot value of zero (Step 6.11). Representative images are presented for 
each gate. 
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Figure 2. Cell images of internalized and surface bound nanoparticles (NP) or 
Salmonella. (A) Representative images of RAW 264.7 cells that internalized NP (left 
panel) and cells to which NP were bound to their surface but not internalized (right 
panel). (B) Representative images of RAW 264.7 cells that internalized Salmonella 
(left panel) and cells to which Salmonella were bound to their surface but not 
internalized (right panel).   
A
B
NP Internalized NP Surface Bound
Salmonella Internalized Salmonella Surface Bound
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Figure 3. Cytochalasin-D treatment of cells inhibited internalization of NP and 
Salmonella. (A) Pretreatment of RAW 264.7 cells with cytochalasin-D or incubation 
at 4°C reduced the incidence of NP or Salmonella internalization as compared to 
RAW 264.7 cells incubated at 37°C in medium. RAW 264.7 cells incubated in 
medium containing DMSO (i.e., vehicle control) showed similar internalization levels 
for NP and Salmonella compared to medium alone (data not shown). (B) 
Pretreatment of RAW 264.7 cells with cytochalasin-D increased the percent of cells 
with surface bound NP while decreasing the percent of cells with surface bound 
Salmonella.  
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APPENDIX 2 
 
Amphiphilic Polyanhydride Nanoparticles Stabilize 
Bacillus anthracis 
Protective Antigen 
 
 
L. K. Petersen1, Y. Phanse2, A. E. Ramer-Tait2, M.J. Wannemuehler2, and B. 
Narasimhan*1 
 
1Department of Chemical and Biological Engineering and 2Department of Veterinary 
Microbiology and Preventive Medicine, Iowa State University, Ames, Iowa 50011, 
United States 
 
A paper published in Molecular Pharmaceutics 2012 Apr 2;9(4):874-82. 
 
ABSTRACT 
Advancements toward an improved vaccine against Bacillus anthracis, the causative 
agent of anthrax, have focused on formulations composed of the protective 
antigen (PA) adsorbed to aluminum hydroxide. However, due to the labile nature of 
PA, antigen stability is a primary concern for vaccine development. Thus, there is a 
need for a delivery system capable of preserving the immunogenicity of PA through 
all the steps of vaccine fabrication, storage, and administration. In this work, we 
demonstrate that biodegrad- able amphiphilic polyanhydride nanoparticles, which 
have previously been shown to provide controlled antigen delivery, antigen stability, 
immune modulation, and protection in a single dose against a pathogenic challenge, 
can stabilize and release functional PA. These nanoparticles demonstrated polymer 
hydrophobicity-dependent preservation of the biological function of PA upon 
encapsulation, storage (over extended times and elevated temperatures), and 
release. Specifically, fabrication of amphiphilic polyanhydride nanoparticles 
composed of 1,6-bis(p- carboxyphenoxy)hexane and 1,8-bis(p-carboxyphenoxy)-
3,6-dioxaoctane best preserved PA functionality. These studies demonstrate the 
versatility and superiority of amphiphilic nanoparticles as vaccine delivery vehicles 
suitable for long-term storage. 
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APPENDIX 3 
 
Rational Design of Pathogen-Mimicking 
Amphiphilic Materials as 
Nanoadjuvants 
 
 
Bret D. Ulery1*, Latrisha K. Petersen1*, Yashdeep Phanse2, Chang Sun Kong3, Scott 
R. Broderick3, Devender Kumar4, Amanda E. Ramer-Tait2, Brenda Carrillo-Conde1, 
Krishna Rajan3, Michael J. Wannemuehler2, Bryan H. Bellaire2, Dennis W. Metzger4 
& Balaji Narasimhan1 
 
1Department of Chemical and Biological Engineering, Iowa State University, Ames, 
IA 50011, 2Department of Veterinary Microbiology and Preventive Medicine, Iowa 
State University, Ames, IA 50011, 3Department of Materials Science and 
Engineering, Iowa State University, Ames, IA 50011, 4Center for Immunology and 
Microbial Disease, Albany Medical College, Albany, NY 12208. 
 
A paper published in Scientific Reports, 2011;1:198. Epub 2011 Dec 16. 
 
 
ABSTRACT 
 
An opportunity exists today for cross-cutting research utilizing advances in materials 
science, immunology, microbial pathogenesis, and computational analysis to 
effectively design the next generation of adjuvants and vaccines. This study 
integrates these advances into a bottom-up approach for the molecular design of 
nanoadjuvants capable of mimicking the immune response induced by a natural 
infection but without the toxic side effects. Biodegradable amphiphilic polyanhydrides 
possess the unique ability to mimic pathogens and pathogen associated molecular 
patterns with respect to persisting within and activating immune cells, respectively. 
The molecular properties responsible for the pathogen-mimicking abilities of these 
materials have been identified. The value of using polyanhydride nanovaccines was 
demonstrated by the induction of long-lived protection against a lethal challenge of 
Yersinia pestis following a single administration ten months earlier. This approach 
has the tantalizing potential to catalyze the development of next generation vaccines 
against diseases caused by emerging and re-emerging pathogens. 
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APPENDIX 4 
 
Mannose-Functionalized “Pathogen-like” Polyanhydride 
Nanoparticles Target C-Type Lectin Receptors on Dendritic 
Cells 
Brenda Carrillo-Conde1, Eun-Ho Song2, Ana Chavez-Santoscoy1, Yashdeep 
Phanse3, Amanda E. Ramer-Tait3, Nicola L. B. Pohl2, Michael J. Wannemuehler3, 
Bryan H. Bellaire3, and Balaji Narasimhan*1, 
 
1Department of Chemical and Biological Engineering, Iowa State University, Ames, 
IA 50011, 2Department of Chemistry, and 3Department of Veterinary Microbiology 
and Preventive Medicine, Iowa State University, Ames, IA 50011. 
A paper published in Molecular Pharmaceutics 2011 Oct 3;8(5):1877-86. 
ABSTRACT 
Targeting pathogen recognition receptors on dendritic cells (DCs) offers the 
advantage of triggering specific signaling pathways to induce a tailored and robust 
immune response. In this work, we describe a novel approach to targeted antigen 
delivery by decorating the surface of polyanhydride nanoparticles with specific 
carbohydrates to provide “pathogen- like” properties that ensure nanoparticles 
engage C-type lectin receptors on DCs. The surface of polyanhydride 
nanoparticles was functionalized by covalent linkage of dimannose and 
lactose residues using an amine_carboxylic acid coupling reaction. Coculture of 
functionalized nanoparticles with bone marrow- derived DCs significantly increased 
cell surface expression of MHC II, the T cell costimulatory molecules CD86 and 
CD40, the C-type lectin receptor CIRE and the mannose receptor CD206 over the 
nonfunctionalized nanoparticles. Both non- functionalized and functionalized 
nanoparticles were efficiently internalized by DCs, indicating that internalization of 
function- alized nanoparticles was necessary but not sufficient to activate DCs. 
Blocking the mannose and CIRE receptors prior to the addition of functionalized 
nanoparticles to the culture inhibited the increased surface expression of MHC II, 
CD40 and CD86. Together, these data indicate that engagement of CIRE and the 
mannose receptor is a key mechanism by which functionalized nanoparticles 
activate DCs. These studies provide valuable insights into the rational design of 
targeted nanovaccine platforms to induce robust immune responses and improve 
vaccine efficacy. 
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APPENDIX 5 
 
Polyanhydride Microparticles Enhance Dendritic Cell 
Antigen Presentation and Activation 
 
Maria P. Torresa, 1, Jennifer H. Wilson-Welderb, 1, Senja K. Lopaca, Yashdeep 
Phanseb, Brenda Carrillo-Condea, Amanda E. Ramer-Taitb, Bryan H. Bellaireb, 
Michael J. Wannemuehlerb, Balaji Narasimhana, 
 
aDepartment of Chemical and Biological Engineering, Iowa State University, Ames, 
IA 50011, USA 
bDepartment of Veterinary Microbiology and Preventive Medicine, Iowa State 
University, Ames, IA 50011, USA 
 
 
A paper published in Acta Biomaterialia 2011 Jul;7(7):2857-64. 
 
ABSTRACT 
The present study was designed to evaluate the adjuvant activity of polyanhydride 
microparticles prepared in the absence of additional stabilizers, excipients or 
immune modulators. Microparticles composed of varying ratios of either 1,6-bis(p-
carboxyphenoxy)hexane (CPH) and sebacic acid or 1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane and CPH were added to in vitro cultures of bone marrow-derived 
dendritic cells (DCs). Microparticles were efficiently and rapidly phagocytosed by 
DCs in the absence of opsonization and without centrifugation or agitation. Within 
2h, internalized particles were rapidly localized to an acidic, phagolysosomal 
compartment. By 48 h, only a minor reduction in microparticle size was observed in 
the phagolysosomal compartment, indicating minimal particle erosion consistent with 
being localized within an intracellular microenvironment favoring particle stability. 
Polyanhydride microparticles increased DC surface expression of major 
histocompatability complex class II, the co-stimulatory molecules CD86 and CD40, 
and the C-type lectin CIRE (murine DC-SIGN; CD209). In addition, microparticle 
stimulation of DCs also enhanced secretion of the cytokines IL-12p40 and IL-6, a 
phenomenon found to be dependent on polymer chemistry. DCs cultured with 
polyanhydride microparticles and ovalbumin induced polymer chemistry-dependent 
antigen-specific proliferation of both CD4(+) OT-II and CD8(+) OT-I T cells. These 
data indicate that polyanhydride particles can be tailored to take advantage of the 
potential plasticity of the immune response, resulting in the ability to induce immune 
protection against many types of pathogens. 
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APPENDIX 6 
 
Polymer Chemistry Influences Monocytic Uptake of 
Polyanhydride Nanospheres 
 
Bret D. Ulery1, Yashdeep Phanse2, Avanti Sinha2, Michael J. Wannemuehler2, Balaji 
Narasimhan1, and Bryan H. Bellaire2 
 
1Department of Chemical and Biological Engineering, Iowa State University, Ames, 
IOWA 50011, USA. 
2Department of Veterinary Microbiology and Preventive Medicine, Iowa State 
University, Ames, IOWA 50011, USA. 
 
 
A paper published in Pharmaceutical Research, 2009 March, Vol. 26, No. 3 
 
ABSTRACT 
 
 Purpose. To demonstrate that polyanhydride copolymer chemistry affects the 
uptake and intracellular compartmentalization of nanospheres by THP-1 human 
monocytic cells. Methods. Polyanhydride nanospheres were prepared by an anti-
solvent nanoprecipitation technique. Morphology and particle diameter were 
confirmed via scanning election microscopy and quasi-elastic light scattering, 
respectively. The effects of varying polymer chemistry on nanosphere and 
fluorescently labeled protein uptake by THP-1 cells were monitored by laser 
scanning confocal microscopy. Results. Polyanhydride nanoparticles composed of 
poly(sebacic anhydride) (SA), and 20:80 and 50:50 copolymers of 1,6-bis-(p-
carboxyphenoxy)hexane (CPH) anhydride and SA were fabricated with similar 
spherical morphology and particle diameter (200 to 800 nm). Exposure of the 
nanospheres to THP-1 monocytes showed that poly(SA) and 20:80 CPH:SA 
nanospheres were readily internalized whereas 50:50 CPH:SA nanospheres had 
limited uptake. The chemistries also differentially enhanced the uptake of a red 
fluorescent protein-labeled antigen. Conclusions. Nanosphere and antigen uptake 
by monocytes can be directly correlated to the chemistry of the nanosphere. These 
results demonstrate the importance of choosing polyanhydride chemistries that 
facilitate enhanced interactions with antigen presenting cells that are necessary in 
the initiation of efficacious immune responses. 
